date,title,description,close,high,low,open,symbol,volume,id,key,subkey,updated,changeOverTime,marketChangeOverTime,uOpen,uClose,uHigh,uLow,uVolume,fOpen,fClose,fHigh,fLow,fVolume,label,change,changePercent
"August 6, 2020",Seattle Genetics Achieves Milestone Payment Under Antibody-Drug Conjugate Collaboration with GlaxoSmithKline Triggered by BLENREP (belantamab mafodotin-blmf) FDA Approval,"Seattle Genetics, Inc. (Nasdaq:SGEN) today announced U.S. Food and Drug Administration (FDA) approval of GlaxoSmithKline‚Äôs (GSK) BLENREP‚Ñ¢ (belantamab mafodotin-blmf), an antibody-drug conjugate (ADC)...",161.8,164.1663,159.25,163.8,SGEN,733405,HISTORICAL_PRICES,SGEN,,1606830572000,0.5342309880523424,0.5342309880523424,163.8,161.8,164.1663,159.25,733405,163.8,161.8,164.1663,159.25,733405,"Aug 6, 20",-0.789999999999992,-0.0049
"August 6, 2020",Alnylam Pharmaceuticals Reports Second Quarter 2020 Financial Results and Highlights Recent Period Activity,"Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter 2020 and reviewed recent business highligh...",144.12,149.21,141.5,148.64,ALNY,705527,HISTORICAL_PRICES,ALNY,,1606830572000,0.45899979752986436,0.45899979752986436,148.64,144.12,149.21,141.5,705527,148.64,144.12,149.21,141.5,705527,"Aug 6, 20",-6.319999999999993,-0.042
"August 6, 2020",Urovant Sciences to Report First Fiscal Quarter 2020 Financial Results,"Urovant Sciences (Nasdaq: UROV) announced today that it will report 2020 first fiscal quarter financial results after the close of U.S. financial markets on Thursday, August 13, 2020. Management will...",8.25,8.615,8.0347,8.4,UROV,42632,HISTORICAL_PRICES,UROV,,1606830572000,-0.17910447761194034,-0.17910447761194034,8.4,8.25,8.615,8.0347,42632,8.4,8.25,8.615,8.0347,42632,"Aug 6, 20",-0.03999999999999915,-0.0048
"August 6, 2020",Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results,"Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today provided an update on its clinical...",8.36,8.4,7.18,7.2,MRNS,828770.75,HISTORICAL_PRICES,MRNS,,1608088648000,0.02450980392156854,0.02450980392156854,1.8,2.09,2.1,1.795,3315083,7.2,8.36,8.4,7.18,828770.75,"Aug 6, 20",1.2799999999999994,0.1808
"August 6, 2020",Aldeyra Therapeutics Announces Second-Quarter 2020 Financial Results and Provides Corporate Update,"Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immun...",6.76,7.2,6.51,7.01,ALDX,1316441,HISTORICAL_PRICES,ALDX,,1606830572000,2.414141414141414,2.414141414141414,7.01,6.76,7.2,6.51,1316441,7.01,6.76,7.2,6.51,1316441,"Aug 6, 20",-0.7000000000000002,-0.0938
"August 6, 2020",Abiomed Announces Q1 FY 2021 Revenue of $165 Million and 21% Operating Margin,"Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies today reported first quarter fiscal 2021 revenue of $164.9 million compared to revenue of $207.7 million for...",314.98,318.46,308.4844,317.04,ABMD,442425,HISTORICAL_PRICES,ABMD,,1606830572000,1.1443256858873991,1.1443256858873991,317.04,314.98,318.46,308.4844,442425,317.04,314.98,318.46,308.4844,442425,"Aug 6, 20",-2.019999999999982,-0.0064
"August 6, 2020",Ironwood Pharmaceuticals Reports Second Quarter 2020 Results; Delivered GAAP Net Income of $25 Million and Adjusted EBITDA of $33 Million,"Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today provided an update on its second quarter 2020 results and recent business performance, as well as an update relate...",10.09,10.45,9.7182,10.1,IRWD,1857251,HISTORICAL_PRICES,IRWD,,1606830572000,-0.01078431372549014,-0.01078431372549014,10.1,10.09,10.45,9.7182,1857251,10.1,10.09,10.45,9.7182,1857251,"Aug 6, 20",0.4499999999999993,0.0467
"August 6, 2020",PolarityTE Reports Second Quarter 2020 Results,"PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today reported financial results for the second calendar quarter of 2020. PolarityTE w...",1.6,1.72,1.48,1.72,PTE,862015,HISTORICAL_PRICES,PTE,,1606830572000,0.37931034482758635,0.37931034482758635,1.72,1.6,1.72,1.48,862015,1.72,1.6,1.72,1.48,862015,"Aug 6, 20",-0.029999999999999805,-0.0184
"August 6, 2020",Concert Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Company Update,"Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the second quarter of 2020. ‚ÄúWe continue to be committed to advancing both of our lead programs as we embark on moving...",9.35,9.8,8.86,9.56,CNCE,187439,HISTORICAL_PRICES,CNCE,,1606830572000,0.06613454960091221,0.06613454960091221,9.56,9.35,9.8,8.86,187439,9.56,9.35,9.8,8.86,187439,"Aug 6, 20",-0.21000000000000085,-0.022
"August 6, 2020",Kala Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update,"Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported financ...",9.17,9.7,9.01,9.33,KALA,918829,HISTORICAL_PRICES,KALA,,1606830572000,0.24931880108991827,0.24931880108991827,9.33,9.17,9.7,9.01,918829,9.33,9.17,9.7,9.01,918829,"Aug 6, 20",0,0
"August 6, 2020",Dicerna Announces Second Quarter 2020 Financial Results and Provides a Business Update,"Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the ‚ÄúCompany‚Äù or ‚ÄúDicerna‚Äù), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported its financial result...",20,22.26,19.59,22.03,DRNA,1160491,HISTORICAL_PRICES,DRNA,,1606830572000,0.1104941699056079,0.1104941699056079,22.03,20,22.26,19.59,1160491,22.03,20,22.26,19.59,1160491,"Aug 6, 20",-1.7800000000000011,-0.0817
"August 6, 2020",Bristol Myers Squibb Reports Second Quarter 2020 Financial Results,"Bristol Myers Squibb (NYSE:BMY) today reports results for the second quarter of 2020, which reflect strong product sales, continued advancement of the pipeline and robust operating performance. ‚ÄúOur s...",61.33,62.97,60.42,62,BMY,18961905,HISTORICAL_PRICES,BMY,,1609460196000,0.24275582573454907,0.24275582573454907,62,61.33,62.97,60.42,18961905,61.0503,60.3905,62.0054,59.4945,18961905,"Aug 6, 20",1.6400000000000006,0.0275
"August 6, 2020",TherapeuticsMD¬Æ Announces Second Quarter 2020 Financial Results,"TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women‚Äôs healthcare company, today reported financial results for the second quarter ended June 30, 2020. ‚ÄúOur organization made significant...",1.61,1.85,1.58,1.79,TXMD,13660469,HISTORICAL_PRICES,TXMD,,1606830572000,0.26771653543307095,0.26771653543307095,1.79,1.61,1.85,1.58,13660469,1.79,1.61,1.85,1.58,13660469,"Aug 6, 20",-0.4399999999999997,-0.2146
"August 6, 2020",ANI Pharmaceuticals Reports Second Quarter 2020 Results,"ANI Pharmaceuticals, Inc. (‚ÄúANI‚Äù or the ‚ÄúCompany‚Äù) (NASDAQ: ANIP) today announced business highlights and financial results for the three and six months ended June 30, 2020. Business and Recent Highli...",29.5,31.42,29.23,30.51,ANIP,119340,HISTORICAL_PRICES,ANIP,,1606830572000,-0.26120711244678185,-0.26120711244678185,30.51,29.5,31.42,29.23,119340,30.51,29.5,31.42,29.23,119340,"Aug 6, 20",-1.5,-0.0484
"August 6, 2020",NanoString and Bio-Techne Announce Offering of RNAscope Reagents Validated for Use With the GeoMx Digital Spatial Profiler,"NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, and Bio-Techne (NASDAQ:TECH), a global life sciences company providing i...",36.04,37.8193,35.71,37.44,NSTG,169316,HISTORICAL_PRICES,NSTG,,1606830572000,0.42902458366375895,0.42902458366375895,37.44,36.04,37.8193,35.71,169316,37.44,36.04,37.8193,35.71,169316,"Aug 6, 20",-1.3000000000000043,-0.0348
"August 6, 2020",Amneal Reports Second Quarter 2020 Financial Results,"Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the ‚ÄúCompany‚Äù) announced its results today for the second quarter ended June 30, 2020. ‚ÄúAmneal executed well against our operational and strategic goals in t...",4.67,4.95,4.42,4.53,AMRX,2921620,HISTORICAL_PRICES,AMRX,,1606830572000,0.33810888252148985,0.33810888252148985,4.53,4.67,4.95,4.42,2921620,4.53,4.67,4.95,4.42,2921620,"Aug 6, 20",-0.5999999999999996,-0.1139
"August 5, 2020","The China Center for Drug Evaluation, National Medical Products Administration Has Recommended Breakthrough Therapy Designation for ciltacabtagene autoleucel (cilta-cel, LCAR-B38M CAR-T Cells), an Investigational BCMA CAR-T Cell Therapy","Legend Biotech Corporation (NASDAQ:LEGN) announced today that the China Center for Drug Evaluation, National Medical Products Administration (CDE, NMPA) has recommended Breakthrough Therapy Designatio...",33.81,35,33.76,34.43,LEGN,454333,HISTORICAL_PRICES,LEGN,,1606830572000,-0.08621621621621615,-0.08621621621621615,34.43,33.81,35,33.76,454333,34.43,33.81,35,33.76,454333,"Aug 5, 20",-0.18999999999999773,-0.0056
"August 5, 2020",Sesen Bio to Present Regulatory and Business Development Update at the Canaccord Genuity 40th Annual Growth Conference,"August 5, 2020 ‚Äì Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced it will be featured...",1,1.05,0.99,1.05,SESN,1451591,HISTORICAL_PRICES,SESN,,1606830572000,0.7543859649122808,0.7543859649122808,1.05,1,1.05,0.99,1451591,1.05,1,1.05,0.99,1451591,"Aug 5, 20",-0.050000000000000044,-0.0476
"August 5, 2020",bluebird bio Reports Second Quarter 2020 Financial Results and Recent Operational Progress,"bluebird bio, Inc. (NASDAQ: BLUE) today reported financial results and business highlights for the second quarter ended June 30, 2020 and shared recent operational progress. ‚ÄúI am incredibly proud of...",62.06,63.8,61.9046,62.95,BLUE,476738,HISTORICAL_PRICES,BLUE,,1606830572000,0.31149619611158075,0.31149619611158075,62.95,62.06,63.8,61.9046,476738,62.95,62.06,63.8,61.9046,476738,"Aug 5, 20",-0.37999999999999545,-0.0061
"August 5, 2020",AVEO Oncology Announces $2.8M Development Milestone Earned from Kyowa Kirin,"AVEO Oncology (Nasdaq: AVEO) today announced that it has earned a $2.8 million development milestone payment from partner Kyowa Kirin Co., Ltd. (Kyowa Kirin). The milestone relates to acceptance by th...",4.44,4.5,4.25,4.48,AVEO,501546,HISTORICAL_PRICES,AVEO,,1606830572000,0.4605263157894738,0.4605263157894738,4.48,4.44,4.5,4.25,501546,4.48,4.44,4.5,4.25,501546,"Aug 5, 20",0.010000000000000675,0.0023
"August 5, 2020",ACADIA Pharmaceuticals Reports Second Quarter 2020 Financial Results,"ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous syste...",42.87,43.9291,42.69,43.62,ACAD,1191734,HISTORICAL_PRICES,ACAD,,1606830572000,0.1263794009458748,0.1263794009458748,43.62,42.87,43.9291,42.69,1191734,43.62,42.87,43.9291,42.69,1191734,"Aug 5, 20",-0.6500000000000057,-0.0149
"August 5, 2020",Tricida Announces Second Quarter 2020 Financial Results,"Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed...",13.8,14.5953,13.56,14.49,TCDA,929863,HISTORICAL_PRICES,TCDA,,1606830572000,-0.3931398416886543,-0.3931398416886543,14.49,13.8,14.5953,13.56,929863,14.49,13.8,14.5953,13.56,929863,"Aug 5, 20",-0.4599999999999991,-0.0323
"August 5, 2020",Surmodics Receives FDA 510(k) Clearance for Sublime‚Ñ¢ Radial Access 0.014 RX PTA Dilatation Catheter,"Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced it has received U.S. Food and Drug Administration (FDA)...",48.48,48.86,46.985,47.62,SRDX,58113,HISTORICAL_PRICES,SRDX,,1606830572000,0.5679172056921085,0.5679172056921085,47.62,48.48,48.86,46.985,58113,47.62,48.48,48.86,46.985,58113,"Aug 5, 20",1.4199999999999946,0.0302
"August 5, 2020",Surmodics Reports Third Quarter Fiscal 2020 Results,"Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2020 third quarter ended Ju...",48.48,48.86,46.985,47.62,SRDX,58113,HISTORICAL_PRICES,SRDX,,1606830572000,0.5679172056921085,0.5679172056921085,47.62,48.48,48.86,46.985,58113,47.62,48.48,48.86,46.985,58113,"Aug 5, 20",1.4199999999999946,0.0302
"August 5, 2020",Atara Biotherapeutics Announces Second Quarter 2020 Financial Results and Operational Progress,"Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases...",12.71,13.07,12.1,12.66,ATRA,503840,HISTORICAL_PRICES,ATRA,,1606830572000,0.40753045404208216,0.40753045404208216,12.66,12.71,13.07,12.1,503840,12.66,12.71,13.07,12.1,503840,"Aug 5, 20",0.39000000000000057,0.0317
"August 5, 2020",Clovis Oncology Announces First Patient Enrolled in the Phase 2 Portion of the LIO-1 Trial Evaluating the Combination of Lucitanib and Opdivo in Gynecologic Cancers,"Clovis Oncology, Inc. (NASDAQ: CLVS) announced today treatment of the first patient in the Phase 2 portion of the LIO-1 trial evaluating the combination of lucitanib, Clovis‚Äô investigational angiogene...",6.465,6.48,6.25,6.33,CLVS,2745072,HISTORICAL_PRICES,CLVS,,1606830572000,0.4593679458239278,0.4593679458239278,6.33,6.465,6.48,6.25,2745072,6.33,6.465,6.48,6.25,2745072,"Aug 5, 20",0.21499999999999986,0.0344
"August 5, 2020",LORBRENA¬Æ (lorlatinib) Significantly Improves Progression-Free Survival in First-Line ALK-Positive Lung Cancer,Pfizer Inc. (NYSE:PFE) today announced that the Phase 3 CROWN study of LORBRENA¬Æ (lorlatinib) in people with previously untreated advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung...,38.45,38.53,38.13,38.47,PFE,23344231,HISTORICAL_PRICES,PFE,,1611800353000,0.29243697478991604,0.29243697478991604,38.47,38.45,38.53,38.13,23344231,37.6686,37.649,37.7274,37.3357,23344231,"Aug 5, 20",0.060000000000002274,0.0016
"August 5, 2020",Charles River Laboratories Announces Second-Quarter 2020 Results,"Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the second quarter of 2020. For the quarter, revenue was $682.6 million, an increase of 3.8% from $657.6 milli...",217.97,220.01,204.56,206.68,CRL,713262,HISTORICAL_PRICES,CRL,,1606830572000,0.8263091746962715,0.8263091746962715,206.68,217.97,220.01,204.56,713262,206.68,217.97,220.01,204.56,713262,"Aug 5, 20",14.050000000000011,0.0689
"August 5, 2020",Rocket Pharmaceuticals Reports Second Quarter 2020 Financial Results and Highlights Recent Progress,"Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (‚ÄúRocket‚Äù), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today reports finan...",25.26,25.48,23.6,25.22,RCKT,405941,HISTORICAL_PRICES,RCKT,,1606830572000,0.687374749498998,0.687374749498998,25.22,25.26,25.48,23.6,405941,25.22,25.26,25.48,23.6,405941,"Aug 5, 20",0.38000000000000256,0.0153
"August 5, 2020",IVERIC bio Reports Second Quarter 2020 Operational Highlights and Financial Results,"IVERIC bio, Inc. (Nasdaq: ISEE) today announced financial and operating results for the fiscal quarter ended June 30, 2020 and provided a general business update. ‚ÄúFollowing the positive results from...",4.41,4.55,4.29,4.4,ISEE,531014,HISTORICAL_PRICES,ISEE,,1606830572000,0.32035928143712583,0.32035928143712583,4.4,4.41,4.55,4.29,531014,4.4,4.41,4.55,4.29,531014,"Aug 5, 20",0.11000000000000032,0.0256
"August 5, 2020",Moderna Reports Second Quarter 2020 Financial Results and Provides Business Updates,"Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today reported fina...",75.8,77.49,73.69,77.49,MRNA,19859902,HISTORICAL_PRICES,MRNA,,1606830572000,1.7939550313306305,1.7939550313306305,77.49,75.8,77.49,73.69,19859902,77.49,75.8,77.49,73.69,19859902,"Aug 5, 20",-2.6599999999999966,-0.0339
"August 5, 2020",Horizon Therapeutics plc Reports Record Second-Quarter 2020 Results; Increases TEPEZZA¬Æ Full-Year Net Sales Guidance to Greater Than $650 Million; Increases Full‚ÄêYear 2020 Net Sales and Adjusted EBITDA Guidance,Horizon Therapeutics plc (Nasdaq: HZNP) today announced record second-quarter 2020 financial results. The Company increased its full-year 2020 net sales and adjusted EBITDA guidance on continued stren...,76.38,77.4499,70,73.35,HZNP,7813740,HISTORICAL_PRICES,HZNP,,1606830572000,1.7027600849256896,1.7027600849256896,73.35,76.38,77.4499,70,7813740,73.35,76.38,77.4499,70,7813740,"Aug 5, 20",14.589999999999996,0.2361
"August 5, 2020", Karuna Therapeutics Reports Second Quarter 2020 Financial Results and Business Highlights,"Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabl...",84.04,87,80.81,84.61,KRTX,116699,HISTORICAL_PRICES,KRTX,,1606830572000,0.25432835820895533,0.25432835820895533,84.61,84.04,87,80.81,116699,84.61,84.04,87,80.81,116699,"Aug 5, 20",-1.8699999999999903,-0.0218
"August 4, 2020","SHAREHOLDER ALERT: Investigation of DBV Technologies Announced by Holzer & Holzer, LLC","Holzer & Holzer, LLC is investigating whether DBV Technologies S.A. (‚ÄúDBV Technologies‚Äù or the ‚ÄúCompany‚Äù) (NASDAQ: DBVT) complied with federal securities laws. On August 4, 2020, DBV Technologies...",2.34,2.6,2.32,2.58,DBVT,6226581,HISTORICAL_PRICES,DBVT,,1606830572000,-0.4,-0.4,2.58,2.34,2.6,2.32,6226581,2.58,2.34,2.6,2.32,6226581,"Aug 4, 20",-1.7599999999999998,-0.4293
"August 4, 2020","Glancy Prongay & Murray LLP, a National Class Action Law Firm, Continues Investigation of Tactile Systems Technology, Inc. (TCMD) on Behalf of Investors","Glancy Prongay & Murray LLP (‚ÄúGPM‚Äù), a national investor rights law firm, continues its investigation on behalf of Tactile Systems Technology, Inc. (""Tactile"" or the ""Company"") (NASDAQ: TCMD) inve...",35.52,42.03,34.85,41.63,TCMD,1149890,HISTORICAL_PRICES,TCMD,,1606830572000,-0.06869428421604608,-0.06869428421604608,41.63,35.52,42.03,34.85,1149890,41.63,35.52,42.03,34.85,1149890,"Aug 4, 20",-7.759999999999998,-0.1793
"August 4, 2020",Quanterix Corporation Releases Operating Results for Second Quarter 2020,"Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced financial results for the three months ending June 30, 2020. ‚Äú...",33,34.2099,31.66,32.18,QTRX,286390,HISTORICAL_PRICES,QTRX,,1606830572000,1.2058823529411764,1.2058823529411764,32.18,33,34.2099,31.66,286390,32.18,33,34.2099,31.66,286390,"Aug 4, 20",0.7100000000000009,0.022
"August 4, 2020","Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2020 Financial Results","Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the second quarter ended June 30, 2020 and provided an update on clinical and corporate developments. ‚ÄúThe second qu...",48.53,49.07,47.51,48.99,DCPH,328096,HISTORICAL_PRICES,DCPH,,1606830572000,0.17392356071601348,0.17392356071601348,48.99,48.53,49.07,47.51,328096,48.99,48.53,49.07,47.51,328096,"Aug 4, 20",-0.9299999999999997,-0.0188
"August 4, 2020","Cardiovascular Systems, Inc. Reports Fiscal 2020 Fourth-Quarter Financial Results","Cardiovascular Systems, Inc. (CSI¬Æ) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery...",30.8,31.4,30.6,31.05,CSII,389065,HISTORICAL_PRICES,CSII,,1606830572000,-0.06468266018827813,-0.06468266018827813,31.05,30.8,31.4,30.6,389065,31.05,30.8,31.4,30.6,389065,"Aug 4, 20",-0.4499999999999993,-0.0144
"August 4, 2020",Cerus Corporation Announces Record Second Quarter 2020 Results,"Cerus Corporation (Nasdaq: CERS) today announced financial results for the second quarter ended June 30, 2020. Recent developments and highlights include: Q2 2020 Total Revenue of $26.8 million - driv...",7.47,7.56,7.21,7.43,CERS,1500438,HISTORICAL_PRICES,CERS,,1606830572000,0.849009900990099,0.849009900990099,7.43,7.47,7.56,7.21,1500438,7.43,7.47,7.56,7.21,1500438,"Aug 4, 20",0.05999999999999961,0.0081
"August 4, 2020",Xencor Reports Second Quarter 2020 Financial Results,"Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today reported financial results...",30.92,32.245,30.54,31.94,XNCR,204985,HISTORICAL_PRICES,XNCR,,1606830572000,0.07473062217587773,0.07473062217587773,31.94,30.92,32.245,30.54,204985,31.94,30.92,32.245,30.54,204985,"Aug 4, 20",-0.9099999999999966,-0.0286
"August 4, 2020",Kala Pharmaceuticals to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference,"Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that...",9.33,9.49,8.95,9.19,KALA,849622,HISTORICAL_PRICES,KALA,,1606830572000,0.2711171662125341,0.2711171662125341,9.19,9.33,9.49,8.95,849622,9.19,9.33,9.49,8.95,849622,"Aug 4, 20",0.0600000000000005,0.0065
"August 4, 2020",Henry Schein Reports Second Quarter 2020 Financial Results,"Henry Schein, Inc. (Nasdaq: HSIC), the world‚Äôs largest provider of health care solutions to office-based dental and medical practitioners, today reported second quarter 2020 financial results from con...",69.13,71.6,64.91,68.25,HSIC,4119372,HISTORICAL_PRICES,HSIC,,1606830572000,0.38177093743753737,0.38177093743753737,68.25,69.13,71.6,64.91,4119372,68.25,69.13,71.6,64.91,4119372,"Aug 4, 20",-1.7700000000000102,-0.025
"August 4, 2020",Incyte Reports 2020 Second Quarter Financial Results and Provides Updates on Key Clinical Programs,"Incyte (Nasdaq: INCY) today reports 2020 second quarter financial results, and provides a status update on the Company‚Äôs development portfolio. ‚ÄúWe continue to execute successfully across all aspects...",99.95,101.96,96.89,101,INCY,1976367,HISTORICAL_PRICES,INCY,,1606830572000,0.4362695789624946,0.4362695789624946,101,99.95,101.96,96.89,1976367,101,99.95,101.96,96.89,1976367,"Aug 4, 20",-1.8400000000000034,-0.0181
"August 4, 2020","Ra Medical Systems to Report Second Quarter 2020 Financial Results on August 11, 2020","Ra Medical Systems, Inc. (NYSE: RMED) announces that it will report second quarter 2020 financial results and provide a business update after market close on Tuesday, August 11, 2020. Ra Medical manag...",7.4075,7.5775,7.25,7.4975,RMED,260330.04000000004,HISTORICAL_PRICES,RMED,,1606830572000,-0.7294063926940639,-0.7294063926940639,0.2999,0.2963,0.3031,0.29,6508251,7.4975,7.4075,7.5775,7.25,260330.04000000004,"Aug 4, 20",0.17249999999999943,0.0238
"August 4, 2020",Epizyme Reports Business Progress and Second Quarter 2020 Financial Results,"Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today provided business and portfolio updates and reported...",12.3,14.37,12.285,14.17,EPZM,3190593,HISTORICAL_PRICES,EPZM,,1606830572000,-0.18918918918918914,-0.18918918918918914,14.17,12.3,14.37,12.285,3190593,14.17,12.3,14.37,12.285,3190593,"Aug 4, 20",-2.0699999999999985,-0.1441
"August 4, 2020",Easterly Government Properties Reports Second Quarter 2020 Results,"Easterly Government Properties, Inc. (NYSE: DEA) (the ‚ÄúCompany‚Äù or ‚ÄúEasterly‚Äù), a fully integrated real estate investment trust (‚ÄúREIT‚Äù) focused primarily on the acquisition, development and managemen...",25.37,25.54,24.07,24.08,DEA,610593,HISTORICAL_PRICES,DEA,,1614824207000,0.11860670194003534,0.11860670194003534,24.08,25.37,25.54,24.07,610593,23.2524,24.498,24.6622,23.2427,610593,"Aug 4, 20",1.3200000000000003,0.0549
"August 3, 2020",Karuna Therapeutics Announces Topline Data From Phase 1b Trial Evaluating KarXT on Experimentally Induced Pain in Healthy Volunteers,"Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabl...",87.64,87.92,81.81,82.1,KRTX,169536,HISTORICAL_PRICES,KRTX,,1606830572000,0.3080597014925373,0.3080597014925373,82.1,87.64,87.92,81.81,169536,82.1,87.64,87.92,81.81,169536,"Aug 3, 20",5.840000000000003,0.0714
"August 3, 2020",Hologic Announces ‚ÄòBack to Screening‚Äô Campaign Encouraging Women to Prioritize Mammograms Delayed due to COVID-19 Pandemic,"Hologic, Inc. (Nasdaq: HOLX), an innovative medical technology company, today launched the Back to Screening campaign encouraging women to schedule their annual mammograms now that healthcare faciliti...",71.32,71.49,70.08,70.6,HOLX,2654992,HISTORICAL_PRICES,HOLX,,1606830572000,1.2107873527588344,1.2107873527588344,70.6,71.32,71.49,70.08,2654992,70.6,71.32,71.49,70.08,2654992,"Aug 3, 20",1.539999999999992,0.0221
"August 3, 2020",TYME Announces Orphan Drug Designation for SM-88 as Potential Treatment for Patients with Pancreatic Cancer,"Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs‚Ñ¢) announced that the U.S. Food and Drug Administration (FDA) has granted t...",1.35,1.44,1.21,1.36,TYME,4350512,HISTORICAL_PRICES,TYME,,1606830572000,0.22727272727272727,0.22727272727272727,1.36,1.35,1.44,1.21,4350512,1.36,1.35,1.44,1.21,4350512,"Aug 3, 20",0.16000000000000014,0.1345
"August 3, 2020",New Blinded Observational Study Shows Greater Depth of Patient Sedation Than Intended During Procedural Colonoscopy,"Masimo (NASDAQ: MASI) today announced that in a new study published in Anesthesia Research and Practice, researchers used Masimo SedLine¬Æ Brain Function Monitoring to investigate the depth of anesthes...",218.25,223.9,217.51,222.15,MASI,400237,HISTORICAL_PRICES,MASI,,1606830572000,0.3656842500469307,0.3656842500469307,222.15,218.25,223.9,217.51,400237,222.15,218.25,223.9,217.51,400237,"Aug 3, 20",-1.8700000000000045,-0.0085
"August 3, 2020","Alnylam Submits CTA Application for ALN-HSD, an Investigational RNAi Therapeutic for the Treatment of Nonalcoholic Steatohepatitis (NASH)","Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company has submitted a clinical trial authorization (CTA) application to The Medicines an...",152.3,153.01,145.58,146.79,ALNY,415576,HISTORICAL_PRICES,ALNY,,1606830572000,0.5418100830127557,0.5418100830127557,146.79,152.3,153.01,145.58,415576,146.79,152.3,153.01,145.58,415576,"Aug 3, 20",6.5400000000000205,0.0449
"August 3, 2020",Ligand Reports Second Quarter 2020 Financial Results,"Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and six months ending June 30, 2020 and provided an operating forecast and program updates. Ligand man...",119.08,120,111.25,120,LGND,607366,HISTORICAL_PRICES,LGND,,1606830572000,0.7033328565298241,0.7033328565298241,120,119.08,120,111.25,607366,120,119.08,120,111.25,607366,"Aug 3, 20",1.8999999999999915,0.0162
"July 31, 2020",Xencor Earns Milestone Payment from MorphoSys for FDA Approval of Monjuvi¬Æ (tafasitamab-cxix) in the United States,"Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, announced that the U.S. Food an...",30.09,31.76,29.28,31.54,XNCR,357979,HISTORICAL_PRICES,XNCR,,1606830572000,0.04588112617309699,0.04588112617309699,31.54,30.09,31.76,29.28,357979,31.54,30.09,31.76,29.28,357979,"Jul 31, 20",-1.5500000000000007,-0.049
"July 31, 2020",Quidel Receives Preliminary Contract Leading to Definitive Agreement for $71 Million Under NIH‚Äôs RADx-ATP Program to Accelerate the Expansion of Its Manufacturing Capacity for Sofia¬Æ SARS-CoV-2 Antigen Detection Test for Rapid Diagnosis of COVID-19,"Quidel Corporation (NASDAQ: QDEL) (‚ÄúQuidel‚Äù), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has entered...",282.47,287.88,267.12,277.19,QDEL,936109,HISTORICAL_PRICES,QDEL,,1606830572000,2.500681621018714,2.500681621018714,277.19,282.47,287.88,267.12,936109,277.19,282.47,287.88,267.12,936109,"Jul 31, 20",11.970000000000027,0.0443
"July 31, 2020","Genprex to Present at Proactive‚Äôs One2One Virtual Investor Forum on August 4, 2020","Genprex, Inc. (‚ÄúGenprex‚Äù or the ‚ÄúCompany‚Äù) (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, announced toda...",3.37,3.5713,3.26,3.55,GNPX,777962,HISTORICAL_PRICES,GNPX,,1606830572000,0.20788530465949823,0.20788530465949823,3.55,3.37,3.5713,3.26,777962,3.55,3.37,3.5713,3.26,777962,"Jul 31, 20",-0.10999999999999988,-0.0316
"July 31, 2020",FDA Approves EUA Amendment Increasing Applied DNA‚Äôs COVID-19 Diagnostic Kit Testing Capacity Through Use of Automated RNA Extraction and Expands Supported Platforms,"Applied DNA Sciences Inc. (NASDAQ: APDN) (‚ÄúApplied DNA‚Äù or the ‚ÄúCompany‚Äù) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, and pre-clinical nuclei...",10,13.08,9.3,13.05,APDN,18595860,HISTORICAL_PRICES,APDN,,1606830572000,1.4509803921568627,1.4509803921568627,13.05,10,13.08,9.3,18595860,13.05,10,13.08,9.3,18595860,"Jul 31, 20",1.2899999999999991,0.1481
"July 31, 2020",GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2020,"GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the second quarter ended June 30, 2020, and highlighted recent company events. Cash and cash equivalents at June 30, 2020 we...",3.94,4.25,3.87,4.18,GLYC,664698,HISTORICAL_PRICES,GLYC,,1606830572000,0.6624472573839661,0.6624472573839661,4.18,3.94,4.25,3.87,664698,4.18,3.94,4.25,3.87,664698,"Jul 31, 20",-0.2100000000000004,-0.0506
"July 31, 2020",VBI Vaccines Announces Second Quarter 2020 Financial Results and Provides Corporate Update,"VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today reported financial results for th...",4.07,4.59,3.9,4.4728,VBIV,12393965,HISTORICAL_PRICES,VBIV,,1606830572000,3.6514285714285717,3.6514285714285717,4.4728,4.07,4.59,3.9,12393965,4.4728,4.07,4.59,3.9,12393965,"Jul 31, 20",-0.25,-0.0579
"July 31, 2020",Sesen Bio announces an exclusive license agreement with Qilu Pharmaceutical for the development and commercialization of Vicineum‚Ñ¢ in Greater China,"Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, and Qilu Pharmaceutical, a leading vertically integra...",1.04,1.22,1.01,1.19,SESN,9650366,HISTORICAL_PRICES,SESN,,1606830572000,0.8245614035087722,0.8245614035087722,1.19,1.04,1.22,1.01,9650366,1.19,1.04,1.22,1.01,9650366,"Jul 31, 20",0.030000000000000027,0.0297
"July 31, 2020",Ocular Therapeutix‚Ñ¢ To Report Second Quarter 2020 Financial Results,"Ocular Therapeutix‚Ñ¢, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, tod...",7.84,8.21,7.63,8.1,OCUL,604011,HISTORICAL_PRICES,OCUL,,1606830572000,0.5617529880478088,0.5617529880478088,8.1,7.84,8.21,7.63,604011,8.1,7.84,8.21,7.63,604011,"Jul 31, 20",-0.2699999999999996,-0.0333
"July 31, 2020","New Topline TEPEZZA¬Æ (teprotumumab-trbw) Data Underscore its Efficacy in Longer Disease Duration, Long-Term Durability and Potential for Retreatment in People Living with Thyroid Eye Disease (TED)",Horizon Therapeutics plc (Nasdaq: HZNP) today announced positive topline data from two clinical trials that add to the growing body of evidence supporting the efficacy and safety of TEPEZZA¬Æ (teprotum...,61.19,63.72,60.3,63.72,HZNP,1955728,HISTORICAL_PRICES,HZNP,,1606830572000,1.1652512384996458,1.1652512384996458,63.72,61.19,63.72,60.3,1955728,63.72,61.19,63.72,60.3,1955728,"Jul 31, 20",-0.8400000000000034,-0.0135
"July 31, 2020",Church & Dwight Reports Q2 Results,"Church & Dwight Co., Inc. (NYSE: CHD) today announced reported second quarter 2020 EPS of $0.75, a 36.4% increase versus year ago. Adjusted EPS, which excludes an acquisition related earn-out adju...",96.33,96.4,92.04,93.77,CHD,4193050,HISTORICAL_PRICES,CHD,,1613096290000,0.5975124378109453,0.5975124378109453,93.77,96.33,96.4,92.04,4193050,92.9914,95.5302,95.5996,91.2758,4193050,"Jul 31, 20",6.269999999999996,0.0696
"July 31, 2020", Merck Announces Second-Quarter 2020 Financial Results,"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2020. ‚ÄúDespite the impact COVID-19 had on patient access to health car...",80.24,81.68,79.15,80.89,MRK,11726443,HISTORICAL_PRICES,MRK,,1615519028000,0.17619466432131334,0.17619466432131334,80.89,80.24,81.68,79.15,11726443,78.9828,78.3481,79.7541,77.2838,11726443,"Jul 31, 20",1.25,0.0158
"July 31, 2020",ImmunoGen Reports Recent Progress and Second Quarter 2020 Financial Results,"ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial re...",4.11,4.5313,3.93,4.5313,IMGN,2957467,HISTORICAL_PRICES,IMGN,,1606830572000,0.12141882673942708,0.12141882673942708,4.5313,4.11,4.5313,3.93,2957467,4.5313,4.11,4.5313,3.93,2957467,"Jul 31, 20",-0.2599999999999998,-0.0595
"July 31, 2020",Pfizer and BioNTech to Supply Japan with 120 Million Doses of their BNT162 mRNA-based Vaccine Candidate,"Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced an agreement with the Ministry of Health, Labour and Welfare (MHLW) in Japan to supply 120 million doses of BNT162 mRNA-based vac...",38.48,38.75,37.86,38.67,PFE,27042691,HISTORICAL_PRICES,PFE,,1611800351000,0.29344537815126037,0.29344537815126037,38.67,38.48,38.75,37.86,27042691,37.8644,37.6784,37.9428,37.0713,27042691,"Jul 31, 20",-0.2600000000000051,-0.0067
"July 30, 2020",Quidel Reports Second Quarter 2020 Financial Results,"Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the second q...",270.5,272.99,256.36,257.88,QDEL,623161,HISTORICAL_PRICES,QDEL,,1606830572000,2.352336101127773,2.352336101127773,257.88,270.5,272.99,256.36,623161,257.88,270.5,272.99,256.36,623161,"Jul 30, 20",11.029999999999973,0.0425
"July 30, 2020",Veracyte Announces Second Quarter 2020 Financial Results,"Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the second quarter ended June 30, 2020 and provided an update on recent business progress. ‚ÄúWe delivered solid second quarter result...",33.21,33.49,29.72,29.76,VCYT,714314,HISTORICAL_PRICES,VCYT,,1606830572000,0.5092024539877301,0.5092024539877301,29.76,33.21,33.49,29.72,714314,29.76,33.21,33.49,29.72,714314,"Jul 30, 20",3.030000000000001,0.1004
"July 30, 2020",Infinity Pharmaceuticals Provides Company Update and Second Quarter 2020 Financial Results,"Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its second quarter 2020 financial results and provided an update on the company, including its second quarter progress with eganelisib (al...",0.8282,0.858,0.82,0.84,INFI,226514,HISTORICAL_PRICES,INFI,,1606830572000,-0.15082538706039159,-0.15082538706039159,0.84,0.8282,0.857999,0.82,226514,0.84,0.8282,0.858,0.82,226514,"Jul 30, 20",0.0032000000000000917,0.0039
"July 30, 2020","Revance to Release Second Quarter 2020 Financial Results on Thursday, August 6, 2020","Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA...",24.14,24.54,23.71,23.9,RVNC,437227,HISTORICAL_PRICES,RVNC,,1606830572000,0.6366101694915255,0.6366101694915255,23.9,24.14,24.54,23.71,437227,23.9,24.14,24.54,23.71,437227,"Jul 30, 20",-0.120000000000001,-0.0049
"July 30, 2020",Seattle Genetics Reports Second Quarter 2020 Financial Results,"Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for the second quarter and six months ended June 30, 2020. The Company also highlighted ADCETRIS (brentuximab vedotin), PADCEV (en...",171.14,172.82,167.22,167.95,SGEN,918880,HISTORICAL_PRICES,SGEN,,1606830572000,0.6227953726531386,0.6227953726531386,167.95,171.14,172.82,167.22,918880,167.95,171.14,172.82,167.22,918880,"Jul 30, 20",2.719999999999999,0.0162
"July 30, 2020",Kala Pharmaceuticals to Report Second Quarter 2020 Financial Results and Host Conference Call,"Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that...",8.86,8.99,8.36,8.55,KALA,1016164,HISTORICAL_PRICES,KALA,,1606830572000,0.20708446866485009,0.20708446866485009,8.55,8.86,8.99,8.36,1016164,8.55,8.86,8.99,8.36,1016164,"Jul 30, 20",0.3099999999999987,0.0363
"July 30, 2020",Vertex Reports Second-Quarter 2020 Financial Results,"Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2020 and revised upward its full-year 2020 financial guidance for...",279.4,282.28,274.662,275.0753,VRTX,1538387,HISTORICAL_PRICES,VRTX,,1606830572000,0.329906230663049,0.329906230663049,275.0753,279.4,282.28,274.662,1538387,275.0753,279.4,282.28,274.662,1538387,"Jul 30, 20",0.67999999999995,0.0024
"July 30, 2020",Gilead Sciences Announces Second Quarter and First Half 2020 Financial Results,"Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the second quarter and first half 2020. ‚ÄúGilead‚Äôs first half performance demonstrates the strength and durability of...",72.33,72.6,71.71,72.55,GILD,9274113,HISTORICAL_PRICES,GILD,,1615518979000,0.03832902670111975,0.03832902670111975,72.55,72.33,72.6,71.71,9274113,70.1952,69.9824,70.2436,69.3825,9274113,"Jul 30, 20",-0.6800000000000068,-0.0093
"July 30, 2020","Applied DNA to Report Fiscal 2020 Third Quarter Financial Results After Market Close on August 6, 2020","Applied DNA Sciences, Inc. (NASDAQ: APDN) announced today that it will report fiscal 2020 third quarter financial results after market close on Thursday, August 6, 2020. The Company‚Äôs management will...",8.71,9.0299,8.44,8.8,APDN,338787,HISTORICAL_PRICES,APDN,,1606830572000,1.1348039215686276,1.1348039215686276,8.8,8.71,9.0299,8.44,338787,8.8,8.71,9.0299,8.44,338787,"Jul 30, 20",-0.15999999999999837,-0.018
"July 30, 2020",Masimo Named NBA Supplier of Pulse Oximetry,"Masimo (NASDAQ: MASI) today announced that it has entered into a partnership with the National Basketball Association (NBA) to be its official supplier of pulse oximetry. As teams return to play, Masi...",220.1,221.05,213.21,216.3,MASI,608229,HISTORICAL_PRICES,MASI,,1606830572000,0.37726049683999746,0.37726049683999746,216.3,220.1,221.05,213.21,608229,216.3,220.1,221.05,213.21,608229,"Jul 30, 20",1.329999999999984,0.0061
"July 30, 2020",TFF Pharmaceuticals Announces Completion of Dosing for Voriconazole Inhalation Powder Phase 1 Clinical Trial,"TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) t...",9.04,9.5,8.1001,8.21,TFFP,1147798,HISTORICAL_PRICES,TFFP,,1606830572000,1.2599999999999998,1.2599999999999998,8.21,9.04,9.5,8.1001,1147798,8.21,9.04,9.5,8.1001,1147798,"Jul 30, 20",0.9599999999999991,0.1188
"July 30, 2020",Cerus Corporation Announces a Five-Year Tender Award by the Hong Kong Red Cross Blood Transfusion Service for INTERCEPT Blood Systems,Cerus Corporation (Nasdaq:CERS) today announced it has been awarded a five-year tender by the Hong Kong Red Cross Blood Transfusion Services (BTS) for INTERCEPT Blood System for platelets. The Hong Ko...,7.19,7.43,6.875,7.11,CERS,3562727,HISTORICAL_PRICES,CERS,,1606830572000,0.7797029702970297,0.7797029702970297,7.11,7.19,7.43,6.875,3562727,7.11,7.19,7.43,6.875,3562727,"Jul 30, 20",0.17000000000000082,0.0242
"July 30, 2020",Genprex CEO Participates in a Second-Round Live Interview on the ‚ÄúBig Biz Show‚Äù,"Genprex, Inc. (‚ÄúGenprex‚Äù or the ‚ÄúCompany‚Äù) (Nasdaq: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announce...",3.48,3.49,3.36,3.42,GNPX,621224,HISTORICAL_PRICES,GNPX,,1606830572000,0.24731182795698922,0.24731182795698922,3.42,3.48,3.49,3.36,621224,3.42,3.48,3.49,3.36,621224,"Jul 30, 20",0.009999999999999787,0.0029
"July 30, 2020","Odonate Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2020","Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced...",36.23,37.56,35,35.94,ODT,146717,HISTORICAL_PRICES,ODT,,1606830572000,0.37861491628614896,0.37861491628614896,35.94,36.23,37.56,35,146717,35.94,36.23,37.56,35,146717,"Jul 30, 20",-0.14000000000000057,-0.0038
"July 30, 2020",Sesen Bio to Host Conference Call to Provide OUS Business Update,"Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Company management will host a c...",1.01,1.09,1,1.04,SESN,2417642,HISTORICAL_PRICES,SESN,,1606830572000,0.7719298245614037,0.7719298245614037,1.04,1.01,1.09,1,2417642,1.04,1.01,1.09,1,2417642,"Jul 30, 20",0.010000000000000009,0.01
"July 30, 2020",Xeris Pharmaceuticals Announces Additional Data From a Phase 1b Comparative Study of Its Novel Concentrated Diazepam Formulation (XP-0863) and an Expedited Clinical Path Forward,"Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formula...",2.9,2.97,2.7,2.79,XERS,4283790,HISTORICAL_PRICES,XERS,,1606830572000,0.5425531914893618,0.5425531914893618,2.79,2.9,2.97,2.7,4283790,2.79,2.9,2.97,2.7,4283790,"Jul 30, 20",0.19999999999999973,0.0741
"July 30, 2020","PolarityTE Announces the Addition of Clinical Development and Regulatory Affairs Executive Jessica Shen, MD, MS to Board of Directors","PolarityTE, Inc. (Nasdaq: PTE) today announced the appointment of Jessica Shen, MD, MS to the Company‚Äôs Board of Directors. Dr. Shen brings extensive clinical development, medical, health economics, r...",1.55,1.63,1.43,1.51,PTE,1070862,HISTORICAL_PRICES,PTE,,1606830572000,0.33620689655172425,0.33620689655172425,1.51,1.55,1.63,1.43,1070862,1.51,1.55,1.63,1.43,1070862,"Jul 30, 20",0.07000000000000006,0.0473
"July 30, 2020",Marinus Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for Ganaxolone for the Treatment of CDKL5 Deficiency Disorder (CDD),"Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, announced today that the U.S. Food and D...",6.84,7.52,6.2,7,MRNS,979813.5,HISTORICAL_PRICES,MRNS,,1608088738000,-0.16176470588235298,-0.16176470588235298,1.75,1.71,1.88,1.55,3919254,7,6.84,7.52,6.2,979813.5,"Jul 30, 20",0.47999999999999954,0.0755
"July 30, 2020","Aerie Pharmaceuticals to Announce Second Quarter 2020 Financial Results and Host Conference Call on Thursday, August 6, 2020","Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients wi...",11.73,11.8977,11.37,11.73,AERI,774296,HISTORICAL_PRICES,AERI,,1606830572000,-0.09699769053117781,-0.09699769053117781,11.73,11.73,11.8977,11.37,774296,11.73,11.73,11.8977,11.37,774296,"Jul 30, 20",-0.1399999999999988,-0.0118
"July 30, 2020",Baxter Reports Second-Quarter 2020 Results,"Baxter International Inc. (NYSE:BAX), a leading global medical products company, today reported results for the second quarter of 2020 and provided its outlook for full-year 2020. ‚ÄúBaxter colleagues w...",86.01,86.11,82.92,85,BAX,8532630,HISTORICAL_PRICES,BAX,,1614219414000,0.16909066195460123,0.16909066195460123,85,86.01,86.11,82.92,8532630,84.223,85.2237,85.3228,82.162,8532630,"Jul 30, 20",-4.719999999999999,-0.052
"July 30, 2020","Lantheus Holdings, Inc. Reports Second Quarter 2020 Financial Results","Lantheus Holdings, Inc. (the ‚ÄúCompany‚Äù) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture an...",14.65,15.7,14.39,15.7,LNTH,670643,HISTORICAL_PRICES,LNTH,,1606830572000,0.2783595113438045,0.2783595113438045,15.7,14.65,15.7,14.39,670643,15.7,14.65,15.7,14.39,670643,"Jul 30, 20",-1.0600000000000005,-0.0675
"July 30, 2020",Merck Announces Two US Regulatory Milestones for KEYTRUDA¬Æ (pembrolizumab) in Triple-Negative Breast Cancer (TNBC),"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted two new supplemental Biologics License Applications...",78.99,79.28,77.63,78.73,MRK,6824952,HISTORICAL_PRICES,MRK,,1615519017000,0.15787159190853117,0.15787159190853117,78.73,78.99,79.28,77.63,6824952,76.8737,77.1276,77.4107,75.7996,6824952,"Jul 30, 20",-0.35999999999999943,-0.0045
"July 30, 2020",Alexion Reports Second Quarter 2020 Results,"Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the second quarter of 2020. Total revenues in the second quarter were $1,444.6 million, a 20 percent increase compared...",104.81,108.48,104.52,105.2,ALXN,2128688,HISTORICAL_PRICES,ALXN,,1606830572000,0.24079554871552034,0.24079554871552034,105.2,104.81,108.48,104.52,2128688,105.2,104.81,108.48,104.52,2128688,"Jul 30, 20",0.21000000000000796,0.002
"July 29, 2020",FSD Pharma Announces Decision to Surrender Health Canada Licenses for Subsidiary FV Pharma Inc.,FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) (‚ÄúFSD Pharma‚Äù or the ‚ÄúCompany‚Äù) today announced that it has notified Health Canada of the Company‚Äôs decision to forfeit the licenses of its wh...,3.74,3.9,3.7201,3.73,HUGE,44379,HISTORICAL_PRICES,HUGE,,1609875856000,0.24252491694352174,0.24252491694352174,3.73,3.74,3.9,3.7201,44379,3.73,3.74,3.9,3.7201,44379,"Jul 29, 20",-0.029999999999999805,-0.008
"July 29, 2020","Taro Provides Results for Quarter Ended June 30, 2020","Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (‚ÄúTaro‚Äù) today provided unaudited financial results for the quarter ended June 30, 2020. Quarter ended June 30, 2020 Highlights - compared to Quarter e...",67.99,68.35,66.3295,67.81,TARO,48027,HISTORICAL_PRICES,TARO,,1606830572000,0.13847957133288674,0.13847957133288674,67.81,67.99,68.35,66.3295,48027,67.81,67.99,68.35,66.3295,48027,"Jul 29, 20",0.6899999999999977,0.0103
"July 29, 2020","Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) to FDA for Idecabtagene Vicleucel (Ide-cel, bb2121) for Adults with Relapsed and Refractory Multiple Myeloma","Bristol Myers Squibb (NYSE: BMY) and bluebird bio, Inc. (Nasdaq: BLUE) today announced the submission of their Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for id...",59.15,59.4,58.59,59.16,BMY,7358112,HISTORICAL_PRICES,BMY,,1609460196000,0.19858156028368787,0.19858156028368787,59.16,59.15,59.4,58.59,7358112,58.2538,58.2439,58.4901,57.6925,7358112,"Jul 29, 20",-0.28000000000000114,-0.0047
"July 29, 2020",Transcat Announces Management Changes,"Transcat, Inc. (Nasdaq: TRNS) (‚ÄúTranscat‚Äù or the ‚ÄúCompany‚Äù), a leading provider of accredited calibration, repair, inspection and laboratory instrument services and value-added distributor of professi...",29,29.6571,28.525,29.49,TRNS,10340,HISTORICAL_PRICES,TRNS,,1606830572000,0.07646622123236818,0.07646622123236818,29.49,29,29.6571,28.525,10340,29.49,29,29.6571,28.525,10340,"Jul 29, 20",-0.48999999999999844,-0.0166
"July 29, 2020",AVITA Therapeutics to Participate at the Canaccord Genuity 40th Annual Growth Conference,"AVITA Therapeutics, Inc. (NASDAQ: RCEL) (ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration f...",22.39,23.24,22.38,23.24,RCEL,102203,HISTORICAL_PRICES,RCEL,,1606830572000,-0.2668631303208906,-0.2668631303208906,23.24,22.39,23.24,22.38,102203,23.24,22.39,23.24,22.38,102203,"Jul 29, 20",-0.870000000000001,-0.0374
"July 29, 2020",Hologic Announces Financial Results for Third Quarter of Fiscal 2020,"Hologic, Inc. (Nasdaq: HOLX) announced today the Company‚Äôs financial results for the fiscal third quarter ended June 27, 2020. ‚ÄúOur strong third quarter financial results reflect the incredible contri...",64,64.21,62.15,62.45,HOLX,2220463,HISTORICAL_PRICES,HOLX,,1606830572000,0.9838809671419716,0.9838809671419716,62.45,64,64.21,62.15,2220463,62.45,64,64.21,62.15,2220463,"Jul 29, 20",1.8999999999999986,0.0306
"July 29, 2020",TFF Pharmaceuticals Comments on Research on the Re-formulation of Remdesivir to a Dry Powder Form for COVID-19 Antiviral Treatment,"TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) te...",8.08,8.49,7.5,7.6,TFFP,1105660,HISTORICAL_PRICES,TFFP,,1606830572000,1.02,1.02,7.6,8.08,8.49,7.5,1105660,7.6,8.08,8.49,7.5,1105660,"Jul 29, 20",0.46999999999999975,0.0618
"July 29, 2020","People with Dementia and Caregivers Share the Significant Burden of Visual Hallucinations and Paranoid Delusions, New Survey Highlights","UsAgainstAlzheimer‚Äôs, the Lewy Body Dementia Association and ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the results of a qualitative and quantitative survey that explored the impact of...",42.53,43.97,42.45,43.53,ACAD,1110356,HISTORICAL_PRICES,ACAD,,1606830572000,0.11744613767735151,0.11744613767735151,43.53,42.53,43.97,42.45,1110356,43.53,42.53,43.97,42.45,1110356,"Jul 29, 20",-0.6199999999999974,-0.0144
"July 29, 2020",AtriCure to Participate at Upcoming Investor Conferences,"AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participat...",42.38,44.67,41.28,44.66,ATRC,945132,HISTORICAL_PRICES,ATRC,,1606830572000,0.4395380434782609,0.4395380434782609,44.66,42.38,44.67,41.28,945132,44.66,42.38,44.67,41.28,945132,"Jul 29, 20",-2.289999999999999,-0.0513
"July 29, 2020","PolarityTE to Report Second Quarter 2020 Financial Results on August 6, 2020","PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report calendar second quarter 2020 financial results by press release on Thursday, August 6, 2020 at approximately 7:00 a.m. Eastern Time....",1.48,1.57,1.43,1.55,PTE,1461291,HISTORICAL_PRICES,PTE,,1606830572000,0.2758620689655173,0.2758620689655173,1.55,1.48,1.57,1.43,1461291,1.55,1.48,1.57,1.43,1461291,"Jul 29, 20",-0.09000000000000008,-0.0573
"July 29, 2020","Deciphera Pharmaceuticals, Inc. to Announce Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 4, 2020","Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that it will report its second quarter 2020 financial results on Tuesday, August 4, 2020. In connection with the earnings release, Deciphe...",46.07,47.39,44.3,47.17,DCPH,552661,HISTORICAL_PRICES,DCPH,,1606830572000,0.11441702951136905,0.11441702951136905,47.17,46.07,47.39,44.3,552661,47.17,46.07,47.39,44.3,552661,"Jul 29, 20",-0.7899999999999991,-0.0169
"July 29, 2020","TherapeuticsMD to Report Second Quarter 2020 Results on August 6, 2020","TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women‚Äôs healthcare company, today announced that it will report its second quarter 2020 financial results on Thursday, August 6, 2020, before the ope...",1.96,2.045,1.8299,1.87,TXMD,3566123,HISTORICAL_PRICES,TXMD,,1606830572000,0.5433070866141732,0.5433070866141732,1.87,1.96,2.045,1.8299,3566123,1.87,1.96,2.045,1.8299,3566123,"Jul 29, 20",0.08999999999999986,0.0481
"July 29, 2020",FDA Grants Breakthrough Therapy Designation to Merck‚Äôs Novel HIF-2Œ± Inhibitor MK-6482 for Treatment of Certain Patients With Von Hippel-Lindau Disease- Associated Renal Cell Carcinoma,"Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to the hypoxia-induc...",79.35,79.74,78.74,79.25,MRK,6105298,HISTORICAL_PRICES,MRK,,1615519174000,0.16314863676341243,0.16314863676341243,79.25,79.35,79.74,78.74,6105298,77.3814,77.4791,77.8599,76.8835,6105298,"Jul 29, 20",-0.3400000000000034,-0.0043
"July 29, 2020",Repare Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Trial of RP-3500,"Repare Therapeutics Inc. (‚ÄúRepare‚Äù or the ‚ÄúCompany‚Äù) (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of no...",24.57,24.57,22.9,22.9,RPTX,70712,HISTORICAL_PRICES,RPTX,,1606830572000,-0.20227272727272727,-0.20227272727272727,22.9,24.57,24.57,22.9,70712,22.9,24.57,24.57,22.9,70712,"Jul 29, 20",1.8300000000000018,0.0805
"July 28, 2020",AtriCure Reports Second Quarter 2020 Financial Results,"AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced second quarter 2020 financial results. ‚ÄúAmid...",44.67,45.655,44.44,45.36,ATRC,274197,HISTORICAL_PRICES,ATRC,,1606830572000,0.5173233695652174,0.5173233695652174,45.36,44.67,45.655,44.44,274197,45.36,44.67,45.655,44.44,274197,"Jul 28, 20",-1.009999999999998,-0.0221
"July 28, 2020",Moderna Announces Publication in The New England Journal of Medicine of Non-Human Primate Preclinical Viral Challenge Study of its mRNA Vaccine Against COVID-19 (mRNA-1273),"Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, toda...",81.49,83.85,79.5,81,MRNA,32946885,HISTORICAL_PRICES,MRNA,,1606830572000,2.0036859565057132,2.0036859565057132,81,81.49,83.85,79.5,32946885,81,81.49,83.85,79.5,32946885,"Jul 28, 20",1.5799999999999983,0.0198
"July 28, 2020",Nemaura Announces Correction and Pricing of Public Offering,"Nemaura Medical Inc. (NASDAQ: NMRD) (‚ÄúNemaura‚Äù or the ‚ÄúCompany‚Äù), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugar...",6.675,7,6.65,6.9,NMRD,278747,HISTORICAL_PRICES,NMRD,,1606830572000,0.12373737373737363,0.12373737373737363,6.9,6.675,7,6.65,278747,6.9,6.675,7,6.65,278747,"Jul 28, 20",-2.585,-0.2792
"July 28, 2020","Turning Point Brands Announces Second Quarter 2020 Results, Increases 2020 Guidance","Turning Point Brands, Inc. (‚ÄúTPB‚Äù) (NYSE: TPB), a leading provider of Other Tobacco Products (‚ÄúOTP‚Äù) and adult consumer alternatives, today announced financial results for the second quarter ended Jun...",33.24,34.32,31.1,31.1,TPB,666371,HISTORICAL_PRICES,TPB,,1616033804000,0.5247706422018349,0.5247706422018349,31.1,33.24,34.32,31.1,666371,30.9811,33.1129,34.1888,30.9811,666371,"Jul 28, 20",2.860000000000003,0.0941
"July 28, 2020",Altria Reports 2020 Second Quarter and First-Half Results; Reestablishes 2020 Full-Year Earnings Guidance; Announces IQOS Expansion Plans; Board Declares Dividend Increase,"Altria Group, Inc. (Altria) (NYSE: MO) today announces its 2020 second-quarter and first-half business results. Altria reestablishes 2020 adjusted diluted earnings per share (EPS) guidance and announc...",42.52,43.2,42.21,42.98,MO,10794221,HISTORICAL_PRICES,MO,,1616552238000,0.23712540005819047,0.23712540005819047,42.98,42.52,43.2,42.21,10794221,40.5839,40.1495,40.7916,39.8568,10794221,"Jul 28, 20",0.39000000000000057,0.0093
"July 28, 2020",Seres Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Updates,"Seres Therapeutics, Inc. (Nasdaq: MCRB) today reported financial results from the second quarter ended June 30, 2020, and provided an operational update. ‚ÄúIn the coming weeks, we are eagerly looking f...",3.99,4.34,3.75,4.2,MCRB,912716,HISTORICAL_PRICES,MCRB,,1606830572000,0.163265306122449,0.163265306122449,4.2,3.99,4.34,3.75,912716,4.2,3.99,4.34,3.75,912716,"Jul 28, 20",-0.20999999999999996,-0.05
"July 28, 2020",Pfizer Reports Second-Quarter 2020 Results,"Pfizer Inc. (NYSE: PFE) reported financial results for second-quarter 2020, increased its 2020 financial guidance for revenues and Adjusted diluted EPS(3) and reaffirmed all other components of its 20...",39.02,39.335,38.06,38.54,PFE,53504653,HISTORICAL_PRICES,PFE,,1611800391000,0.3115966386554623,0.3115966386554623,38.54,39.02,39.335,38.06,53504653,37.3719,37.8373,38.1428,36.9064,53504653,"Jul 28, 20",1.480000000000004,0.0394
"July 28, 2020",Epizyme Announces Date of Second Quarter 2020 Financial Results and Participation at 2020 Wedbush PacGrow Healthcare Virtual Conference,"Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that management will host a conferenc...",14.47,14.85,14.28,14.79,EPZM,545748,HISTORICAL_PRICES,EPZM,,1606830572000,-0.04614370468029,-0.04614370468029,14.79,14.47,14.85,14.28,545748,14.79,14.47,14.85,14.28,545748,"Jul 28, 20",-0.33999999999999986,-0.023
"July 28, 2020",Xerox Releases Second-Quarter Results,Xerox Holdings Corporation (NYSE: XRX) announced its second-quarter 2020 financial results. ‚ÄúI am proud of our employees who did what was necessary during this unprecedented disruption to support our...,15.21,16.38,15.035,16.03,XRX,4701589,HISTORICAL_PRICES,XRX,,1609377435000,-0.18313641245972073,-0.18313641245972073,16.03,15.21,16.38,15.035,4701589,15.6417,14.8416,15.9833,14.6708,4701589,"Jul 28, 20",-0.6099999999999994,-0.0386
"July 27, 2020",Shareholder Alert: Robbins LLP Announces the Shareholder Class Action Against Acer Therapeutics Inc. (ACER) Survives Motion to Dismiss,Shareholder rights law firm Robbins LLP announces that Acer Therapeutics Inc. (NASDAQ: ACER) may face damages caused by a pending securities class action. Acer Therapeutics is a pharmaceutical company...,3.46,3.6682,3.3,3.65,ACER,362088,HISTORICAL_PRICES,ACER,,1606830572000,0.7563451776649747,0.7563451776649747,3.65,3.46,3.6682,3.3,362088,3.65,3.46,3.6682,3.3,362088,"Jul 27, 20",0.1499999999999999,0.0453
"July 27, 2020",Pfizer and BioNTech Choose Lead mRNA Vaccine Candidate Against COVID-19 and Commence Pivotal Phase 2/3 Global Study,Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the start of a global (except for China) Phase 2/3 safety and efficacy clinical study to evaluate a single nucleoside-modified me...,37.54,37.75,37.23,37.36,PFE,26224224,HISTORICAL_PRICES,PFE,,1611800361000,0.2618487394957983,0.2618487394957983,37.36,37.54,37.75,37.23,26224224,36.2277,36.4022,36.6058,36.1016,26224224,"Jul 27, 20",-0.11999999999999744,-0.0032
"July 27, 2020",Cardiovascular Systems Presents REACH PVI Study at the New Cardiovascular Horizons Conference,"Cardiovascular Systems, Inc. (CSI¬Æ) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery...",30.68,30.85,29.2146,29.54,CSII,405582,HISTORICAL_PRICES,CSII,,1606830572000,-0.06832675372001215,-0.06832675372001215,29.54,30.68,30.85,29.2146,405582,29.54,30.68,30.85,29.2146,405582,"Jul 27, 20",1.0700000000000003,0.0361
"July 27, 2020","Nemaura Enters into Letter of Intent to Acquire Healthimation, LLC to Augment proBEAT‚Ñ¢ Launch in the U.S.","Nemaura Medical, Inc. (NASDAQ: NMRD) (‚ÄúNemaura‚Äù or the ‚ÄúCompany‚Äù), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing suga...",9.26,10.66,9.0001,9.33,NMRD,111460,HISTORICAL_PRICES,NMRD,,1606830572000,0.5589225589225588,0.5589225589225588,9.33,9.26,10.66,9.0001,111460,9.33,9.26,10.66,9.0001,111460,"Jul 27, 20",-0.21000000000000085,-0.0222
"July 27, 2020","Puma Biotechnology Announces Publication of Results from Phase II SUMMIT Trial Evaluating Neratinib in HER2-Mutant, Metastatic Cervical Cancers","Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that data from the cervical cancer cohort of SUMMIT, an ongoing Phase II basket trial examining the safety and efficacy...",10.05,10.13,9.77,9.82,PBYI,533585,HISTORICAL_PRICES,PBYI,,1606830572000,0.08648648648648656,0.08648648648648656,9.82,10.05,10.13,9.77,533585,9.82,10.05,10.13,9.77,533585,"Jul 27, 20",0.22000000000000064,0.0224
"July 27, 2020",Oncternal Therapeutics to Host Call on Cirmtuzumab and the Current Treatment Landscape for Mantle Cell Lymphoma,"Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will host a call with a key opin...",3.04,3.09,2.89,3.05,ONCT,175731,HISTORICAL_PRICES,ONCT,,1606830572000,0.1647509578544062,0.1647509578544062,3.05,3.04,3.09,2.89,175731,3.05,3.04,3.09,2.89,175731,"Jul 27, 20",0.14000000000000012,0.0483
"July 27, 2020",Masimo Expands the Masimo SafetyNet‚Ñ¢ Remote Patient Management Solution with Continuous Body Temperature Measurement,"Masimo (NASDAQ: MASI) today announced a significant expansion to the Masimo SafetyNet‚Ñ¢ platform with the introduction of Radius T¬∫‚Ñ¢, a wearable, wireless sensor that provides continuous body temperatu...",235.71,237.9092,233.565,234.37,MASI,343129,HISTORICAL_PRICES,MASI,,1606830572000,0.47493899005068524,0.47493899005068524,234.37,235.71,237.9092,233.565,343129,234.37,235.71,237.9092,233.565,343129,"Jul 27, 20",2.25,0.0096
"July 27, 2020",scPharmaceuticals Announces FDA Acceptance of FUROSCIX¬Æ New Drug Application Resubmission,"scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patien...",7.37,7.705,7.21,7.51,SCPH,206614,HISTORICAL_PRICES,SCPH,,1606830572000,-0.1380116959064328,-0.1380116959064328,7.51,7.37,7.705,7.21,206614,7.51,7.37,7.705,7.21,206614,"Jul 27, 20",0.0600000000000005,0.0082
"July 27, 2020",Moderna Announces Phase 3 COVE Study of mRNA Vaccine Against COVID-19 (mRNA-1273) Begins,"Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, toda...",79.91,80.98,76.16,80.63,MRNA,44710713,HISTORICAL_PRICES,MRNA,,1606830572000,1.9454478437154443,1.9454478437154443,80.63,79.91,80.98,76.16,44710713,80.63,79.91,80.98,76.16,44710713,"Jul 27, 20",6.700000000000003,0.0915
"July 27, 2020",Aerie Pharmaceuticals Reports Positive Topline Results for AR-1105 (Dexamethasone Intravitreal Implant) Phase 2 Clinical Trial in Patients with Macular Edema Due to Retinal Vein Occlusion,"Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients wi...",12.37,13.2221,11.84,13.12,AERI,830744,HISTORICAL_PRICES,AERI,,1606830572000,-0.04772902232486536,-0.04772902232486536,13.12,12.37,13.2221,11.84,830744,13.12,12.37,13.2221,11.84,830744,"Jul 27, 20",0.1899999999999995,0.0156
"July 24, 2020","U.S. FDA Approves Kite‚Äôs Tecartus‚Ñ¢, the First and Only CAR T Treatment for Relapsed or Refractory Mantle Cell Lymphoma","Kite, a Gilead Company (Nasdaq: GILD), today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Tecartus‚Ñ¢ (brexucabtagene autoleucel, formerly KTE-X19), the...",73.64,75.65,73.12,75.47,GILD,8148980,HISTORICAL_PRICES,GILD,,1615518983000,0.0571346540338789,0.0571346540338789,75.47,73.64,75.65,73.12,8148980,73.0205,71.2499,73.1946,70.7467,8148980,"Jul 24, 20",-1.9200000000000017,-0.0254
"July 24, 2020",Baxter and VIPUN Medical Announce Collaboration to Commercialize Innovative Gastric Monitoring System to Help Enhance Clinical Nutrition,"Baxter International Inc. (NYSE: BAX), a global leader in clinical nutrition, and VIPUN Medical, a company developing technology solutions to help improve medical nutrition, today announced an agreeme...",89.26,89.42,88.33,89.32,BAX,2362021,HISTORICAL_PRICES,BAX,,1614219427000,0.21326627701508785,0.21326627701508785,89.32,89.26,89.42,88.33,2362021,88.5035,88.444,88.6026,87.5225,2362021,"Jul 24, 20",-0.22999999999998977,-0.0026
"July 24, 2020",PolarityTE Announces Positive Top-Line Data from Interim Analysis of SkinTE‚Ñ¢ Diabetic Foot Ulcer Trial,"PolarityTE, Inc. (Nasdaq: PTE) announced positive results from a protocol-specified interim analysis of the first 50 patients enrolled in a multi-center randomized controlled trial evaluating treatmen...",1.78,2.38,1.67,2.04,PTE,23589473,HISTORICAL_PRICES,PTE,,1606830572000,0.5344827586206898,0.5344827586206898,2.04,1.78,2.38,1.67,23589473,2.04,1.78,2.38,1.67,23589473,"Jul 24, 20",0.16999999999999993,0.1056
"July 23, 2020",Revance Completes Previously Announced Acquisition of HintMD and its Proprietary Fintech Platform for Aesthetic Practices,"Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its investigational neuromodulator product, DaxibotulinumtoxinA...",23.5,24.15,23.25,24.03,RVNC,290070,HISTORICAL_PRICES,RVNC,,1606830572000,0.5932203389830508,0.5932203389830508,24.03,23.5,24.15,23.25,290070,24.03,23.5,24.15,23.25,290070,"Jul 23, 20",-0.5300000000000011,-0.0221
"July 23, 2020",Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results,"Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, August 6, 2020, following the release of its second quarte...",9.96,10.3745,9.885,10.09,PBYI,400077,HISTORICAL_PRICES,PBYI,,1606830572000,0.07675675675675685,0.07675675675675685,10.09,9.96,10.3745,9.885,400077,10.09,9.96,10.3745,9.885,400077,"Jul 23, 20",-0.16999999999999993,-0.0168
"July 23, 2020","Premier Inc. Recommends FDA, DEA Reforms to Prevent Drug Shortages",Premier Inc. (NASDAQ: PINC) today provided the U.S. Food and Drug Administration (FDA) and the U.S. Drug Enforcement Administration (DEA) with a list of reforms and regulatory waivers that the company...,35.11,35.42,34.6294,34.93,PINC,610301,HISTORICAL_PRICES,PINC,,1614385072000,0.24327195467422102,0.24327195467422102,34.93,35.11,35.42,34.6294,610301,34.3412,34.5182,34.823,34.0457,610301,"Jul 23, 20",0.28000000000000114,0.008
"July 23, 2020",The Importance of Science-Based Decision-Making Highlighted in Latest Issue of Philip Morris International‚Äôs Scientific Update,"Philip Morris International Inc. (PMI) (NYSE: PM) has published the 10th issue of its Scientific Update, a regularly issued report on the company‚Äôs efforts to develop and scientifically assess a range...",76.3,76.39,75.23,75.88,PM,5117127,HISTORICAL_PRICES,PM,,1616120173000,0.1548357802330862,0.1548357802330862,75.88,76.3,76.39,75.23,5117127,72.657,73.0591,73.1453,72.0346,5117127,"Jul 23, 20",0.29999999999999716,0.0039
"July 23, 2020","Cerus Corporation to Release Second Quarter 2020 Financial Results on August 4, 2020","Cerus Corporation (Nasdaq:CERS) announced today that its second quarter 2020 financial results will be released on Tuesday, August 4, 2020, after the close of the stock market. The Company will host a...",6.61,6.895,6.59,6.64,CERS,1434914,HISTORICAL_PRICES,CERS,,1606830572000,0.6361386138613861,0.6361386138613861,6.64,6.61,6.895,6.59,1434914,6.64,6.61,6.895,6.59,1434914,"Jul 23, 20",-0.0699999999999994,-0.0105
"July 23, 2020",Nemaura Medical to Integrate Activity Data From Third Party Wearable Devices to Its proBEAT‚Ñ¢ App,"Nemaura Medical, Inc. (NASDAQ: NMRD) (‚ÄúNemaura‚Äù or the ‚ÄúCompany‚Äù), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing suga...",9.73,10.4299,8.4,8.6,NMRD,127223,HISTORICAL_PRICES,NMRD,,1606830572000,0.638047138047138,0.638047138047138,8.6,9.73,10.4299,8.4,127223,8.6,9.73,10.4299,8.4,127223,"Jul 23, 20",1.1300000000000008,0.1314
"July 23, 2020",Incyte Announces REACH3 Trial of Ruxolitinib (Jakafi¬Æ) in Patients with Chronic Graft-Versus-Host Disease Met Primary and Both Key Secondary Endpoints,Incyte (Nasdaq:INCY) today announced that the Phase 3 REACH3 study evaluating ruxolitinib (Jakafi¬Æ) in patients with moderate or severe steroid-refractory or steroid dependent chronic graft-versus-hos...,101.68,107.09,101.405,106.33,INCY,1154260,HISTORICAL_PRICES,INCY,,1606830572000,0.46112947262537723,0.46112947262537723,106.33,101.68,107.09,101.405,1154260,106.33,101.68,107.09,101.405,1154260,"Jul 23, 20",-3.6899999999999977,-0.035
"July 23, 2020",Ocular Therapeutix Announces Second Medicare Administrative Contractor to Establish New Published Physician Fee Schedule for Administration of Intracanalicular Inserts,"Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today...",8.64,9.2111,8.46,8.9,OCUL,831188,HISTORICAL_PRICES,OCUL,,1606830572000,0.7211155378486058,0.7211155378486058,8.9,8.64,9.2111,8.46,831188,8.9,8.64,9.2111,8.46,831188,"Jul 23, 20",-0.10999999999999943,-0.0126
"July 22, 2020",Pfizer and BioNTech Announce an Agreement with U.S. Government for up to 600 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2,Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the execution of an agreement with the U.S. Department of Health and Human Services and the Department of Defense to meet the U.S...,38.56,38.73,37.52,38.23,PFE,86058379,HISTORICAL_PRICES,PFE,,1611800399000,0.2961344537815127,0.2961344537815127,38.23,38.56,38.73,37.52,86058379,37.0713,37.3913,37.5561,36.3828,86058379,"Jul 22, 20",1.8700000000000045,0.051
"July 21, 2020",Transcat Reports Operating Income of $1.0 Million from Service Segment Revenue and Margin Growth for Fiscal 2021 First Quarter,"Transcat, Inc. (Nasdaq: TRNS) (‚ÄúTranscat‚Äù or the ‚ÄúCompany‚Äù), a leading provider of accredited calibration, repair, inspection and laboratory instrument services and value-added distributor of professi...",27.08,28.07,26.55,28.06,TRNS,18505,HISTORICAL_PRICES,TRNS,,1606830572000,0.005196733481811322,0.005196733481811322,28.06,27.08,28.07,26.55,18505,28.06,27.08,28.07,26.55,18505,"Jul 21, 20",-0.620000000000001,-0.0224
"July 21, 2020",Shareholder Alert: Robbins LLP Is Investigating the Officers and Directors of Vanda Pharmaceuticals Inc. (VNDA),"Shareholder rights law firm Robbins LLP announces that it is investigating the officers and directors of Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) for breaches of fiduciary duties, unjust enrichment,...",10.87,11.13,10.74,11.1,VNDA,853252,HISTORICAL_PRICES,VNDA,,1606830572000,0.17513513513513504,0.17513513513513504,11.1,10.87,11.13,10.74,853252,11.1,10.87,11.13,10.74,853252,"Jul 21, 20",-0.23000000000000043,-0.0207
"July 21, 2020",Novo estudo expande evid√™ncias que demonstram os benef√≠cios da triagem para cardiopatia cong√™nita cr√≠tica (CCC) usando a oximetria de pulso Masimo SET¬Æ,"A Masimo (NASDAQ: MASI) anunciou hoje os resultados de um estudo prospectivo publicado no International Journal of Neonatal Screening, no qual pesquisadores de Marraquexe, Marrocos, realizaram o prime...",245.25,248.875,240.6,247.96,MASI,613383,HISTORICAL_PRICES,MASI,,1606830572000,0.534634878918716,0.534634878918716,247.96,245.25,248.875,240.6,613383,247.96,245.25,248.875,240.6,613383,"Jul 21, 20",-1.5600000000000023,-0.0063
"July 21, 2020",National Institutes of Health (NIH) Awards Research Grant of $2.59 Million to University of Pittsburgh for Diabetes Gene Therapy Technology Licensed by Genprex,"Genprex, Inc. (‚ÄúGenprex‚Äù or the ‚ÄúCompany‚Äù) (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announce...",3.41,3.77,3.32,3.4,GNPX,5532788,HISTORICAL_PRICES,GNPX,,1606830572000,0.22222222222222227,0.22222222222222227,3.4,3.41,3.77,3.32,5532788,3.4,3.41,3.77,3.32,5532788,"Jul 21, 20",0.31000000000000005,0.1
"July 21, 2020",Gamida Cell Announces Appointment of Michele Korfin as Chief Operating and Chief Commercial Officer,"Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today announced the appointment of Michele Korfin as chief op...",4.53,4.59,4.48,4.55,GMDA,174120,HISTORICAL_PRICES,GMDA,,1606830572000,0.37272727272727285,0.37272727272727285,4.55,4.53,4.59,4.48,174120,4.55,4.53,4.59,4.48,174120,"Jul 21, 20",0,0
"July 21, 2020",PerkinElmer Releases New Dried Blood Spot Based COVID-19 Serology Test,"PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced the launch of a dry blood spot (DBS) based test for SARS-CoV-2 IgG using its GSP¬Æ/DELFIA¬Æ p...",111.59,112.96,110,110.47,PKI,1027098,HISTORICAL_PRICES,PKI,,1611195410000,0.4878666666666667,0.4878666666666667,110.47,111.59,112.96,110,1027098,110.3555,111.4744,112.843,109.886,1027098,"Jul 21, 20",1.7800000000000011,0.0162
"July 21, 2020",Ironwood Announces Updates Designed to Strengthen IW-3718 Phase III Program for Refractory Gastroesophageal Reflux Disease (GERD),"Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a leading GI-focused healthcare company, today announced that it has reached alignment with the U.S. Food and Drug Administration (FDA) on certain update...",9.86,10.84,9.7801,10.73,IRWD,3424865,HISTORICAL_PRICES,IRWD,,1606830572000,-0.03333333333333332,-0.03333333333333332,10.73,9.86,10.84,9.7801,3424865,10.73,9.86,10.84,9.7801,3424865,"Jul 21, 20",-0.7400000000000002,-0.0698
"July 21, 2020",Êñ∞Á†îÁ©∂ÁöÑÊâ©Â§ßËØÅÊçÆÊòæÁ§∫Masimo SET¬ÆËÑâÊêèÊ∞ßÈ•±ÂíåÂ∫¶‰ª™Á≠õÊü•Âç±ÈáçÂûãÂÖàÂ§©ÊÄßÂøÉËÑèÁóÖ(CCHD)ÁöÑÊî∂Áõä,(ÁæéÂõΩÂïÜ‰∏öËµÑËÆØ)--Masimo (NASDAQ: MASI)‰ªäÂ§©ÂèëÂ∏É„ÄäÂõΩÈôÖÊñ∞ÁîüÂÑøÁ≠õÊü•ÊùÇÂøó„Äã(International Journal of Neonatal Screening)ÂèëË°®ÁöÑ‰∏ÄÈ°πÂâçÁûªÊÄßÁ†îÁ©∂ÁªìÊûúÔºåËØ•Á†îÁ©∂‰∏≠ÔºåÊë©Ê¥õÂì•È©¨ÊãâÂñÄ‰ªÄÁöÑÁ†îÁ©∂‰∫∫ÂëòÂºÄÂ±ïÊë©Ê¥õÂì•È¶ñÊ¨°Masimo SET¬ÆËÑâÊêèÊ∞ßÈ•±ÂíåÂ∫¶‰ª™Á≠õÊü•Êñ∞ÁîüÂÑøÂç±ÈáçÂûãÂÖàÂ§©ÊÄßÂøÉËÑèÁóÖ(CCHD)ÁöÑÁ†îÁ©∂1„ÄÇ‰ΩúËÄÖÁöÑÁªìËÆ∫ÊòØÔºö‚ÄúÊàë‰ª¨ÁöÑÁªìÊûúÈºìÂä±Êàë‰ª¨Âú®Êñ∞ÁîüÂÑøÂ∏∏ËßÑÁ≠õÊü•Â∑•ÂÖ∑‰∏≠Ê∑ª...,245.25,248.875,240.6,247.96,MASI,613383,HISTORICAL_PRICES,MASI,,1606830572000,0.534634878918716,0.534634878918716,247.96,245.25,248.875,240.6,613383,247.96,245.25,248.875,240.6,613383,"Jul 21, 20",-1.5600000000000023,-0.0063
"July 21, 2020",Êñ∞Á†îÁ©∂ÁöÑÊì¥Â§ßË≠âÊìöÈ°ØÁ§∫Masimo SET¬ÆËÑàÊêèË°ÄÊ∞ßÈ£ΩÂíåÂ∫¶ÂÑÄÁØ©Ê™¢Âç±ÊÄ•ÂûãÂÖàÂ§©ÊÄßÂøÉËáüÁóÖ(CCHD)ÁöÑÊïàÁõä,(ÁæéÂúãÂïÜÊ•≠Ë≥áË®ä)--Masimo (NASDAQ: MASI)‰ªäÂ§©ÁôºÂ∏É„ÄäÂúãÈöõÊñ∞ÁîüÂÖíÁØ©Ê™¢ÈõúË™å„Äã(International Journal of Neonatal Screening)ÁôºË°®ÁöÑ‰∏ÄÈ†ÖÂâçÁûªÊÄßÁ†îÁ©∂ÁµêÊûúÔºåË©≤Á†îÁ©∂‰∏≠ÔºåÊë©Ê¥õÂì•È¶¨ÊãâÂñÄ‰ªÄÁöÑÁ†îÁ©∂‰∫∫Âì°Â±ïÈñãÊë©Ê¥õÂì•È¶ñÊ¨°Masimo SET¬ÆËÑàÊêèË°ÄÊ∞ßÈ£ΩÂíåÂ∫¶ÂÑÄÁØ©Ê™¢Êñ∞ÁîüÂÖíÂç±ÊÄ•ÂûãÂÖàÂ§©ÊÄßÂøÉËáüÁóÖ(CCHD)ÁöÑÁ†îÁ©∂1„ÄÇ‰ΩúËÄÖÁöÑÁµêË´ñÊòØÔºö„ÄåÊàëÂÄëÁöÑÁµêÊûúÈºìÂãµÊàëÂÄëÂú®Êñ∞ÁîüÂÖíÂ∏∏Ë¶èÁØ©Ê™¢Â∑•ÂÖ∑‰∏≠...,245.25,248.875,240.6,247.96,MASI,613383,HISTORICAL_PRICES,MASI,,1606830572000,0.534634878918716,0.534634878918716,247.96,245.25,248.875,240.6,613383,247.96,245.25,248.875,240.6,613383,"Jul 21, 20",-1.5600000000000023,-0.0063
"July 20, 2020",Un nuevo estudio ampl√≠a la evidencia que demuestra los beneficios de la prueba de detecci√≥n de cardiopat√≠as cong√©nitas cr√≠ticas (CCHD) con la oximetr√≠a de pulso Masimo SET¬Æ,"Masimo (NASDAQ: MASI) anunci√≥ hoy los resultados de un estudio prospectivo que se public√≥ en la International Journal of Neonatal Screening (Revista internacional de pruebas de detecci√≥n neonatales),...",246.81,247.42,234.55,234.55,MASI,821978,HISTORICAL_PRICES,MASI,,1606830572000,0.5443964708090858,0.5443964708090858,234.55,246.81,247.42,234.55,821978,234.55,246.81,247.42,234.55,821978,"Jul 20, 20",11.860000000000014,0.0505
"July 20, 2020",ACADIA Pharmaceuticals Announces U.S. FDA Accepted for Filing the Supplemental New Drug Application for NUPLAZID¬Æ (pimavanserin) for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis,ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its supplemental New Drug Application (sNDA) for NUPLAZID¬Æ (pimavans...,55.42,55.965,54.92,55.3,ACAD,956502,HISTORICAL_PRICES,ACAD,,1606830572000,0.4561219127693116,0.4561219127693116,55.3,55.42,55.965,54.92,956502,55.3,55.42,55.965,54.92,956502,"Jul 20, 20",0.45000000000000284,0.0082
"July 20, 2020",ACADIA Pharmaceuticals Announces Top-line Results from the Phase 3 CLARITY Study Evaluating Pimavanserin for the Adjunctive Treatment of Major Depressive Disorder,"ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from its 298 patient Phase 3 CLARITY study which combined two identical, double-blind, placebo-controlled studies evaluating...",55.42,55.965,54.92,55.3,ACAD,956502,HISTORICAL_PRICES,ACAD,,1606830572000,0.4561219127693116,0.4561219127693116,55.3,55.42,55.965,54.92,956502,55.3,55.42,55.965,54.92,956502,"Jul 20, 20",0.45000000000000284,0.0082
"July 20, 2020","Erkenntnisse aus neuer Studie geben weitere Hinweise auf die Vorteile des Screenings schwerer angeborener Herzfehler (Critical Congenital Heart Disease, CCHD) mit Masimo SET¬Æ Pulsoximetrie","Masimo (NASDAQ: MASI) ver√∂ffentlichte heute die Ergebnisse einer prospektiven Studie, die im International Journal of Neonatal Screening erschienen ist, in welcher Forscher in Marrakesch, Marokko, die...",246.81,247.42,234.55,234.55,MASI,821978,HISTORICAL_PRICES,MASI,,1606830572000,0.5443964708090858,0.5443964708090858,234.55,246.81,247.42,234.55,821978,234.55,246.81,247.42,234.55,821978,"Jul 20, 20",11.860000000000014,0.0505
"July 20, 2020",Positive Phase 3 Study Results for TRIKAFTA¬Æ (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People Ages 12 and Older With Cystic Fibrosis Who Have One Copy of the F508del Mutation and One Gating or Residual Function Mutation,Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results of a global Phase 3 study of TRIKAFTA¬Æ (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in people with cystic fibrosis (CF) a...,303.1,304,292.69,292.69,VRTX,1256143,HISTORICAL_PRICES,VRTX,,1606830572000,0.44271502689323633,0.44271502689323633,292.69,303.1,304,292.69,1256143,292.69,303.1,304,292.69,1256143,"Jul 20, 20",8.57000000000005,0.0291
"July 20, 2020","Tenax Therapeutics Expands Board of Directors with the Appointment of Two New Directors, Steven Boyd and Keith Maher, MD","Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high...",1.2,1.24,1.1,1.24,TENX,435237,HISTORICAL_PRICES,TENX,,1606830572000,1.2271714922049,1.2271714922049,1.24,1.2,1.24,1.1,435237,1.24,1.2,1.24,1.1,435237,"Jul 20, 20",-0.010000000000000009,-0.0083
"July 20, 2020","PolarityTE Announces Interim Data from Diabetic Foot Ulcer Trial will be Presented at Symposium on Advanced Wound Care to be Held July 24-26, 2020","PolarityTE, Inc. (Nasdaq: PTE) announced that data from a protocol-specified interim analysis of the first 50 patients enrolled in a multi-center randomized controlled trial (RCT) entitled ‚ÄúSkinTE‚Ñ¢ in...",1.85,2.04,1.5,1.51,PTE,9707624,HISTORICAL_PRICES,PTE,,1606830572000,0.5948275862068967,0.5948275862068967,1.51,1.85,2.04,1.5,9707624,1.51,1.85,2.04,1.5,9707624,"Jul 20, 20",0.40000000000000013,0.2759
"July 20, 2020",Orthofix Receives FDA Clearance and CE Mark for the JuniOrtho Plating System,"Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company focused on musculoskeletal healing products, today announced it has received the U.S. Food and Drug Administration (FDA) 510(k) cle...",31.17,32.52,31.055,31.73,OFIX,57734,HISTORICAL_PRICES,OFIX,,1606830572000,0.17136414881623457,0.17136414881623457,31.73,31.17,32.52,31.055,57734,31.73,31.17,32.52,31.055,57734,"Jul 20, 20",-0.7399999999999984,-0.0232
"July 17, 2020",Quidel‚Äôs Sofia¬Æ SARS Antigen FIA Updates EUA Performance Data to 96.7% PPA Versus PCR; Product Supports U.S. Initiatives to Expand Access to COVID-19 Testing in Nursing Homes; Receives CE Mark for Use With Sofia¬Æ and Sofia¬Æ 2 Instruments,"Quidel Corporation (NASDAQ: QDEL) (‚ÄúQuidel‚Äù), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has updated...",267,268.2099,243.56,244.29,QDEL,1102430,HISTORICAL_PRICES,QDEL,,1606830572000,2.308960218118726,2.308960218118726,244.29,267,268.2099,243.56,1102430,244.29,267,268.2099,243.56,1102430,"Jul 17, 20",24.27000000000001,0.1
"July 17, 2020",Frequency Therapeutics Announces $42 Million Private Placement,"Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body‚Äôs innate biology to repair or reverse damage caused by a broad range of degenerative...",21.53,22.217,20.89,21.38,FREQ,84172,HISTORICAL_PRICES,FREQ,,1606830572000,0.09846938775510201,0.09846938775510201,21.38,21.53,22.217,20.89,84172,21.38,21.53,22.217,20.89,84172,"Jul 17, 20",0.060000000000002274,0.0028
"July 17, 2020",Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4),"Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company‚Äôs 2017 Equity Incentive Plan in...",11.11,11.185,10.91,10.95,KALA,471032,HISTORICAL_PRICES,KALA,,1606830572000,0.5136239782016349,0.5136239782016349,10.95,11.11,11.185,10.91,471032,10.95,11.11,11.185,10.91,471032,"Jul 17, 20",0.1399999999999988,0.0128
"July 17, 2020",ADC Therapeutics gibt Dosierung des ersten Patienten im zulassungsrelevanten Phase-II-Teil der klinischen Studie LOTIS 3 von Loncastuximab-Tesirin (Lonca) in Kombination mit Ibrutinib bekannt,"ADC Therapeutics SA (NYSE: ADCT), ein im Bereich der sp√§ten klinischen Forschung t√§tiges Biotechnologieunternehmen mit Schwerpunkt auf Onkologie, das Vorreiter bei der Entwicklung und Vermarktung von...",49,50.34,46.75,48.01,ADCT,155218,HISTORICAL_PRICES,ADCT,,1606830572000,0.6526138279932547,0.6526138279932547,48.01,49,50.34,46.75,155218,48.01,49,50.34,46.75,155218,"Jul 17, 20",1.509999999999998,0.0318
"July 17, 2020",ADC Therapeutics annonce qu'un premier dosage a √©t√© d√©termin√© en phase II de l'essai clinique pivot LOTIS 3 du loncastuximab t√©sirine (Lonca) combin√© √† l'ibrutinib,"ADC Therapeutics SA (NYSE:ADCT), une soci√©t√© de biotechnologie sp√©cialis√©e dans l'oncologie au stade clinique avanc√©, pionni√®re du d√©veloppement et de la commercialisation de conjugu√©s anticorps-m√©dic...",49,50.34,46.75,48.01,ADCT,155218,HISTORICAL_PRICES,ADCT,,1606830572000,0.6526138279932547,0.6526138279932547,48.01,49,50.34,46.75,155218,48.01,49,50.34,46.75,155218,"Jul 17, 20",1.509999999999998,0.0318
"July 17, 2020","Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Verrica Pharmaceuticals, Inc. ‚Äì VRCA","Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Verrica Pharmaceuticals, Inc. (NASDAQ: VRCA) between Sept...",8.57,8.7,8.1959,8.22,VRCA,97470,HISTORICAL_PRICES,VRCA,,1606830572000,-0.2436010591350397,-0.2436010591350397,8.22,8.57,8.7,8.1959,97470,8.22,8.57,8.7,8.1959,97470,"Jul 17, 20",0.39000000000000057,0.0477
"July 17, 2020",Phibro Animal Health Corporation Reiterates Safety of Mecadox¬Æ,"(NASDAQ:PAHC) Today, the Food and Drug Administration (FDA) provided notice of Federal Register publication of its intention to take a number of actions related to its ongoing review of the regulatory...",25.43,26.3599,25.34,25.34,PAHC,85807,HISTORICAL_PRICES,PAHC,,1614687378000,0.4294547498594717,0.4294547498594717,25.34,25.43,26.3599,25.34,85807,24.9045,24.993,25.9069,24.9045,85807,"Jul 17, 20",-0.46000000000000085,-0.0178
"July 17, 2020",Ocular Therapeutix Presents at the 12th Annual Ophthalmology Innovation Summit (OIS),"Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, part...",8.845,9,8.52,8.56,OCUL,898507,HISTORICAL_PRICES,OCUL,,1606830572000,0.7619521912350601,0.7619521912350601,8.56,8.845,9,8.52,898507,8.56,8.845,9,8.52,898507,"Jul 17, 20",0.3150000000000013,0.0369
"July 17, 2020",ADC Therapeutics Announces First Patient Dosed in Pivotal Phase 2 Portion of LOTIS 3 Clinical Trial of Loncastuximab Tesirine (Lonca) in Combination With Ibrutinib,"ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (A...",49,50.34,46.75,48.01,ADCT,155218,HISTORICAL_PRICES,ADCT,,1606830572000,0.6526138279932547,0.6526138279932547,48.01,49,50.34,46.75,155218,48.01,49,50.34,46.75,155218,"Jul 17, 20",1.509999999999998,0.0318
"July 17, 2020",Applied DNA and Takis Report Positive Preclinical Results from LineaDNA‚Ñ¢ Vaccine Candidates for COVID-19,"Applied DNA Sciences Inc. (NASDAQ: APDN) (‚ÄúApplied DNA‚Äù or the ‚ÄúCompany‚Äù) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, pre-clinical nucleic ac...",10.73,14.84,10.07,13.05,APDN,22577999,HISTORICAL_PRICES,APDN,,1606830572000,1.6299019607843137,1.6299019607843137,13.05,10.73,14.84,10.07,22577999,13.05,10.73,14.84,10.07,22577999,"Jul 17, 20",1.7400000000000002,0.1935
"July 16, 2020",Puma Biotechnology Licensing Partner Specialised Therapeutics Receives Marketing Approval in Malaysia for NERLYNX¬Æ (neratinib) for Extended Adjuvant Treatment of Early Stage HER2-Positive Breast Cancer,"Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that its licensing partner Specialised Therapeutics Asia (STA) has received marketing approval of NERLYNX¬Æ (neratinib) i...",9.77,10.02,9.6,9.86,PBYI,536535,HISTORICAL_PRICES,PBYI,,1606830572000,0.05621621621621617,0.05621621621621617,9.86,9.77,10.02,9.6,536535,9.86,9.77,10.02,9.6,536535,"Jul 16, 20",-0.09999999999999964,-0.0101
"July 16, 2020",PhaseBio Doses First Patient in VANGARD Phase 2 Clinical Trial to Evaluate PB1046 for Hospitalized COVID-19 Patients,"PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announ...",4.7,4.92,4.63,4.78,PHAS,817170,HISTORICAL_PRICES,PHAS,,1606830572000,0.6319444444444445,0.6319444444444445,4.78,4.7,4.92,4.63,817170,4.78,4.7,4.92,4.63,817170,"Jul 16, 20",-0.16999999999999993,-0.0349
"July 16, 2020","Shareholder Alert: Robbins LLP Reminds Investors Chembio Diagnostics, Inc. (CEMI) Sued for Misleading Shareholders","Shareholder rights law firm Robbins LLP reminds investors that a purchaser of Chembio Diagnostics, Inc. (NASDAQ: CEMI) filed a class action complaint against the Company for alleged violations of the...",5.01,5.27,4.9,4.98,CEMI,4611848,HISTORICAL_PRICES,CEMI,,1606830572000,0.024539877300613522,0.024539877300613522,4.98,5.01,5.27,4.9,4611848,4.98,5.01,5.27,4.9,4611848,"Jul 16, 20",-0.08999999999999986,-0.0176
"July 16, 2020",Shareholder Alert: Robbins LLP Announces Verrica Pharmaceuticals Inc. (VRCA) Accused of Misleading Shareholders,Shareholder rights law firm Robbins LLP announces that a purchaser of Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) filed a class action complaint against the Company for alleged violations of the Secur...,8.18,8.5,7.97,8.39,VRCA,170928,HISTORICAL_PRICES,VRCA,,1606830572000,-0.2780229479258606,-0.2780229479258606,8.39,8.18,8.5,7.97,170928,8.39,8.18,8.5,7.97,170928,"Jul 16, 20",0.2599999999999998,0.0328
"July 16, 2020","Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Kirby Corporation (KEX) on Behalf of Investors","Glancy Prongay & Murray LLP (‚ÄúGPM‚Äù), a leading national shareholder rights law firm, continues its investigation on behalf of Kirby Corporation (‚ÄúKirby‚Äù or the ‚ÄúCompany‚Äù) (NYSE: KEX) investors con...",47.02,48.4,46.56,47.43,KEX,420817,HISTORICAL_PRICES,KEX,,1606830572000,0.13794772507260414,0.13794772507260414,47.43,47.02,48.4,46.56,420817,47.43,47.02,48.4,46.56,420817,"Jul 16, 20",-0.6699999999999946,-0.014
"July 16, 2020","VRCA Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Verrica Pharmaceuticals Inc. and Encourages Investors to Contact the Firm","Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Verrica Pharmaceuticals Inc. (‚ÄúVerrica‚Äù or ""the Company"") (NASDAQ: VRCA) and certain of its...",8.18,8.5,7.97,8.39,VRCA,170928,HISTORICAL_PRICES,VRCA,,1606830572000,-0.2780229479258606,-0.2780229479258606,8.39,8.18,8.5,7.97,170928,8.39,8.18,8.5,7.97,170928,"Jul 16, 20",0.2599999999999998,0.0328
"July 16, 2020",Samenvatting: FDA keurt gegevensstreaming vanuit de Impella-console goed en zet de toon voor kunstmatige intelligentie-algoritmen om de pati√´ntresultaten verder te verbeteren,"De Amerikaanse Food and Drug Administration (FDA) heeft eenzijdige digitale datastreaming goedgekeurd tijdens pati√´ntenondersteuning door Abiomed‚Äôs (NASDAQ: ABMD) Automated Impella Controller (AIC), d...",273.04,276.795,271.22,273.55,ABMD,176802,HISTORICAL_PRICES,ABMD,,1606830572000,0.8588059091837432,0.8588059091837432,273.55,273.04,276.795,271.22,176802,273.55,273.04,276.795,271.22,176802,"Jul 16, 20",-3.599999999999966,-0.013
"July 16, 2020",Turning Point Brands Completes Merger With Standard Diversified,"Turning Point Brands, Inc. (‚ÄúTPB‚Äù) (NYSE: TPB), a leading provider of Other Tobacco Products (‚ÄúOTP‚Äù) and adult consumer alternatives, and Standard Diversified Inc. (‚ÄúSDI‚Äù) (NYSE: SDI) announced today...",29.53,30.38,28.82,29.19,TPB,151481,HISTORICAL_PRICES,TPB,,1616033806000,0.35458715596330276,0.35458715596330276,29.19,29.53,30.38,28.82,151481,29.0784,29.4171,30.2639,28.7098,151481,"Jul 16, 20",0.40000000000000213,0.0137
"July 16, 2020",AngioDynamics Reports Fiscal 2020 Fourth Quarter and Full-Year Financial Results,"AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced financial resul...",9.455,10.44,9.01,10.26,ANGO,740239,HISTORICAL_PRICES,ANGO,,1606830572000,-0.014077163712200186,-0.014077163712200186,10.26,9.455,10.44,9.01,740239,10.26,9.455,10.44,9.01,740239,"Jul 16, 20",-1.2300000000000004,-0.1151
"July 16, 2020","FDA Approves Data Streaming from the Impella Console, Setting the Stage for Artificial Intelligence Algorithms to Further Improve Patient Outcomes","The United States Food and Drug Administration (FDA) has approved one-way digital data streaming during patient support from Abiomed's (NASDAQ: ABMD) Automated Impella Controller (AIC), the external c...",273.04,276.795,271.22,273.55,ABMD,176802,HISTORICAL_PRICES,ABMD,,1606830572000,0.8588059091837432,0.8588059091837432,273.55,273.04,276.795,271.22,176802,273.55,273.04,276.795,271.22,176802,"Jul 16, 20",-3.599999999999966,-0.013
"July 16, 2020",FDA Grants Priority Review to Merck‚Äôs New Drug Application for Vericiguat,"Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has accepted for priority review the New Drug Application (NDA) f...",79.4,79.81,78.75,79.78,MRK,5582878,HISTORICAL_PRICES,MRK,,1615519044000,0.16388155965992388,0.16388155965992388,79.78,79.4,79.81,78.75,5582878,77.8989,77.5279,77.9282,76.8932,5582878,"Jul 16, 20",-0.03999999999999204,-0.0005
"July 15, 2020",Tricida Provides Regulatory Update on Veverimer,"Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed...",26.2,26.62,25.91,26.19,TCDA,393151,HISTORICAL_PRICES,TCDA,,1606830572000,0.15215479331574322,0.15215479331574322,26.19,26.2,26.62,25.91,393151,26.19,26.2,26.62,25.91,393151,"Jul 15, 20",0.25,0.0096
"July 15, 2020",INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Verrica Pharmaceuticals Inc. (VRCA) Investors,"Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Verrica Pharmaceuticals Inc. (""Verrica"" or the ""Company"") (NASDAQ: VRCA) securi...",7.92,8.99,7.8,8.35,VRCA,292117,HISTORICAL_PRICES,VRCA,,1606830572000,-0.3009708737864078,-0.3009708737864078,8.35,7.92,8.99,7.8,292117,8.35,7.92,8.99,7.8,292117,"Jul 15, 20",-0.5500000000000007,-0.0649
"July 15, 2020",Varex to Showcase New X-Ray Components at ECR 2020 Virtual Exhibition,"Varex Imaging Corporation (Nasdaq: VREX) today announced that it will showcase its latest X-ray tubes and sources, digital detectors, connect and control devices, and software solutions at the 32nd an...",16.39,16.47,15.67,15.77,VREX,784096,HISTORICAL_PRICES,VREX,,1606830572000,-0.18009004502251116,-0.18009004502251116,15.77,16.39,16.47,15.67,784096,15.77,16.39,16.47,15.67,784096,"Jul 15, 20",1.0099999999999998,0.0657
"July 15, 2020",Henry Schein Announces Exclusive Distribution Agreement of Radic8 Air Purifier Systems in the U.S. and Canada,"Henry Schein (Nasdaq: HSIC) today announced that it has entered into an exclusive agreement with Radic8, a UK-based manufacturer of air purifier systems, to distribute their devices in the U.S. and Ca...",63.68,63.86,60.43,60.58,HSIC,1503089,HISTORICAL_PRICES,HSIC,,1606830572000,0.2728362982210673,0.2728362982210673,60.58,63.68,63.86,60.43,1503089,60.58,63.68,63.86,60.43,1503089,"Jul 15, 20",3.990000000000002,0.0668
"July 15, 2020",Catabasis Pharmaceuticals to Present at Parent Project Muscular Dystrophy Virtual Annual Conference,"Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today that it will present information on the edasalonexent program in Phase 3 development for the...",6.65,6.79,6.42,6.64,CATB,116896,HISTORICAL_PRICES,CATB,,1606830572000,0.6299019607843138,0.6299019607843138,6.64,6.65,6.79,6.42,116896,6.64,6.65,6.79,6.42,116896,"Jul 15, 20",0.1200000000000001,0.0184
"July 15, 2020",Ocular Therapeutix Announces Its First Published Physician Fee Schedule for Administration of Intracanalicular Inserts,"Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today...",8.37,8.52,7.8,7.8,OCUL,1219505,HISTORICAL_PRICES,OCUL,,1606830572000,0.6673306772908366,0.6673306772908366,7.8,8.37,8.52,7.8,1219505,7.8,8.37,8.52,7.8,1219505,"Jul 15, 20",0.8199999999999994,0.1086
"July 15, 2020",Applied DNA Appoints New Head of Investor Relations and Corporate Communications,"Applied DNA Sciences Inc. (NASDAQ: APDN) (‚ÄúApplied DNA‚Äù or the ‚ÄúCompany‚Äù) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, and pre-clinical nuclei...",8.03,8.0999,7.61,7.88,APDN,404865,HISTORICAL_PRICES,APDN,,1606830572000,0.9681372549019606,0.9681372549019606,7.88,8.03,8.0999,7.61,404865,7.88,8.03,8.0999,7.61,404865,"Jul 15, 20",0.21999999999999975,0.0282
"July 15, 2020","UnitedHealth Group Continues Efforts to Combat COVID-19, Reports Second Quarter Performance","During the second quarter of 2020, UnitedHealth Group (NYSE: UNH) expanded its COVID-19 response efforts, proactively supporting patients, customers, care providers and communities, including investin...",304.07,310.69,298.66,301.12,UNH,5116869,HISTORICAL_PRICES,UNH,,1615519136000,0.29672907160220047,0.29672907160220047,301.12,304.07,310.69,298.66,5116869,297.7514,300.6684,307.2143,295.3189,5116869,"Jul 15, 20",-4.449999999999989,-0.0144
"July 14, 2020",Moderna Announces Publication in The New England Journal of Medicine of Interim Results From Phase 1 Study of Its mRNA Vaccine Against COVID-19 (mRNA-1273),"Moderna, Inc., (Nasdaq:MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today...",75.04,76.9486,70.6201,74,MRNA,38708760,HISTORICAL_PRICES,MRNA,,1606830572000,1.7659417618872102,1.7659417618872102,74,75.04,76.9486,70.6201,38708760,74,75.04,76.9486,70.6201,38708760,"Jul 14, 20",3.260000000000005,0.0454
"July 14, 2020","Masimo to Report Second Quarter 2020 Financial Results after Market Close on Tuesday, July 28","Masimo (NASDAQ: MASI) will release second quarter 2020 financial results for the period ended June 27, 2020, after the market closes on Tuesday, July 28, 2020. The conference call to review the result...",224.35,224.58,215.24,220.04,MASI,368422,HISTORICAL_PRICES,MASI,,1606830572000,0.40385457731055624,0.40385457731055624,220.04,224.35,224.58,215.24,368422,220.04,224.35,224.58,215.24,368422,"Jul 14, 20",3.819999999999993,0.0173
"July 14, 2020",Masimo Announces UniView: 60‚Ñ¢ Digital Charting Solution,"Masimo (NASDAQ: MASI) today announced its latest automation and connectivity solution, UniView: 60‚Ñ¢. UniView: 60 uses the Masimo Hospital Automation‚Ñ¢ platform to aggregate and display pertinent patien...",224.35,224.58,215.24,220.04,MASI,368422,HISTORICAL_PRICES,MASI,,1606830572000,0.40385457731055624,0.40385457731055624,220.04,224.35,224.58,215.24,368422,220.04,224.35,224.58,215.24,368422,"Jul 14, 20",3.819999999999993,0.0173
"July 14, 2020",Nemaura Medical Evaluates New Applications for Continuous Lactate Monitoring Using its BEAT‚Ñ¢ Platform,"Nemaura Medical, Inc. (NASDAQ: NMRD) (‚ÄúNemaura‚Äù or the ‚ÄúCompany‚Äù), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing suga...",7.97,8.01,7.69,7.98,NMRD,19264,HISTORICAL_PRICES,NMRD,,1606830572000,0.34175084175084164,0.34175084175084164,7.98,7.97,8.01,7.69,19264,7.98,7.97,8.01,7.69,19264,"Jul 14, 20",-0.020000000000000462,-0.0025
"July 14, 2020",Deciphera Announces Australian Therapeutic Goods Administration‚Äôs Approval of QINLOCK‚Ñ¢ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor,"Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that the Australian Therapeutic Goods Administration (TGA) has approved QINLOCK‚Ñ¢ (ripretinib), a switch-control tyrosine kinase inhibitor,...",52.46,52.77,50.37,52.39,DCPH,363124,HISTORICAL_PRICES,DCPH,,1606830572000,0.2689888727624576,0.2689888727624576,52.39,52.46,52.77,50.37,363124,52.39,52.46,52.77,50.37,363124,"Jul 14, 20",0.23000000000000398,0.0044
"July 13, 2020",Invacare Corporation Announces Preliminary Financial Results for 2Q20 and Provides Business Update,"Invacare Corporation (‚ÄúInvacare‚Äù)(NYSE:IVC) will participate on Tuesday, July 14, 2020 in the 20th Annual CJS Securities New Ideas Summer Conference where the company's management will provide a busin...",6.33,6.62,6.1,6.25,IVC,519627,HISTORICAL_PRICES,IVC,,1606830572000,0.10471204188481668,0.10471204188481668,6.25,6.33,6.62,6.1,519627,6.25,6.33,6.62,6.1,519627,"Jul 13, 20",0.16999999999999993,0.0276
"July 13, 2020",Alnylam Announces that the United Kingdom‚Äôs MHRA Grants Early Access to Lumasiran,"Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the UK‚Äôs Medicines and Healthcare Products Regulatory Agency (MHRA) has granted lumasiran, an...",152.74,162.89,152.01,162.66,ALNY,667921,HISTORICAL_PRICES,ALNY,,1606830572000,0.5462644259971655,0.5462644259971655,162.66,152.74,162.89,152.01,667921,162.66,152.74,162.89,152.01,667921,"Jul 13, 20",-9.509999999999991,-0.0586
"July 13, 2020",Premier Inc. ProvideGx‚Ñ¢ Program Partners with Fresenius Kabi to Secure the Supply of Sedation Drug Essential for COVID-19 Care,"Premier Inc. (NASDAQ: PINC), through its ProvideGx‚Ñ¢ program, has partnered with Fresenius Kabi to supply Diprivan¬Æ (propofol) injectable emulsion, USP to healthcare providers, helping to stabilize the...",31.2,31.905,31.17,31.87,PINC,363181,HISTORICAL_PRICES,PINC,,1614385072000,0.10481586402266292,0.10481586402266292,31.87,31.2,31.905,31.17,363181,31.3328,30.6741,31.3672,30.6446,363181,"Jul 13, 20",-0.4800000000000004,-0.0152
"July 13, 2020",Pfizer and BioNTech Granted FDA Fast Track Designation for Two Investigational mRNA-based Vaccine Candidates Against SARS-CoV-2,"Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, ‚ÄúBioNTech‚Äù) today announced that two of the companies‚Äô four investigational vaccine candidates from their BNT162 mRNA-based vaccine program (BNT1...",35.21,35.72,34.52,34.73,PFE,53670893,HISTORICAL_PRICES,PFE,,1611800325000,0.1835294117647059,0.1835294117647059,34.73,35.21,35.72,34.52,53670893,33.6774,34.1428,34.6374,33.4737,53670893,"Jul 13, 20",1.3800000000000026,0.0408
"July 13, 2020",Axonics¬Æ Reports Preliminary Second Quarter 2020 Revenue,"Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of...",37.71,41.845,37.43,40.9,AXNX,1267809,HISTORICAL_PRICES,AXNX,,1606830572000,0.6902734199910355,0.6902734199910355,40.9,37.71,41.845,37.43,1267809,40.9,37.71,41.845,37.43,1267809,"Jul 13, 20",-1.6300000000000026,-0.0414
"July 10, 2020",Gilead Presents Additional Data on Investigational Antiviral Remdesivir for the Treatment of COVID-19,"Gilead Sciences, Inc. (Nasdaq: GILD) today announced additional data on remdesivir, an investigational antiviral for the treatment of COVID-19, adding to the available body of knowledge on treatment o...",76.32,76.85,75.52,76.1,GILD,9553834,HISTORICAL_PRICES,GILD,,1615518989000,0.09560723514211882,0.09560723514211882,76.1,76.32,76.85,75.52,9553834,73.63,73.8429,74.3557,73.0688,9553834,"Jul 10, 20",1.6099999999999994,0.0215
"July 10, 2020",Amneal Launches Generic Fluphenazine Following ANDA Approval by FDA,"Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (‚ÄúAmneal‚Äù or the ‚ÄúCompany‚Äù) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (...",4.65,4.72,4.3,4.31,AMRX,1536202,HISTORICAL_PRICES,AMRX,,1606830572000,0.332378223495702,0.332378223495702,4.31,4.65,4.72,4.3,1536202,4.31,4.65,4.72,4.3,1536202,"Jul 10, 20",0.29000000000000004,0.0665
"July 9, 2020",Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4),"Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on July 8, 2020 the Compensation Committee of Puma‚Äôs Board of Directors approved the grant of inducement restricted...",10.24,10.41,9.97,10.2,PBYI,1212123,HISTORICAL_PRICES,PBYI,,1606830572000,0.10702702702702704,0.10702702702702704,10.2,10.24,10.41,9.97,1212123,10.2,10.24,10.41,9.97,1212123,"Jul 9, 20",0.009999999999999787,0.001
"July 9, 2020",Shareholder Alert: Robbins LLP Reminds Investors Co-Diagnostics Inc. (CODX) Sued for Misleading Shareholders,Shareholder rights law firm Robbins LLP reminds investors that a purchaser of Co-Diagnostics Inc. (NASDAQ: CODX) filed a class action complaint against the Company for alleged violations of the Securi...,18.01,19,17.56,18.82,CODX,2182945,HISTORICAL_PRICES,CODX,,1606830572000,1.0100446428571428,1.0100446428571428,18.82,18.01,19,17.56,2182945,18.82,18.01,19,17.56,2182945,"Jul 9, 20",-0.9599999999999973,-0.0506
"July 9, 2020",Shareholder Alert: Robbins LLP Is Investigating the Officers and Directors of Acer Therapeutics Inc. (ACER),"Shareholder rights law firm Robbins LLP announces that it is investigating the officers and directors of Acer Therapeutics Inc. (NYSE: ACER) for breaches of fiduciary duty, waste of corporate assets,...",3.63,3.78,3.33,3.75,ACER,871029,HISTORICAL_PRICES,ACER,,1606830572000,0.8426395939086294,0.8426395939086294,3.75,3.63,3.78,3.33,871029,3.75,3.63,3.78,3.33,871029,"Jul 9, 20",0.4099999999999997,0.1273
"July 9, 2020",CMS Establishes Unique J-Code for Eagle Pharmaceuticals‚Äô PEMFEXY‚Ñ¢ (Pemetrexed for Injection),"Eagle Pharmaceuticals, Inc. (‚ÄúEagle‚Äù or the ‚ÄúCompany‚Äù) (NASDAQ: EGRX) today announced that the Centers for Medicare & Medicaid Services (CMS) has established a unique, product-specific billing cod...",47.22,47.85,45.04,46.37,EGRX,153446,HISTORICAL_PRICES,EGRX,,1606830572000,0.13892908827785813,0.13892908827785813,46.37,47.22,47.85,45.04,153446,46.37,47.22,47.85,45.04,153446,"Jul 9, 20",0.8699999999999974,0.0188
"July 9, 2020",The Law Offices of Frank R. Cruz Continues Its Investigation of Verrica Pharmaceuticals Inc. (VRCA) on Behalf of Investors,"The Law Offices of Frank R. Cruz continues its investigation on behalf of Verrica Pharmaceuticals Inc. (""Verrica"" or the ""Company"") (NASDAQ: VRCA) investors concerning the Company and its officers‚Äô po...",8.76,9.0666,8.2924,8.9,VRCA,154351,HISTORICAL_PRICES,VRCA,,1606830572000,-0.2268314210061783,-0.2268314210061783,8.9,8.76,9.0666,8.2924,154351,8.9,8.76,9.0666,8.2924,154351,"Jul 9, 20",-0.040000000000000924,-0.0045
"July 9, 2020",Baxter Announces U.S. FDA Clearance of Altapore Shape Bioactive Bone Graft for Use in Surgery,"Baxter International Inc. (NYSE:BAX), a global leader in advancing surgical innovation, today announced U.S. Food and Drug Administration (FDA) clearance of Altapore Shape Bioactive Bone Graft, the la...",85.69,86.01,84.2,84.2,BAX,2445834,HISTORICAL_PRICES,BAX,,1614219404000,0.1647410629332609,0.1647410629332609,84.2,85.69,86.01,84.2,2445834,83.4303,84.9067,85.2237,83.4303,2445834,"Jul 9, 20",1.509999999999991,0.0179
"July 9, 2020","Centers for Medicare & Medicaid Services (CMS) Issues Permanent J-Code for TEPEZZA¬Æ (teprotumumab-trbw) Effective Oct. 1, 2020","Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the U.S. Centers for Medicare and Medicaid Services (CMS) has assigned a permanent, product-specific Healthcare Common Procedure Coding Sys...",58,59.21,56.89,59.02,HZNP,1905287,HISTORICAL_PRICES,HZNP,,1606830572000,1.0523708421797593,1.0523708421797593,59.02,58,59.21,56.89,1905287,59.02,58,59.21,56.89,1905287,"Jul 9, 20",-0.759999999999998,-0.0129
"July 9, 2020","Enanta Pharmaceuticals Announces Clinical Trial Progress for EDP-514, its Lead Core Inhibitor for Hepatitis B Virus","Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced advancements in...",51.1,51.99,49.99,49.99,ENTA,156408,HISTORICAL_PRICES,ENTA,,1606830572000,0.09586103366931158,0.09586103366931158,49.99,51.1,51.99,49.99,156408,49.99,51.1,51.99,49.99,156408,"Jul 9, 20",0.7800000000000011,0.0155
"July 9, 2020",FDA Grants Priority Review to Merck‚Äôs Supplemental Biologics License Application for KEYTRUDA¬Æ (pembrolizumab) for Second-Line Treatment of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma,"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review for a new supplemental B...",76.69,78.35,76.04,77.94,MRK,7601213,HISTORICAL_PRICES,MRK,,1615519019000,0.124157138669012,0.124157138669012,77.94,76.69,78.35,76.04,7601213,76.1023,74.8818,76.5027,74.2471,7601213,"Jul 9, 20",-1.230000000000004,-0.0158
"July 9, 2020",Applied DNA Forms Clinical Testing Subsidiary to Maximize Utility of FDA EUA-Approved Linea‚Ñ¢ COVID-19 Assay Kit and Expands Utility with Successful EUA Amendment,"Applied DNA Sciences Inc. (NASDAQ: APDN) (‚ÄúApplied DNA‚Äù or the ‚ÄúCompany‚Äù) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, and pre-clinical nuclei...",8.135,8.71,7.82,8.6,APDN,1318856,HISTORICAL_PRICES,APDN,,1606830572000,0.9938725490196078,0.9938725490196078,8.6,8.135,8.71,7.82,1318856,8.6,8.135,8.71,7.82,1318856,"Jul 9, 20",0.11500000000000021,0.0143
"July 8, 2020",Turning Point Brands Announces Pricing of Secondary Offering of Two Million Shares of Common Stock by its Significant Stockholders,"Turning Point Brands, Inc. (‚ÄúTPB‚Äù or the ‚ÄúCompany‚Äù) (NYSE: TPB) today announced the pricing of the previously announced underwritten public offering of 1,800,000 shares of Company common stock by Stan...",26.46,26.58,24.85,24.99,TPB,228686,HISTORICAL_PRICES,TPB,,1616033797000,0.21376146788990827,0.21376146788990827,24.99,26.46,26.58,24.85,228686,24.8945,26.3589,26.4784,24.755,228686,"Jul 8, 20",2.039999999999999,0.0835
"July 8, 2020", Turning Point Brands Announces Preliminary Second Quarter 2020 Results,"Turning Point Brands, Inc. (‚ÄúTPB‚Äù or the ‚ÄúCompany‚Äù) (NYSE: TPB), a leading provider of Other Tobacco Products (‚ÄúOTP‚Äù) and adult consumer alternatives, today announced preliminary sales results for the...",26.46,26.58,24.85,24.99,TPB,228686,HISTORICAL_PRICES,TPB,,1616033797000,0.21376146788990827,0.21376146788990827,24.99,26.46,26.58,24.85,228686,24.8945,26.3589,26.4784,24.755,228686,"Jul 8, 20",2.039999999999999,0.0835
"July 8, 2020",Turning Point Brands Announces Proposed Secondary Offering of Two Million Shares of Common Stock by its Significant Stockholders,"Turning Point Brands, Inc. (‚ÄúTPB‚Äù or the ‚ÄúCompany‚Äù) (NYSE: TPB), a leading provider of Other Tobacco Products and adult consumer alternatives, today announced the proposed underwritten public offering...",26.46,26.58,24.85,24.99,TPB,228686,HISTORICAL_PRICES,TPB,,1616033797000,0.21376146788990827,0.21376146788990827,24.99,26.46,26.58,24.85,228686,24.8945,26.3589,26.4784,24.755,228686,"Jul 8, 20",2.039999999999999,0.0835
"July 8, 2020",Moderna Completes Enrollment of Phase 2 Study of its mRNA Vaccine Against COVID-19 (mRNA-1273),"Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, toda...",61.58,62.46,59.45,60.79,MRNA,7590861,HISTORICAL_PRICES,MRNA,,1606830572000,1.2698120162182087,1.2698120162182087,60.79,61.58,62.46,59.45,7590861,60.79,61.58,62.46,59.45,7590861,"Jul 8, 20",0.4899999999999949,0.008
"July 8, 2020",Novocure Announces Over 100 Physicians in the U.S. Now Certified to Prescribe Optune Lua‚Ñ¢,"Novocure (NASDAQ: NVCR) today announced that over 100 physicians from more than 50 cancer treatment centers in the U.S. are now certified to prescribe Optune Lua, which is approved for the first-line...",60.97,61.1,59.37,59.37,NVCR,856364,HISTORICAL_PRICES,NVCR,,1606830572000,-0.021819348628268884,-0.021819348628268884,59.37,60.97,61.1,59.37,856364,59.37,60.97,61.1,59.37,856364,"Jul 8, 20",1.3900000000000006,0.0233
"July 8, 2020",Concert Pharmaceuticals Receives FDA Breakthrough Therapy Designation for CTP-543 for the Treatment of Alopecia Areata,"Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for the Company‚Äôs oral Janus kinase inhibitor, CT...",10.56,11.63,10.19,11.25,CNCE,420699,HISTORICAL_PRICES,CNCE,,1606830572000,0.20410490307867743,0.20410490307867743,11.25,10.56,11.63,10.19,420699,11.25,10.56,11.63,10.19,420699,"Jul 8, 20",0.5700000000000003,0.0571
"July 8, 2020",LYNPARZA¬Æ (olaparib) Approved in the EU for Germline BRCA-mutated Metastatic Pancreatic Cancer,"AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that LYNPARZA has been approved in the European Union (EU) as a monotherapy for the maintenance tr...",77.92,78.9642,77.48,78.63,MRK,7831109,HISTORICAL_PRICES,MRK,,1615519169000,0.14218704192318973,0.14218704192318973,78.63,77.92,78.9642,77.48,7831109,76.776,76.0828,77.1024,75.6532,7831109,"Jul 8, 20",-0.7999999999999972,-0.0102
"July 8, 2020",Merck and Eisai Receive Complete Response Letter for KEYTRUDA¬Æ (pembrolizumab) plus LENVIMA¬Æ (lenvatinib) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma,"Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding M...",77.92,78.9642,77.48,78.63,MRK,7831109,HISTORICAL_PRICES,MRK,,1615519169000,0.14218704192318973,0.14218704192318973,78.63,77.92,78.9642,77.48,7831109,76.776,76.0828,77.1024,75.6532,7831109,"Jul 8, 20",-0.7999999999999972,-0.0102
"July 8, 2020",Gilead Sciences Presents Survey Findings on PrEP Access and Utilization in the U.S. During COVID-19 Shelter-in-Place Orders,"Gilead Sciences, Inc. (Nasdaq: GILD) today announced data presented at the 23rd International AIDS Conference (AIDS 2020: Virtual) evaluating the impact of COVID-19 shelter-in-place orders (SIPOs) and...",75.61,77,74.93,76.7,GILD,6293450,HISTORICAL_PRICES,GILD,,1615518968000,0.0854148722365777,0.0854148722365777,76.7,75.61,77,74.93,6293450,74.2105,73.1559,74.5008,72.498,6293450,"Jul 8, 20",-0.8100000000000023,-0.0106
"July 7, 2020",INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Verrica Pharmaceuticals Inc. (VRCA) on Behalf of Investors,"Law Offices of Howard G. Smith continues its investigation on behalf of Verrica Pharmaceuticals Inc. (""Verrica"" or the ""Company"") (NASDAQ: VRCA) investors concerning the Company and its officers‚Äô poss...",9.66,10.397,9.01,10.1,VRCA,179027,HISTORICAL_PRICES,VRCA,,1606830572000,-0.147396293027361,-0.147396293027361,10.1,9.66,10.397,9.01,179027,10.1,9.66,10.397,9.01,179027,"Jul 7, 20",-0.33999999999999986,-0.034
"July 7, 2020",FDA Authorizes Marketing of the IQOS Tobacco Heating System as a Modified Risk Tobacco Product,"Altria Group, Inc. (Altria) (NYSE: MO) announces today that the U.S. Food and Drug Administration (FDA) authorized the marketing of the IQOS tobacco heating system as a modified risk tobacco product w...",39.94,40.24,39.12,39.19,MO,8659898,HISTORICAL_PRICES,MO,,1616552281000,0.16205993599068957,0.16205993599068957,39.19,39.94,40.24,39.12,8659898,37.0052,37.7134,37.9966,36.9391,8659898,"Jul 7, 20",0.3399999999999963,0.0086
"July 7, 2020",Á†îÁ©∂Ë™øÊü•ËÑàÊêèË°ÄÊ∞ßÈ£ΩÂíåÂ∫¶ÂÑÄ‰ΩøÁî®Masimo RRp¬ÆËÆÄÂèñÂÖíÁßëÊÇ£ËÄÖÂëºÂê∏ÁéáÁöÑÁ≤æÂ∫¶,(ÁæéÂúãÂïÜÊ•≠Ë≥áË®ä)--Masimo (NASDAQ: MASI)‰ªäÂ§©ÁôºÂ∏É„ÄäËÇ∫ÁÇé„Äã(Pneumonia)ÈõúË™åÁôºË°®ÁöÑ‰∏ÄÈ†ÖÁ†îÁ©∂ÁµêÊûúÔºåË©≤Á†îÁ©∂‰∏≠ÔºåÂç∞Â∫¶Êñ∞Âæ∑ÈáåÁöÑÁç®Á´ãÁ†îÁ©∂‰∫∫Âì°Ë™øÊü•Rad-G‚Ñ¢ËÑàÊêèË°ÄÊ∞ßÈ£ΩÂíåÂ∫¶ÂÑÄÊê≠ÈÖçMasimo RRp¬ÆÂú®ÂÖíÁßëÊÇ£ËÄÖ‰∏≠ÁöÑÁ≤æÂ∫¶Ôºå‰∏¶ÂèäÈñòÊÄ•Ë®∫Êî∂‰ΩèÊÇ£ÂÖíÂ±ïÈñãÂ∏∏Ë¶èË©ï‰º∞ÊôÇËá®Â∫äÂ∑•‰ΩúËÄÖÁ¢∫ÂÆöÁöÑÊï∏ÂÄºÈÄ≤Ë°åÊØîËºÉ1„ÄÇRRpÊèê‰æõÁöÑÂëºÂê∏ÁéáÁî±ËÑàÊêèË°ÄÊ∞ßÈ£ΩÂíåÂ∫¶ÂÑÄ‰∏≠‰ΩøÁî®ÁöÑÈ´îÁ©çÊèèË®òÊ≥ïÁ¢∫ÂÆö„ÄÇ AlwadhiÂçöÂ£´ÂèäÂÖ∂Âêå‰∫ãÊåáÂá∫Ôºå‰∏ñÁïåË®±...,233.89,241.14,233.69,234.34,MASI,586023,HISTORICAL_PRICES,MASI,,1606830572000,0.463550466178587,0.463550466178587,234.34,233.89,241.14,233.69,586023,234.34,233.89,241.14,233.69,586023,"Jul 7, 20",-0.710000000000008,-0.003
"July 7, 2020",Á†îÁ©∂Ë∞ÉÊü•ËÑâÊêèË°ÄÊ∞ßÈ•±ÂíåÂ∫¶‰ª™‰ΩøÁî®Masimo RRp¬ÆËØªÂèñÂÑøÁßëÊÇ£ËÄÖÂëºÂê∏ÁéáÁöÑÁ≤æÂ∫¶,(ÁæéÂõΩÂïÜ‰∏öËµÑËÆØ)--Masimo (NASDAQ: MASI)‰ªäÂ§©ÂèëÂ∏É„ÄäËÇ∫ÁÇé„Äã(Pneumonia)ÊùÇÂøóÂèëË°®ÁöÑ‰∏ÄÈ°πÁ†îÁ©∂ÁªìÊûúÔºåËØ•Á†îÁ©∂‰∏≠ÔºåÂç∞Â∫¶Êñ∞Âæ∑ÈáåÁöÑÁã¨Á´ãÁ†îÁ©∂‰∫∫ÂëòË∞ÉÊü•Rad-G‚Ñ¢ËÑâÊêèË°ÄÊ∞ßÈ•±ÂíåÂ∫¶‰ª™Êê≠ÈÖçMasimo RRp¬ÆÂú®ÂÑøÁßëÊÇ£ËÄÖ‰∏≠ÁöÑÁ≤æÂ∫¶ÔºåÂπ∂‰∏éÈó®ÊÄ•ËØäÊî∂‰ΩèÊÇ£ÂÑøÂºÄÂ±ïÂ∏∏ËßÑËØÑ‰º∞Êó∂‰∏¥Â∫äÂ∑•‰ΩúËÄÖÁ°ÆÂÆöÁöÑÊï∞ÂÄºËøõË°åÊØîËæÉ1„ÄÇRRpÊèê‰æõÁöÑÂëºÂê∏ÁéáÁî±ËÑâÊêèË°ÄÊ∞ßÈ•±ÂíåÂ∫¶‰ª™‰∏≠‰ΩøÁî®ÁöÑ‰ΩìÁßØÊèèËÆ∞Ê≥ïÁ°ÆÂÆö„ÄÇ AlwadhiÂçöÂ£´ÂèäÂÖ∂Âêå‰∫ãÊåáÂá∫Ôºå‰∏ñÁïåËÆ∏...,233.89,241.14,233.69,234.34,MASI,586023,HISTORICAL_PRICES,MASI,,1606830572000,0.463550466178587,0.463550466178587,234.34,233.89,241.14,233.69,586023,234.34,233.89,241.14,233.69,586023,"Jul 7, 20",-0.710000000000008,-0.003
"July 7, 2020","Gap Inc. Launches B2B Sales for Organizations to Purchase Reusable, Non-Medical Grade Cloth Face Masks","Gap Inc. (NYSE: GPS) today announced it has launched a B2B product program focused on offering large organizations high-quality reusable, non-medical grade cloth face masks* to supply to their employe...",11.97,12.34,11.82,12.29,GPS,16663616,HISTORICAL_PRICES,GPS,,1606830572000,0.33296213808463254,0.33296213808463254,12.29,11.97,12.34,11.82,16663616,12.29,11.97,12.34,11.82,16663616,"Jul 7, 20",-0.5399999999999991,-0.0432
"July 7, 2020",Cerus Corporation Reports Successful Inactivation of SARS-CoV-2 with the INTERCEPT Blood System for Plasma,"Cerus Corporation (Nasdaq:CERS) announced today study results demonstrating that the INTERCEPT Blood System inactivates SARS-CoV-2, the causative agent for COVID-19, in plasma components intended for...",7.12,7.49,6.94,7.21,CERS,4458317,HISTORICAL_PRICES,CERS,,1606830572000,0.7623762376237624,0.7623762376237624,7.21,7.12,7.49,6.94,4458317,7.21,7.12,7.49,6.94,4458317,"Jul 7, 20",0.2599999999999998,0.0379
"July 7, 2020",AtriCure to Announce Second Quarter 2020 Financial Results,"AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its second quarter 2020...",43.25,47.385,43.075,45.73,ATRC,358009,HISTORICAL_PRICES,ATRC,,1606830572000,0.4690896739130434,0.4690896739130434,45.73,43.25,47.385,43.075,358009,45.73,43.25,47.385,43.075,358009,"Jul 7, 20",-2.950000000000003,-0.0639
"July 7, 2020",Aldeyra Therapeutics Announces New Drug Application (NDA) Development Plans for Dry Eye Disease,"Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immun...",4.33,4.6,4.21,4.6,ALDX,1877848,HISTORICAL_PRICES,ALDX,,1606830572000,1.1868686868686869,1.1868686868686869,4.6,4.33,4.6,4.21,1877848,4.6,4.33,4.6,4.21,1877848,"Jul 7, 20",0.33000000000000007,0.0825
"July 7, 2020",LabCorp Launches First Digital COVID-19 Service That Improves the Doctor and Patient Experience,"LabCorp (NYSE: LH) today launched the LabCorp At Home COVID-19 Test Collection Service, the first seamless digital service aimed at helping doctors protect patients by testing them for COVID-19 before...",173.12,174.51,171.745,171.87,LH,991966,HISTORICAL_PRICES,LH,,1606830572000,0.4095424198013354,0.4095424198013354,171.87,173.12,174.51,171.745,991966,171.87,173.12,174.51,171.745,991966,"Jul 7, 20",0.5300000000000011,0.0031
"July 7, 2020","Whole Earth Brands, Inc. Launches New Whole Earth¬Æ Allulose Baking Blends and Provides Update on Brand Growth","Whole Earth Brands, Inc. (Nasdaq: FREE), Just in time for the fall baking season, Whole Earth Brands, Inc. is launching new Whole Earth¬Æ Allulose Baking Blends. The launch is the latest for Whole Eart...",7.06,7.63,7.06,7.47,FREE,1370097,HISTORICAL_PRICES,FREE,,1606830572000,-0.28614762386248743,-0.28614762386248743,7.47,7.06,7.63,7.06,1370097,7.47,7.06,7.63,7.06,1370097,"Jul 7, 20",-0.3600000000000003,-0.0485
"July 7, 2020",Nemaura Medical Submits PMA Application for sugarBEAT¬Æ to U.S. FDA,"Nemaura Medical, Inc. (NASDAQ: NMRD) (‚ÄúNemaura‚Äù or the ‚ÄúCompany‚Äù), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing suga...",7.82,9.24,7.8,8.4,NMRD,36882,HISTORICAL_PRICES,NMRD,,1606830572000,0.31649831649831645,0.31649831649831645,8.4,7.82,9.24,7.8,36882,8.4,7.82,9.24,7.8,36882,"Jul 7, 20",-0.29999999999999893,-0.0369
"July 7, 2020",Estudo investiga a precis√£o da frequ√™ncia respirat√≥ria obtida pela oximetria de pulso em pacientes pedi√°tricos que usam RRp¬Æ da Masimo,"Masimo (NASDAQ: MASI) anunciou hoje os resultados de um estudo publicado na Pneumonia no qual pesquisadores independentes em Nova Delhi, √çndia, investigaram a precis√£o do RRp¬Æ da Masimo em pacientes p...",233.89,241.14,233.69,234.34,MASI,586023,HISTORICAL_PRICES,MASI,,1606830572000,0.463550466178587,0.463550466178587,234.34,233.89,241.14,233.69,586023,234.34,233.89,241.14,233.69,586023,"Jul 7, 20",-0.710000000000008,-0.003
"July 7, 2020",Studie zur Genauigkeit der durch Pulsoximetrie mit Hilfe von RRp¬Æ gemessenen Atemfrequenz an p√§diatrischen Patienten,"Masimo (NASDAQ: MASI) gab heute die Ergebnisse einer in Pneumonia ver√∂ffentlichten Studie bekannte, bei der unabh√§ngige Forscher in Neu-Delhi, Indien, die Genauigkeit von Masimo RRp¬Æ an p√§diatrischen...",233.89,241.14,233.69,234.34,MASI,586023,HISTORICAL_PRICES,MASI,,1606830572000,0.463550466178587,0.463550466178587,234.34,233.89,241.14,233.69,586023,234.34,233.89,241.14,233.69,586023,"Jul 7, 20",-0.710000000000008,-0.003
"July 6, 2020",Un estudio investiga la precisi√≥n de la frecuencia respiratoria obtenida de la oximetr√≠a de pulso en pacientes pedi√°tricos que usan Masimo RRp¬Æ,"Masimo (NASDAQ: MASI) anunci√≥ hoy los resultados de un estudio publicado en Pneumonia, donde investigadores independientes de Nueva Delhi, India, investigaron la precisi√≥n de Masimo RRp¬Æ en pacientes...",234.6,238.02,233,233.69,MASI,505293,HISTORICAL_PRICES,MASI,,1606830572000,0.4679932419748451,0.4679932419748451,233.69,234.6,238.02,233,505293,233.69,234.6,238.02,233,505293,"Jul 6, 20",2.8799999999999955,0.0124
"July 6, 2020",Shareholder Alert: Robbins LLP Announces It Is Investigating the Officers and Directors of Verrica Pharmaceuticals Inc. (VRCA) on Behalf of Shareholders,Shareholder rights law firm Robbins LLP announces it is investigating whether certain officers and directors of Verrica Pharmaceuticals Inc. (NYSE: VRCA) violated federal securities laws. Verrica is a...,10,10.6599,10,10.6,VRCA,72134,HISTORICAL_PRICES,VRCA,,1606830572000,-0.11738746690203002,-0.11738746690203002,10.6,10,10.6599,10,72134,10.6,10,10.6599,10,72134,"Jul 6, 20",-0.3000000000000007,-0.0291
"July 6, 2020",Quidel Announces Preliminary Revenue for Second Quarter 2020,"Quidel Corporation (NASDAQ: QDEL) (‚ÄúQuidel‚Äù), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it expects revenue...",235.57,236.7599,226.8,227.5,QDEL,1145150,HISTORICAL_PRICES,QDEL,,1606830572000,1.9194447886974841,1.9194447886974841,227.5,235.57,236.7599,226.8,1145150,227.5,235.57,236.7599,226.8,1145150,"Jul 6, 20",8.530000000000001,0.0376
"July 6, 2020",ADC Therapeutics annonce que l'Agence am√©ricaine des produits alimentaires et m√©dicamenteux a lev√© la suspension clinique partielle dont faisait l‚Äôobjet l‚Äô√©tude clinique pivot de Phase 2 sur le camidanlumab t√©sirine,"ADC Therapeutics SA (NYSE:ADCT), une soci√©t√© de biotechnologie sp√©cialis√©e dans l‚Äôoncologie au stade clinique avanc√©, pionni√®re du d√©veloppement et de la mise sur le march√© de conjugu√©s anticorps-m√©di...",48.93,53.61,48.17,52.22,ADCT,113984,HISTORICAL_PRICES,ADCT,,1606830572000,0.6502529510961215,0.6502529510961215,52.22,48.93,53.61,48.17,113984,52.22,48.93,53.61,48.17,113984,"Jul 6, 20",-2.1199999999999974,-0.0415
"July 6, 2020",ADC Therapeutics meldet Aufhebung der teilweisen Unterbrechung der zulassungsrelevanten klinischen Phase-2-Studie mit Camidanlumab-Tesirin durch die US-Zulassungsbeh√∂rde FDA,"ADC Therapeutics SA (NYSE:ADCT), ein in der klinischen Forschung t√§tiges Biotechnologieunternehmen mit Schwerpunkt auf Onkologie und Vorreiter in der Entwicklung und Vermarktung von Antik√∂rper-Wirksto...",48.93,53.61,48.17,52.22,ADCT,113984,HISTORICAL_PRICES,ADCT,,1606830572000,0.6502529510961215,0.6502529510961215,52.22,48.93,53.61,48.17,113984,52.22,48.93,53.61,48.17,113984,"Jul 6, 20",-2.1199999999999974,-0.0415
"July 6, 2020","Notice of Lead Plaintiff Deadline for Shareholders in the Co-Diagnostics, Inc. Class Action Lawsuit","Robbins Geller Rudman & Dowd LLP announces that a class action lawsuit has been filed in the District of Utah on behalf of purchasers of Co-Diagnostics, Inc. (NASDAQ:CODX) securities between Febru...",18.07,19.22,18,19.1,CODX,2332529,HISTORICAL_PRICES,CODX,,1606830572000,1.0167410714285712,1.0167410714285712,19.1,18.07,19.22,18,2332529,19.1,18.07,19.22,18,2332529,"Jul 6, 20",-0.8200000000000003,-0.0434
"July 6, 2020",ADC Therapeutics Announces U.S. Food and Drug Administration Has Lifted Partial Clinical Hold on Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine,"ADC Therapeutics SA (NYSE:ADCT), a clinical-stage oncology-focused biotechnology company leading the development and commercialization of next-generation antibody drug conjugates (ADCs) with highly po...",48.93,53.61,48.17,52.22,ADCT,113984,HISTORICAL_PRICES,ADCT,,1606830572000,0.6502529510961215,0.6502529510961215,52.22,48.93,53.61,48.17,113984,52.22,48.93,53.61,48.17,113984,"Jul 6, 20",-2.1199999999999974,-0.0415
"July 6, 2020",Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),"Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, today announced the...",1.61,1.7,1.58,1.69,VSTM,5759824,HISTORICAL_PRICES,VSTM,,1606830572000,-0.29385964912280693,-0.29385964912280693,1.69,1.61,1.7,1.58,5759824,1.69,1.61,1.7,1.58,5759824,"Jul 6, 20",-0.05999999999999983,-0.0359
"July 2, 2020",Deciphera Announces Presentation of Analysis of Crossover Population from the INVICTUS Phase 3 Study of QINLOCK‚Ñ¢ (ripretinib) in Patients with Fourth-Line Advanced GIST,"Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the presentation of new data from an exploratory analysis of progression-free survival (PFS) and overall survival (OS) for patients who cr...",56.71,58.64,55.42,58.6,DCPH,327329,HISTORICAL_PRICES,DCPH,,1606830572000,0.3717948717948717,0.3717948717948717,58.6,56.71,58.64,55.42,327329,58.6,56.71,58.64,55.42,327329,"Jul 2, 20",-1.4499999999999957,-0.0249
"July 2, 2020",HanesBrands Introduces Consumer Face Masks and Completes Production of Cloth Face Coverings for U.S. Government,HanesBrands (NYSE:HBI) has completed production and distribution of more than 450 million all-cotton cloth face coverings and more than 20 million medical gowns supplied to the U.S. government for use...,11.46,11.88,11.33,11.37,HBI,7614406,HISTORICAL_PRICES,HBI,,1613621930000,0.28475336322869965,0.28475336322869965,11.37,11.46,11.88,11.33,7614406,11.0318,11.1191,11.5266,10.993,7614406,"Jul 2, 20",0.40000000000000036,0.0362
"July 2, 2020",Alexion Completes Acquisition of Portola,"Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the successful completion of its acquisition of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). The acquisition adds Factor Xa inhibitor revers...",112.3,114.49,111.72,114.49,ALXN,1283159,HISTORICAL_PRICES,ALXN,,1606830572000,0.3294660826328874,0.3294660826328874,114.49,112.3,114.49,111.72,1283159,114.49,112.3,114.49,111.72,1283159,"Jul 2, 20",-0.09000000000000341,-0.0008
"July 1, 2020","Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of J2 Global, Inc. (JCOM) on Behalf of Investors","Glancy Prongay & Murray LLP (‚ÄúGPM‚Äù), a leading national shareholder rights law firm, continues its investigation on behalf of J2 Global, Inc. (""J2"" or ""the Company"") (NASDAQ: JCOM) investors conce...",64.1,65.815,64,64.11,JCOM,2302024,HISTORICAL_PRICES,JCOM,,1606830572000,-0.027018822100789333,-0.027018822100789333,64.11,64.1,65.815,64,2302024,64.11,64.1,65.815,64,2302024,"Jul 1, 20",0.8899999999999935,0.0141
"July 1, 2020","ROSEN, A LEADING LAW FIRM, Reminds Chembio Diagnostics, Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm ‚Äì CEMI","Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Chembio Diagnostics, Inc. (NASDAQ: CEMI) between March 12, 2020 and June 16, 2020, inclusive (the ‚ÄúClass Peri...",3.28,3.32,3.08,3.22,CEMI,4404786,HISTORICAL_PRICES,CEMI,,1606830572000,-0.3292433537832311,-0.3292433537832311,3.22,3.28,3.32,3.08,4404786,3.22,3.28,3.32,3.08,4404786,"Jul 1, 20",0.029999999999999805,0.0092
"July 1, 2020",Axonics¬Æ Receives FDA Approval for 3T Full-Body MRI Scans,"Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of...",36.41,36.57,34.48,35.02,AXNX,604536,HISTORICAL_PRICES,AXNX,,1606830572000,0.632003585835948,0.632003585835948,35.02,36.41,36.57,34.48,604536,35.02,36.41,36.57,34.48,604536,"Jul 1, 20",1.2999999999999972,0.037
"July 1, 2020","Gilead Sciences Demonstrates Commitment to Scientific Innovation In HIV With New Prevention, Treatment and Cure Research Data Presented At AIDS 2020: Virtual","Gilead Sciences, Inc. (Nasdaq:GILD) today announced that new data from the company‚Äôs HIV research and development program will be presented at the 23rd International AIDS Conference (AIDS 2020: Virtua...",76.06,77.23,75.9,77.1,GILD,7786921,HISTORICAL_PRICES,GILD,,1615518991000,0.09187482055699119,0.09187482055699119,77.1,76.06,77.23,75.9,7786921,74.5976,73.5913,74.7233,73.4365,7786921,"Jul 1, 20",-0.8799999999999955,-0.0114
"July 1, 2020","Everbridge Launches Industry‚Äôs First COVID-19 Return-to-Work Connectivity Hub, Everbridge Control Center‚Ñ¢, for Automating Health and Safety Monitoring and Mitigation","Everbridge, Inc. (NASDAQ: EVBG), the global leader in critical event management (CEM), today announced Everbridge Control Center, the industry‚Äôs first and proven off-the-shelf physical security inform...",147.97,149.485,137.0001,137.98,EVBG,529912,HISTORICAL_PRICES,EVBG,,1606830572000,0.3370380410228607,0.3370380410228607,137.98,147.97,149.485,137.0001,529912,137.98,147.97,149.485,137.0001,529912,"Jul 1, 20",9.609999999999985,0.0695
"July 1, 2020",scPharmaceuticals Announces FUROSCIX¬Æ NDA Resubmission,"scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patien...",7.17,7.5,7.06,7.34,SCPH,86758,HISTORICAL_PRICES,SCPH,,1606830572000,-0.1614035087719299,-0.1614035087719299,7.34,7.17,7.5,7.06,86758,7.34,7.17,7.5,7.06,86758,"Jul 1, 20",-0.1900000000000004,-0.0258
"July 1, 2020",Lantheus Holdings to Showcase the Potential of PyL‚Ñ¢ Imaging Agent at the Virtual Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2020 Annual Meeting,"Lantheus Holdings, Inc. (the ‚ÄúCompany‚Äù) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture an...",14.1,14.65,13.95,14.32,LNTH,536629,HISTORICAL_PRICES,LNTH,,1606830572000,0.23036649214659674,0.23036649214659674,14.32,14.1,14.65,13.95,536629,14.32,14.1,14.65,13.95,536629,"Jul 1, 20",-0.20000000000000107,-0.014
"July 1, 2020",KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results,"KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors today provided...",12.12,12.59,11.91,12.59,KALV,146624,HISTORICAL_PRICES,KALV,,1606830572000,0.662551440329218,0.662551440329218,12.59,12.12,12.59,11.91,146624,12.59,12.12,12.59,11.91,146624,"Jul 1, 20",0.019999999999999574,0.0017
"June 30, 2020",Revance Announces Last Patient Enrolled in Modified JUNIPER Phase 2 Upper Limb Spasticity Trial of DaxibotulinumtoxinA for Injection,"Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA...",24.42,26.02,24.18,25.54,RVNC,1457116,HISTORICAL_PRICES,RVNC,,1606830572000,0.6555932203389832,0.6555932203389832,25.54,24.42,26.02,24.18,1457116,25.54,24.42,26.02,24.18,1457116,"Jun 30, 20",-1.1499999999999986,-0.045
"June 30, 2020",The Law Offices of Frank R. Cruz Announces Investigation on Behalf of Verrica Pharmaceuticals Inc. Investors (VRCA),"The Law Offices of Frank R. Cruz announces an investigation on behalf of Verrica Pharmaceuticals Inc. (""Verrica"" or the ""Company"") (NASDAQ: VRCA) investors concerning the Company and its officers‚Äô pos...",11.01,11.43,10.29,11.3,VRCA,356539,HISTORICAL_PRICES,VRCA,,1606830572000,-0.028243601059135065,-0.028243601059135065,11.3,11.01,11.43,10.29,356539,11.3,11.01,11.43,10.29,356539,"Jun 30, 20",-3.0600000000000005,-0.2175
"June 30, 2020",INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Verrica Pharmaceuticals Inc. (VRCA) on Behalf of Investors,"Law Offices of Howard G. Smith announces an investigation on behalf of Verrica Pharmaceuticals Inc. (""Verrica"" or the ""Company"") (NASDAQ: VRCA) investors concerning the Company and its officers‚Äô possi...",11.01,11.43,10.29,11.3,VRCA,356539,HISTORICAL_PRICES,VRCA,,1606830572000,-0.028243601059135065,-0.028243601059135065,11.3,11.01,11.43,10.29,356539,11.3,11.01,11.43,10.29,356539,"Jun 30, 20",-3.0600000000000005,-0.2175
"June 30, 2020",Humana to Offer LabCorp At-Home COVID-19 Test Collection and Collaborate with Walmart and Quest Diagnostics to Offer Drive-Thru Testing for Humana Members,"Leading health and well-being company Humana Inc. (NYSE: HUM) announced a pilot home-testing program today that will enable at-home COVID-19 test collection for members, making Humana the first insure...",387.75,389.3,379,381.03,HUM,909248,HISTORICAL_PRICES,HUM,,1609377542000,0.44139623062339695,0.44139623062339695,381.03,387.75,389.3,379,909248,379.8519,386.5512,388.0964,377.8282,909248,"Jun 30, 20",8.389999999999986,0.0221
"June 30, 2020",Everbridge Receives FedRAMP Authorization Renewal as Company Continues Rapid Growth in Federal Market; Helps Government Agencies Mitigate the Impacts of COVID-19,"Everbridge, Inc. (NASDAQ: EVBG), the global leader in Critical Event Management (CEM), today announced the company successfully renewed its Federal Risk and Authorization Management Program (FedRAMP)...",138.36,138.71,135.56,136.41,EVBG,575998,HISTORICAL_PRICES,EVBG,,1606830572000,0.25020330712930344,0.25020330712930344,136.41,138.36,138.71,135.56,575998,136.41,138.36,138.71,135.56,575998,"Jun 30, 20",3.170000000000016,0.0234
"June 30, 2020",Jabil Launches High-Volume Mask Production in the United States,Jabil Inc. (NYSE: JBL) today announced the launch of a substantial face mask manufacturing operation in the United States to address demand for face masks and other personal protective equipment (PPE)...,32.08,32.49,31.6,31.85,JBL,1461302,HISTORICAL_PRICES,JBL,,1613020680000,0.3575962759204401,0.3575962759204401,31.85,32.08,32.49,31.6,1461302,31.6502,31.8787,32.2862,31.4017,1461302,"Jun 30, 20",-0.19000000000000483,-0.0059
"June 30, 2020","Revance Announces Positive Results in Two Phase 2a Studies of DaxibotulinumtoxinA For Injection for the Treatment of Forehead Lines and Crow‚Äôs Feet, Respectively","Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA...",24.42,26.02,24.18,25.54,RVNC,1457116,HISTORICAL_PRICES,RVNC,,1606830572000,0.6555932203389832,0.6555932203389832,25.54,24.42,26.02,24.18,1457116,25.54,24.42,26.02,24.18,1457116,"Jun 30, 20",-1.1499999999999986,-0.045
"June 30, 2020",Oncternal Therapeutics Announces Orphan Drug Designations of Cirmtuzumab ROR1 Antibody for Treatment of Mantle Cell Lymphoma and for Treatment of Chronic Lymphocytic Leukemia,"Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the United States Food and Drug Adm...",2.84,3.21,2.7601,3.1,ONCT,125218,HISTORICAL_PRICES,ONCT,,1606830572000,0.08812260536398467,0.08812260536398467,3.1,2.84,3.21,2.7601,125218,3.1,2.84,3.21,2.7601,125218,"Jun 30, 20",-0.14000000000000012,-0.047
"June 30, 2020",Oncternal Therapeutics Announces Increased Focus of the Cirmtuzumab ROR1 Antibody Program on Mantle Cell Lymphoma,"Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced an updated clinical strategy for its inv...",2.84,3.21,2.7601,3.1,ONCT,125218,HISTORICAL_PRICES,ONCT,,1606830572000,0.08812260536398467,0.08812260536398467,3.1,2.84,3.21,2.7601,125218,3.1,2.84,3.21,2.7601,125218,"Jun 30, 20",-0.14000000000000012,-0.047
"June 30, 2020",IVERIC bio Announces First Patient Dosed in Second Zimura¬Æ Phase 3 Clinical Trial for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration,"IVERIC bio, Inc. (Nasdaq: ISEE) today announced the first patient has been dosed in GATHER2, also known as ISEE2008, the second Phase 3 clinical trial for Zimura¬Æ (avacincaptad pegol), a novel complem...",5.1,5.3717,4.75,5.34,ISEE,1543905,HISTORICAL_PRICES,ISEE,,1606830572000,0.5269461077844311,0.5269461077844311,5.34,5.1,5.3717,4.75,1543905,5.34,5.1,5.3717,4.75,1543905,"Jun 30, 20",-0.2600000000000007,-0.0485
"June 30, 2020","Nemaura Medical Reports Results and Provides Business Update for the Fiscal Year Ended March 31, 2020","Nemaura Medical Inc. (NASDAQ: NMRD) (‚ÄúNemaura‚Äù), a medical technology company commercializing sugarBEAT¬Æ, a non-invasive and flexible continuous glucose monitor (CGM), together with BEAT¬Ædiabetes, a h...",9.25,9.9799,9.03,9.03,NMRD,29770,HISTORICAL_PRICES,NMRD,,1606830572000,0.5572390572390571,0.5572390572390571,9.03,9.25,9.9799,9.03,29770,9.03,9.25,9.9799,9.03,29770,"Jun 30, 20",0.2400000000000002,0.0266
"June 29, 2020",Seattle Genetics Announces Positive Topline Results from Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer,"Seattle Genetics, Inc. (Nasdaq:SGEN) today announced positive topline results from the phase 2 single-arm clinical trial known as innovaTV 204 evaluating tisotumab vedotin administered every three wee...",164.37,166.58,163.23,165.78,SGEN,1010114,HISTORICAL_PRICES,SGEN,,1606830572000,0.5586004172197991,0.5586004172197991,165.78,164.37,166.58,163.23,1010114,165.78,164.37,166.58,163.23,1010114,"Jun 29, 20",-1.2199999999999989,-0.0074
"June 29, 2020",FDA Approves Merck‚Äôs KEYTRUDA¬Æ (pembrolizumab) for First-Line Treatment of Patients With Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer,"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck‚Äôs anti-PD-1 therapy, as monotherapy...",76.12,76.51,75.52,75.9,MRK,6899781,HISTORICAL_PRICES,MRK,,1615519028000,0.11580181764878343,0.11580181764878343,75.9,76.12,76.51,75.52,6899781,74.1104,74.3252,74.706,73.7394,6899781,"Jun 29, 20",0.9300000000000068,0.0124
"June 29, 2020","The Law Offices of Frank R. Cruz Announces Investigation on Behalf of Intercept Pharmaceuticals, Inc. Investors (ICPT)","The Law Offices of Frank R. Cruz announces an investigation on behalf of Intercept Pharmaceuticals, Inc. (""Intercept"" or the ""Company"") (NASDAQ: ICPT) investors concerning the Company and its officers...",46.7,50,44.5,47.25,ICPT,10289656,HISTORICAL_PRICES,ICPT,,1606830572000,-0.24689566199000154,-0.24689566199000154,47.25,46.7,50,44.5,10289656,47.25,46.7,50,44.5,10289656,"Jun 29, 20",-30.789999999999992,-0.3973
"June 29, 2020","INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Intercept Pharmaceuticals, Inc. (ICPT) on Behalf of Investors","Law Offices of Howard G. Smith announces an investigation on behalf of Intercept Pharmaceuticals, Inc. (""Intercept"" or the ""Company"") (NASDAQ: ICPT) investors concerning the Company and its officers‚Äô...",46.7,50,44.5,47.25,ICPT,10289656,HISTORICAL_PRICES,ICPT,,1606830572000,-0.24689566199000154,-0.24689566199000154,47.25,46.7,50,44.5,10289656,47.25,46.7,50,44.5,10289656,"Jun 29, 20",-30.789999999999992,-0.3973
"June 29, 2020",TFF Pharmaceuticals Announces First Human Dosing With Tacrolimus Inhalation Powder and Topline Data for Voriconazole Inhalation Powder,"TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) t...",5.7,5.99,5.7,5.865,TFFP,90835,HISTORICAL_PRICES,TFFP,,1606830572000,0.42500000000000004,0.42500000000000004,5.865,5.7,5.99,5.7,90835,5.865,5.7,5.99,5.7,90835,"Jun 29, 20",-0.03000000000000025,-0.0052
"June 29, 2020",Genprex Added to Russell 3000¬Æ Index,"Genprex, Inc. (‚ÄúGenprex‚Äù or the ‚ÄúCompany‚Äù) (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announce...",3.15,3.28,3.09,3.2,GNPX,1102008,HISTORICAL_PRICES,GNPX,,1606830572000,0.12903225806451607,0.12903225806451607,3.2,3.15,3.28,3.09,1102008,3.2,3.15,3.28,3.09,1102008,"Jun 29, 20",0.020000000000000018,0.0064
"June 29, 2020",Masimo Announces Bridge‚Ñ¢,"Masimo (NASDAQ: MASI) today announced Bridge‚Ñ¢, an opioid withdrawal solution that uses neuromodulation to aid in the reduction of symptoms associated with opioid withdrawal. Bridge, which has been gra...",219.73,220.13,212.58,216.65,MASI,435448,HISTORICAL_PRICES,MASI,,1606830572000,0.3749452474813841,0.3749452474813841,216.65,219.73,220.13,212.58,435448,216.65,219.73,220.13,212.58,435448,"Jun 29, 20",2.2299999999999898,0.0103
"June 29, 2020",Incyte Announces Approval of Tabrecta‚Ñ¢ (capmatinib) in Japan for the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with METex14,"Incyte (Nasdaq: INCY) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved Tabrecta‚Ñ¢ (capmatinib) for MET exon 14 skipping (METex14) mutation-positive advanced and/...",102.48,103.87,100.08,101.48,INCY,1075728,HISTORICAL_PRICES,INCY,,1606830572000,0.47262537720936915,0.47262537720936915,101.48,102.48,103.87,100.08,1075728,101.48,102.48,103.87,100.08,1075728,"Jun 29, 20",1.0499999999999972,0.0104
"June 29, 2020",Orthofix Announces FDA Clearance and First Patient Implants of FIREBIRD SI Fusion System for Low Back Pain,"Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company focused on musculoskeletal healing products, announced the U.S. Food and Drug Administration (FDA) 510(k) clearance and the first p...",31.04,31.18,29.84,30.06,OFIX,113721,HISTORICAL_PRICES,OFIX,,1606830572000,0.16647876738068396,0.16647876738068396,30.06,31.04,31.18,29.84,113721,30.06,31.04,31.18,29.84,113721,"Jun 29, 20",1.1699999999999982,0.0392
"June 29, 2020",Rocket Pharmaceuticals Announces FDA Clearance of IND for RP-L401 Gene Therapy for Infantile Malignant Osteopetrosis,"Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (‚ÄúRocket‚Äù), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces tha...",21.09,21.69,20.5,21.18,RCKT,954750,HISTORICAL_PRICES,RCKT,,1606830572000,0.408817635270541,0.408817635270541,21.18,21.09,21.69,20.5,954750,21.18,21.09,21.69,20.5,954750,"Jun 29, 20",-0.019999999999999574,-0.0009
"June 26, 2020","Shareholder Alert: Robbins LLP Announces Chembio Diagnostics, Inc. (CEMI) Sued for Misleading Shareholders","Shareholder rights law firm Robbins LLP announces that a purchaser of Chembio Diagnostics, Inc. (NASDAQ: CEMI) filed a class action complaint against the Company for alleged violations of the Securiti...",3.27,3.42,3.22,3.39,CEMI,4043292,HISTORICAL_PRICES,CEMI,,1606830572000,-0.3312883435582822,-0.3312883435582822,3.39,3.27,3.42,3.22,4043292,3.39,3.27,3.42,3.22,4043292,"Jun 26, 20",-0.18999999999999995,-0.0549
"June 26, 2020","Phunware Announces Joint Venture with AnyPlace MD to Provide an End-to-End, Tech-Enabled Solution to COVID-19","Phunware, Inc. (NASDAQ: PHUN) (the ‚ÄúCompany‚Äù), a fully-integrated enterprise cloud platform for mobile that provides products, solutions, data and services for brands worldwide, announced today a join...",1.34,1.39,1.26,1.38,PHUN,8289674,HISTORICAL_PRICES,PHUN,,1606830572000,0.8873239436619721,0.8873239436619721,1.38,1.34,1.39,1.26,8289674,1.38,1.34,1.39,1.26,8289674,"Jun 26, 20",0.1100000000000001,0.0894
"June 26, 2020",Nemaura Medical Interview to Air on Bloomberg International on the RedChip Money Report,"Nemaura Medical, Inc. (NASDAQ: NMRD) (‚ÄúNemaura‚Äù or the ‚ÄúCompany‚Äù), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing suga...",9.6,10.64,9.49,10.6,NMRD,858112,HISTORICAL_PRICES,NMRD,,1606830572000,0.616161616161616,0.616161616161616,10.6,9.6,10.64,9.49,858112,10.6,9.6,10.64,9.49,858112,"Jun 26, 20",-1,-0.0943
"June 26, 2020",Applied DNA Sciences Set to Join Russell Microcap Index,"Applied DNA Sciences Inc. (NASDAQ: APDN) (‚ÄúApplied DNA‚Äù or the ‚ÄúCompany‚Äù) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing that enables in vitro diagnostics, pre-clinical nucleic ac...",9.09,9.4,8.3,9.4,APDN,1047092,HISTORICAL_PRICES,APDN,,1606830572000,1.227941176470588,1.227941176470588,9.4,9.09,9.4,8.3,1047092,9.4,9.09,9.4,8.3,1047092,"Jun 26, 20",-0.1899999999999995,-0.0205
"June 25, 2020",Masimo Announces FDA Clearance of Centroid‚Ñ¢,"Masimo (NASDAQ: MASI) announced today that Centroid‚Ñ¢, a wearable, wireless patient orientation, activity, and respiration rate sensor, has received FDA clearance. Centroid helps clinicians monitor pat...",220.55,222.44,216.98,222.44,MASI,478853,HISTORICAL_PRICES,MASI,,1606830572000,0.3800763406545273,0.3800763406545273,222.44,220.55,222.44,216.98,478853,222.44,220.55,222.44,216.98,478853,"Jun 25, 20",-1.5199999999999818,-0.0068
"June 25, 2020","Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of ECMOHO Limited Investors (MOHO) on Behalf of Investors","Glancy Prongay & Murray LLP (‚ÄúGPM‚Äù), a leading national shareholder rights law firm, continues its investigation on behalf of ECMOHO Limited (""ECMOHO"" or the ""Company"") (NASDAQ: MOHO) investors co...",2.88,2.9,2.74,2.85,MOHO,236921,HISTORICAL_PRICES,MOHO,,1606830572000,-0.6611764705882353,-0.6611764705882353,2.85,2.88,2.9,2.74,236921,2.85,2.88,2.9,2.74,236921,"Jun 25, 20",0.009999999999999787,0.0035
"June 25, 2020",Genprex Receives USAN Approval of Non-Proprietary Name for Lead Drug Candidate,"Genprex, Inc. (‚ÄúGenprex‚Äù or the ‚ÄúCompany‚Äù) (Nasdaq: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announce...",3.48,3.8,3.33,3.7,GNPX,3266278,HISTORICAL_PRICES,GNPX,,1606830572000,0.24731182795698922,0.24731182795698922,3.7,3.48,3.8,3.33,3266278,3.7,3.48,3.8,3.33,3266278,"Jun 25, 20",-0.16000000000000014,-0.044
"June 25, 2020",Moderna and Catalent Announce Collaboration for Fill-Finish Manufacturing of Moderna‚Äôs COVID-19 Vaccine Candidate,"Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, and...",62,67,58.51,67,MRNA,26905664,HISTORICAL_PRICES,MRNA,,1606830572000,1.2852930335422044,1.2852930335422044,67,62,67,58.51,26905664,67,62,67,58.51,26905664,"Jun 25, 20",-2.8400000000000034,-0.0438
"June 25, 2020",Moderna and Catalent Announce Collaboration for Fill-Finish Manufacturing of Moderna‚Äôs COVID-19 Vaccine Candidate,"Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, and...",62,67,58.51,67,MRNA,26905664,HISTORICAL_PRICES,MRNA,,1606830572000,1.2852930335422044,1.2852930335422044,67,62,67,58.51,26905664,67,62,67,58.51,26905664,"Jun 25, 20",-2.8400000000000034,-0.0438
"June 24, 2020",FDA Approves Merck‚Äôs KEYTRUDA¬Æ (pembrolizumab) for the Treatment of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) that is Not Curable by Surgery or Radiation,"Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck‚Äôs anti-PD-1 therapy, as monotherapy...",75.87,76.89,75.45,76.73,MRK,7714623,HISTORICAL_PRICES,MRK,,1615519117000,0.112137203166227,0.112137203166227,76.73,75.87,76.89,75.45,7714623,74.9208,74.0811,75.0771,73.671,7714623,"Jun 24, 20",-1.25,-0.0162
"June 24, 2020",SINTX Technologies Announces Publication of Study to Reduce the Spread and Transfer of Coronavirus,"SINTX Technologies, Inc. (NASDAQ: SINT) (‚ÄúSINTX‚Äù or the ‚ÄúCompany‚Äù), an original equipment manufacturer (OEM) ceramics company focused on silicon nitride and its applications, today announced positive...",2.1,2.57,1.53,1.6,SINT,134763899,HISTORICAL_PRICES,SINT,,1606830572000,5.461538461538462,5.461538461538462,1.6,2.1,2.57,1.53,134763899,1.6,2.1,2.57,1.53,134763899,"Jun 24, 20",0.6800000000000002,0.4789
"June 24, 2020",Alexion Announces Phase 3 Study of Weekly Subcutaneous ULTOMIRIS¬Æ (ravulizumab-cwvz) Met Primary Endpoint,"Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced topline results from a Phase 3 study of weekly self-administered subcutaneous (SC) ULTOMIRIS¬Æ (ravulizumab-cwvz) in adults with paroxysmal n...",111.95,115.75,111.36,113.96,ALXN,2096673,HISTORICAL_PRICES,ALXN,,1606830572000,0.3253225997395526,0.3253225997395526,113.96,111.95,115.75,111.36,2096673,113.96,111.95,115.75,111.36,2096673,"Jun 24, 20",-3.539999999999992,-0.0307
"June 24, 2020",UCI Health Deploys Everbridge‚Äôs Industry-Leading Mobile Wayfinding Solution to Improve Patient Experience and Safety Amid COVID-19 Precautions,"Everbridge, Inc. (NASDAQ: EVBG), the global leader in Critical Event Management (CEM), today announced that UCI Health in Orange County, California integrated the Everbridge MediNav‚Ñ¢ solution with its...",134.33,142.83,132.23,140.31,EVBG,787412,HISTORICAL_PRICES,EVBG,,1606830572000,0.2137887413029729,0.2137887413029729,140.31,134.33,142.83,132.23,787412,140.31,134.33,142.83,132.23,787412,"Jun 24, 20",-6.1699999999999875,-0.0439
"June 24, 2020",Genprex CEO to Interview Live on ‚ÄúThe Big Biz Show‚Äù,"Genprex, Inc. (‚ÄúGenprex‚Äù or the ‚ÄúCompany‚Äù) (Nasdaq: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announce...",3.64,3.75,3.1258,3.19,GNPX,5493741,HISTORICAL_PRICES,GNPX,,1606830572000,0.30465949820788535,0.30465949820788535,3.19,3.64,3.75,3.1258,5493741,3.19,3.64,3.75,3.1258,5493741,"Jun 24, 20",0.54,0.1742
"June 23, 2020","EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Chembio Diagnostics, Inc. ‚Äì CEMI","Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Chembio Diagnostics, Inc. (NASDAQ: CEMI) between March 12...",3.41,3.59,3.36,3.56,CEMI,3013778,HISTORICAL_PRICES,CEMI,,1606830572000,-0.3026584867075664,-0.3026584867075664,3.56,3.41,3.59,3.36,3013778,3.56,3.41,3.59,3.36,3013778,"Jun 23, 20",-0.2599999999999998,-0.0708
"June 23, 2020","CEMI INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Class Action Against Chembio Diagnostics, Inc. and Encourages Investors to Contact the Firm","Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Chembio Diagnostics, Inc. (""Chembio"" or ""the Company"") (NASDAQ: CEMI) and certain of its of...",3.41,3.59,3.36,3.56,CEMI,3013778,HISTORICAL_PRICES,CEMI,,1606830572000,-0.3026584867075664,-0.3026584867075664,3.56,3.41,3.59,3.36,3013778,3.56,3.41,3.59,3.36,3013778,"Jun 23, 20",-0.2599999999999998,-0.0708
"June 23, 2020","Nemaura Medical CEO to Participate in Investor Webinar and Q&A Session on July 7, 2020","Nemaura Medical, Inc. (NASDAQ: NMRD) (‚ÄúNemaura‚Äù or the ‚ÄúCompany‚Äù), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing suga...",11.76,15.66,10.8399,15.66,NMRD,187425,HISTORICAL_PRICES,NMRD,,1606830572000,0.9797979797979797,0.9797979797979797,15.66,11.76,15.66,10.8399,187425,15.66,11.76,15.66,10.8399,187425,"Jun 23, 20",-3.620000000000001,-0.2354
"June 23, 2020",Karuna Therapeutics Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for KarXT for the Treatment of Acute Psychosis in Patients with Schizophrenia,"Karuna Therapeutics, Inc. (NASDAQ: KRTX), an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabl...",105.74,107.65,103.5,106.18,KRTX,419656,HISTORICAL_PRICES,KRTX,,1606830572000,0.5782089552238805,0.5782089552238805,106.18,105.74,107.65,103.5,419656,106.18,105.74,107.65,103.5,419656,"Jun 23, 20",1.6999999999999886,0.0163
"June 22, 2020",Verastem Oncology Announces Presentation of Preclinical Data Supporting the Combination of VS-6766 and Defactinib in Metastatic Uveal Melanoma,"Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, today announced resu...",1.85,1.88,1.76,1.8,VSTM,6099698,HISTORICAL_PRICES,VSTM,,1606830572000,-0.18859649122807007,-0.18859649122807007,1.8,1.85,1.88,1.76,6099698,1.8,1.85,1.88,1.76,6099698,"Jun 22, 20",0.050000000000000044,0.0278
"June 22, 2020","SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Chembio Diagnostics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm","The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Chembio Diagnostics, Inc. (‚ÄúChembio‚Äù or ‚Äúthe Company‚Äù) (NASDAQ: CEMI) for vio...",3.67,3.73,3.245,3.54,CEMI,6484194,HISTORICAL_PRICES,CEMI,,1606830572000,-0.24948875255623718,-0.24948875255623718,3.54,3.67,3.73,3.245,6484194,3.54,3.67,3.73,3.245,6484194,"Jun 22, 20",0.1200000000000001,0.0338
"June 22, 2020",Everbridge Recognized as One of The Fastest-Growing Public Companies in Massachusetts,"Everbridge, Inc. (NASDAQ: EVBG), the global leader in Critical Event Management (CEM), today announced its recognition on the 2020 Boston Business Journal list of Fastest-Growing Public Companies in M...",134.29,135.32,130,131,EVBG,394885,HISTORICAL_PRICES,EVBG,,1606830572000,0.21342730640643345,0.21342730640643345,131,134.29,135.32,130,394885,131,134.29,135.32,130,394885,"Jun 22, 20",4.1699999999999875,0.032
"June 22, 2020",Pfizer Announces Start of Four Phase 3 Clinical Trials for Investigational Vaccines,Pfizer Inc. (NYSE:PFE) today announced the initiation of four Phase 3 clinical trials within its current pipeline of investigational vaccines: Two studies (NCT04382326 and NCT04379713) of the 20-valen...,33.11,33.36,32.91,33.33,PFE,22137128,HISTORICAL_PRICES,PFE,,1611800358000,0.11294117647058821,0.11294117647058821,33.33,33.11,33.36,32.91,22137128,32.3198,32.1065,32.3489,31.9125,22137128,"Jun 22, 20",-0.3100000000000023,-0.0093
"June 22, 2020","Seres Therapeutics Appoints Terri Young, Ph.D., R.Ph., Experienced Commercial Leader, as Executive Vice President, Chief Commercial and Strategy Officer","Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the appointment of Terri Young, Ph.D., R.Ph., as Executive Vice President, Chief Commercial and Strategy Officer, effective June 29, 2020. Dr. Y...",4.86,5.02,4.62,4.81,MCRB,559975,HISTORICAL_PRICES,MCRB,,1606830572000,0.41690962099125367,0.41690962099125367,4.81,4.86,5.02,4.62,559975,4.81,4.86,5.02,4.62,559975,"Jun 22, 20",0.0600000000000005,0.0125
"June 22, 2020",Deciphera Announces Health Canada‚Äôs Authorization of QINLOCK‚Ñ¢ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor,"Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that Health Canada has authorized QINLOCK‚Ñ¢ (ripretinib), a switch-control tyrosine kinase inhibitor, for sale in Canada for the treatment...",65.03,65.58,61.91,62.52,DCPH,708645,HISTORICAL_PRICES,DCPH,,1606830572000,0.5730527334300918,0.5730527334300918,62.52,65.03,65.58,61.91,708645,62.52,65.03,65.58,61.91,708645,"Jun 22, 20",2.3100000000000023,0.0368
"June 22, 2020",Lantheus Completes Merger with Progenics,"Lantheus Holdings, Inc. (the ‚ÄúCompany‚Äù) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. (‚ÄúLMI‚Äù), a global leader in the development, manufacture and commercialization of innovativ...",13.98,14.5,13.499,14.44,LNTH,1534412,HISTORICAL_PRICES,LNTH,,1606830572000,0.21989528795811514,0.21989528795811514,14.44,13.98,14.5,13.499,1534412,14.44,13.98,14.5,13.499,1534412,"Jun 22, 20",-0.8499999999999996,-0.0573
"June 22, 2020","Merck Announces That V114, Its Investigational 15-valent Pneumococcal Conjugate Vaccine, Met Safety and Immunogenicity Objectives in Initial Phase 3 Studies in Adults","Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from two initial Phase 3 studies evaluating the safety, tolerability and immunogenicity of V114, the compa...",76.75,77.63,76.43,77.37,MRK,7131940,HISTORICAL_PRICES,MRK,,1615519017000,0.12503664614482557,0.12503664614482557,77.37,76.75,77.63,76.43,7131940,75.5458,74.9404,75.7996,74.6279,7131940,"Jun 22, 20",-1.1500000000000057,-0.0148
"June 22, 2020",Merck‚Äôs KEYTRUDA¬Æ (pembrolizumab) Approved in China for Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Whose Tumors Express PD-L1 (CPS ‚â•10),"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck‚Äôs anti-PD-1 therapy, has been approved by the National Medical Products Administration (NMPA)...",76.75,77.63,76.43,77.37,MRK,7131940,HISTORICAL_PRICES,MRK,,1615519017000,0.12503664614482557,0.12503664614482557,77.37,76.75,77.63,76.43,7131940,75.5458,74.9404,75.7996,74.6279,7131940,"Jun 22, 20",-1.1500000000000057,-0.0148
"June 19, 2020","SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Chembio Diagnostics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm","The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Chembio Diagnostics, Inc. (‚ÄúChembio‚Äù or ‚Äúthe Company‚Äù) (NASDAQ: CEMI) for vio...",3.55,3.83,3.53,3.77,CEMI,7133916,HISTORICAL_PRICES,CEMI,,1606830572000,-0.2740286298568507,-0.2740286298568507,3.77,3.55,3.83,3.53,7133916,3.77,3.55,3.83,3.53,7133916,"Jun 19, 20",-0.20500000000000007,-0.0546
"June 19, 2020","INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Co-Diagnostics, Inc. (CODX) Investors","Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Co-Diagnostics, Inc. (""Co-Diagnostics"" or the ""Company"") (NASDAQ: CODX) securit...",17.24,17.8,15.82,15.95,CODX,3213618,HISTORICAL_PRICES,CODX,,1606830572000,0.9241071428571425,0.9241071428571425,15.95,17.24,17.8,15.82,3213618,15.95,17.24,17.8,15.82,3213618,"Jun 19, 20",1.3099999999999987,0.0822
"June 19, 2020",Masimo Announces Masimo SafetyNet-Open‚Ñ¢,"Masimo (NASDAQ: MASI) today announced Masimo SafetyNet-Open‚Ñ¢, designed to help businesses, governments, and schools more responsibly manage employee and student health and safety during COVID-19. As t...",226.03,226.87,220.3525,223.13,MASI,878581,HISTORICAL_PRICES,MASI,,1606830572000,0.4143670608848007,0.4143670608848007,223.13,226.03,226.87,220.3525,878581,223.13,226.03,226.87,220.3525,878581,"Jun 19, 20",4.6200000000000045,0.0209
"June 19, 2020","Masimo Announces Masimo Sleep‚Ñ¢, a New Wellness Solution That Allows Users to Better Understand Their Sleep Quality","Masimo (NASDAQ: MASI) announced today a new health and wellness home monitoring solution, Masimo Sleep‚Ñ¢, designed to help consumers better understand the quality of their sleep. Masimo Sleep is fueled...",226.03,226.87,220.3525,223.13,MASI,878581,HISTORICAL_PRICES,MASI,,1606830572000,0.4143670608848007,0.4143670608848007,223.13,226.03,226.87,220.3525,878581,223.13,226.03,226.87,220.3525,878581,"Jun 19, 20",4.6200000000000045,0.0209
"June 18, 2020","INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Chembio Diagnostics, Inc. (CEMI) Investors","Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Chembio Diagnostics, Inc. (""Chembio"" or the ""Company"") (NASDAQ: CEMI) common st...",3.755,4.3,3.73,3.98,CEMI,13968644,HISTORICAL_PRICES,CEMI,,1606830572000,-0.23210633946830264,-0.23210633946830264,3.98,3.755,4.3,3.73,13968644,3.98,3.755,4.3,3.73,13968644,"Jun 18, 20",-0.13500000000000023,-0.0347
"June 18, 2020","The Law Offices of Frank R. Cruz Announces Investigation on Behalf of Chembio Diagnostics, Inc. Investors (CEMI)","The Law Offices of Frank R. Cruz announces an investigation on behalf of Chembio Diagnostics, Inc. (""Chembio"" or the ""Company"") (NASDAQ: CEMI) investors concerning the Company and its officers‚Äô possib...",3.755,4.3,3.73,3.98,CEMI,13968644,HISTORICAL_PRICES,CEMI,,1606830572000,-0.23210633946830264,-0.23210633946830264,3.98,3.755,4.3,3.73,13968644,3.98,3.755,4.3,3.73,13968644,"Jun 18, 20",-0.13500000000000023,-0.0347
"June 18, 2020",Urovant Sciences Reports Fiscal Year and Fourth Quarter 2019 Results,"Urovant Sciences (Nasdaq: UROV) today reported financial results for the three months and 2019 fiscal year ended March 31, 2020. The fiscal fourth quarter of 2019 marked achievement of key milestones...",11.5,12.06,10.95,11,UROV,78088,HISTORICAL_PRICES,UROV,,1606830572000,0.14427860696517406,0.14427860696517406,11,11.5,12.06,10.95,78088,11,11.5,12.06,10.95,78088,"Jun 18, 20",0.5600000000000005,0.0512
"June 18, 2020",Shareholder Alert: Robbins LLP Announces Co-Diagnostics Inc. (CODX) Sued for Misleading Shareholders,Shareholder rights law firm Robbins LLP announces that a purchaser of Co-Diagnostics Inc. (NASDAQ: CODX) filed a class action complaint against the Company for alleged violations of the Securities Exc...,15.93,16.57,15.7752,16.15,CODX,1971992,HISTORICAL_PRICES,CODX,,1606830572000,0.7779017857142855,0.7779017857142855,16.15,15.93,16.57,15.7752,1971992,16.15,15.93,16.57,15.7752,1971992,"Jun 18, 20",-0.5800000000000018,-0.0351
"June 18, 2020", Epizyme Announces U.S. FDA Accelerated Approval of TAZVERIK‚Ñ¢ (tazemetostat) for Relapsed/Refractory Follicular Lymphoma,"Epizyme, Inc. (Nasdaq:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing novel epigenetic therapies, today announced that the U.S. Food and Drug Administration (FDA) has...",20.46,22,18.02,19.7,EPZM,6255850,HISTORICAL_PRICES,EPZM,,1606830572000,0.3487145682267634,0.3487145682267634,19.7,20.46,22,18.02,6255850,19.7,20.46,22,18.02,6255850,"Jun 18, 20",0.9400000000000013,0.0482
"June 18, 2020","INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Chembio Diagnostics, Inc. (CEMI) on Behalf of Investors","Law Offices of Howard G. Smith announces an investigation on behalf of Chembio Diagnostics, Inc. (""Chembio"" or the ""Company"") (NASDAQ: CEMI) investors concerning the Company and its officers‚Äô possible...",3.755,4.3,3.73,3.98,CEMI,13968644,HISTORICAL_PRICES,CEMI,,1606830572000,-0.23210633946830264,-0.23210633946830264,3.98,3.755,4.3,3.73,13968644,3.98,3.755,4.3,3.73,13968644,"Jun 18, 20",-0.13500000000000023,-0.0347
"June 18, 2020",TFF Pharmaceuticals Receives Orphan Drug Designation for Tacrolimus Inhalation Powder,"TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) t...",6.02,6.24,5.91,6.1,TFFP,168482,HISTORICAL_PRICES,TFFP,,1606830572000,0.5049999999999999,0.5049999999999999,6.1,6.02,6.24,5.91,168482,6.1,6.02,6.24,5.91,168482,"Jun 18, 20",-0.0600000000000005,-0.0099
"June 18, 2020",Xeris Pharmaceuticals Announces Positive Topline Results from the Phase 2 Comparative Study of a Novel Pramlintide-insulin Co-formulation (XP-3924) in Adults with Type 1 Diabetes Mellitus,"Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formula...",5.49,5.67,5.18,5.2,XERS,411288,HISTORICAL_PRICES,XERS,,1606830572000,1.920212765957447,1.920212765957447,5.2,5.49,5.67,5.18,411288,5.2,5.49,5.67,5.18,411288,"Jun 18, 20",0.33000000000000007,0.064
"June 18, 2020",Urovant Sciences Announces Collaboration with Sunovion Pharmaceuticals,Urovant Sciences (Nasdaq: UROV) today announced it has entered into an exclusive three-year distribution agreement with Sunovion Pharmaceuticals Inc. (Sunovion) for services to support the commerciali...,11.5,12.06,10.95,11,UROV,78088,HISTORICAL_PRICES,UROV,,1606830572000,0.14427860696517406,0.14427860696517406,11,11.5,12.06,10.95,78088,11,11.5,12.06,10.95,78088,"Jun 18, 20",0.5600000000000005,0.0512
"June 18, 2020",Dicerna Receives Rare Pediatric Disease Designation From U.S. Food and Drug Administration for Nedosiran for Treatment of Primary Hyperoxaluria,"Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the ‚ÄúCompany‚Äù or ‚ÄúDicerna‚Äù), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the U.S. Food...",24.56,24.73,23.04,23.15,DRNA,568116,HISTORICAL_PRICES,DRNA,,1606830572000,0.3636868406440864,0.3636868406440864,23.15,24.56,24.73,23.04,568116,23.15,24.56,24.73,23.04,568116,"Jun 18, 20",1.2699999999999996,0.0545
"June 18, 2020",Neurocrine BiosciencesÂíåÊ≠¶Áî∞ÂÆ£Â∏ÉÂêà‰ΩúÂºÄÂèëÂíåÂïÜ‰∏öÂåñÁ≤æÁ•ûÁñæÁóÖÊΩúÂú®Ê≤ªÁñóËçØÁâ©,"(ÁæéÂõΩÂïÜ‰∏öËµÑËÆØ)--Neurocrine Biosciences, Inc. (Nasdaq:NBIX)ÂíåÊ≠¶Áî∞ËçØÂìÅÂ∑•‰∏öÊ†™Âºè‰ºöÁ§æ(Takeda Pharmaceutical Company Limited, TSE:4502/NYSE:TAK)Ôºà‚ÄúÊ≠¶Áî∞‚ÄùÔºâ‰ªäÂ§©ÂÆ£Â∏É‰∏ÄÈ°πÊó®Âú®ÂºÄÂèëÂíåÂïÜ‰∏öÂåñÊ≠¶Áî∞Êó©ÊúüËá≥‰∏≠ÊúüÁ≤æÁ•ûÁßë‰∫ßÂìÅÁÆ°Á∫øÁöÑÊàòÁï•Âêà‰Ωú„ÄÇÂÖ∑‰ΩìËÄåË®ÄÔºåÊ≠¶Áî∞ÂêëNeurocrine BiosciencesÊéí‰ªñÊÄßÊéàÊùÉ‰∏É‰∏™ÁÆ°Á∫ø...",121.03,121.47,118.41,118.41,NBIX,530957,HISTORICAL_PRICES,NBIX,,1606830572000,0.34134988363072144,0.34134988363072144,118.41,121.03,121.47,118.41,530957,118.41,121.03,121.47,118.41,530957,"Jun 18, 20",1.7600000000000051,0.0148
"June 18, 2020",Neurocrine BiosciencesÂíåÊ≠¶Áî∞ÂÆ£‰ΩàÂêà‰ΩúÈñãÁôºÁ≤æÁ•ûÁñæÁóÖÊΩõÂú®Ê≤ªÁôÇËó•Áâ©‰∏¶ÈÄ≤Ë°åÂïÜÊ•≠Âåñ,"(ÁæéÂúãÂïÜÊ•≠Ë≥áË®ä)--Neurocrine Biosciences, Inc. (Nasdaq:NBIX)ÂíåÊ≠¶Áî∞Ëó•ÂìÅÂ∑•Ê•≠Ê†™ÂºèÊúÉÁ§æ(Takeda Pharmaceutical Company Limited, TSE:4502/NYSE:TAK)Ôºà„ÄåÊ≠¶Áî∞„ÄçÔºâ‰ªäÂ§©ÂÆ£‰ΩàÁ≠ñÁï•ÊÄßÂêà‰ΩúÔºåÊó®Âú®ÈñãÁôºÊ≠¶Áî∞Êó©ÊúüËá≥‰∏≠ÊúüÁ≤æÁ•ûÁßëÁî¢ÂìÅÁ∑ö‰∏¶ÈÄ≤Ë°åÂïÜÊ•≠Âåñ„ÄÇÂÖ∑È´îËÄåË®ÄÔºåÊ≠¶Áî∞Â∞çNeurocrine BiosciencesÊèê‰æõ‰∏ÉÂÄãÁî¢ÂìÅÁ∑öË®àÁï´...",121.03,121.47,118.41,118.41,NBIX,530957,HISTORICAL_PRICES,NBIX,,1606830572000,0.34134988363072144,0.34134988363072144,118.41,121.03,121.47,118.41,530957,118.41,121.03,121.47,118.41,530957,"Jun 18, 20",1.7600000000000051,0.0148
"June 17, 2020","Abiomed lance un programme d‚Äô√©ducation m√©dicale en ligne, CAMP PCI, afin d‚Äôam√©liorer les r√©sultats pour les patients subissant une ICP √† haut risque","Aujourd‚Äôhui, Abiomed (NASDAQ: ABMD) a lanc√© sa plateforme d‚Äô√©ducation num√©rique ultra-moderne CAMP PCI, qui signifie en anglais Coronary Artery & Myocardial Protected Percutaneous Coronary Interve...",254.73,256,249.153,252.04,ABMD,381594,HISTORICAL_PRICES,ABMD,,1606830572000,0.7341548097215604,0.7341548097215604,252.04,254.73,256,249.153,381594,252.04,254.73,256,249.153,381594,"Jun 17, 20",5.590000000000003,0.0224
"June 17, 2020",Tandem Diabetes Care Announces Expanded Pediatric Indication of the t:slim X2 Insulin Pump with Control-IQ Advanced Hybrid Closed-Loop Technology,"Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced U.S. Food and Drug Administration (FDA) clearance of an expanded pediatric indica...",86.71,89.53,80.51,81.34,TNDM,3140075,HISTORICAL_PRICES,TNDM,,1606830572000,0.5079999999999999,0.5079999999999999,81.34,86.71,89.53,80.51,3140075,81.34,86.71,89.53,80.51,3140075,"Jun 17, 20",5.319999999999993,0.0654
"June 17, 2020",Clovis Oncology to Highlight Rubraca¬Æ (rucaparib) and Lucitanib Non-Clinical Data at the AACR Virtual Annual Meeting II 2020,"Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that four abstracts showcasing non-clinical data from rucaparib and lucitanib development programs have been accepted for on-demand viewing and pub...",6.965,7.41,6.92,7.25,CLVS,3524171,HISTORICAL_PRICES,CLVS,,1606830572000,0.572234762979684,0.572234762979684,7.25,6.965,7.41,6.92,3524171,7.25,6.965,7.41,6.92,3524171,"Jun 17, 20",-0.3849999999999998,-0.0524
"June 17, 2020","FDA Approves Second Biomarker-Based Indication for Merck‚Äôs KEYTRUDA¬Æ (pembrolizumab), Regardless of Tumor Type","Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck‚Äôs anti-PD-1 therapy, as monotherapy...",76.29,77.45,75.625,77.36,MRK,13342640,HISTORICAL_PRICES,MRK,,1615519069000,0.11829375549692184,0.11829375549692184,77.36,76.29,77.45,75.625,13342640,75.536,74.4912,75.6239,73.8419,13342640,"Jun 17, 20",-0.6799999999999926,-0.0088
"June 17, 2020",ChromaDex Research & Development Facility Earns ISO/IEC 17025:2017 Accreditation,"ChromaDex Corp. (NASDAQ:CDXC) announced today it has achieved ISO/IEC 17025:2017 quality standard for laboratory testing, the world‚Äôs most respected quality management standard. This accreditation cov...",4.25,4.4,4.22,4.39,CDXC,144521,HISTORICAL_PRICES,CDXC,,1606830572000,0.44067796610169485,0.44067796610169485,4.39,4.25,4.4,4.22,144521,4.39,4.25,4.4,4.22,144521,"Jun 17, 20",-0.11000000000000032,-0.0252
"June 16, 2020","Abiomed f√ºhrt das virtuelle Fortbildungsprogamm CAMP PCI f√ºr √Ñrzte ein, um die Ergebnisse bei Hochrisiko-PCI-Patienten zu verbessern","Heute f√ºhrte Abiomed (NASDAQ: ABMD), eine hochmoderne Ausbildungsplattform unter dem Namen CAMP PCI ein. Dies steht f√ºr ‚ÄûCoronary Artery & Myocardial Protected Percutaneous Coronary Intervention‚Äù,...",249.14,252.49,246.295,252.49,ABMD,419003,HISTORICAL_PRICES,ABMD,,1606830572000,0.6960991217918171,0.6960991217918171,252.49,249.14,252.49,246.295,419003,252.49,249.14,252.49,246.295,419003,"Jun 16, 20",2.809999999999974,0.0114
"June 16, 2020",Neurocrine Biosciences und Takeda k√ºndigen Zusammenarbeit bei der Entwicklung und Vermarktung m√∂glicher Therapien f√ºr psychische St√∂rungen an,"Neurocrine Biosciences, Inc. (Nasdaq:NBIX) und die Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (‚ÄûTakeda‚Äù) gaben heute eine strategische Zusammenarbeit bei der Entwicklung und Vermarktung...",118.89,119.42,114.75,117.72,NBIX,778445,HISTORICAL_PRICES,NBIX,,1606830572000,0.317632716391444,0.317632716391444,117.72,118.89,119.42,114.75,778445,117.72,118.89,119.42,114.75,778445,"Jun 16, 20",3.5600000000000023,0.0309
"June 16, 2020",Neurocrine Biosciences et Takeda annoncent une collaboration pour le d√©veloppement et la mise sur le march√© de th√©rapies potentielles contre les troubles psychiatriques,"Neurocrine Biosciences, Inc. (Nasdaq:NBIX) et Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (¬´ Takeda ¬ª) annoncent ce jour une collaboration strat√©gique pour le d√©veloppement et la mise su...",118.89,119.42,114.75,117.72,NBIX,778445,HISTORICAL_PRICES,NBIX,,1606830572000,0.317632716391444,0.317632716391444,117.72,118.89,119.42,114.75,778445,117.72,118.89,119.42,114.75,778445,"Jun 16, 20",3.5600000000000023,0.0309
"June 16, 2020",Merck and Pfizer‚Äôs SGLT2 Inhibitor STEGLATROTM (ertugliflozin) Meets Primary Endpoint in VERTIS CV Trial for Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease,"Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Pfizer Inc. (NYSE:PFE), today announced the presentation of results from the Phase 3 VERTIS CV cardiovascular (CV) outcomes tr...",76.97,77.41,74.83,75.38,MRK,20460690,HISTORICAL_PRICES,MRK,,1615519138000,0.12826150688947524,0.12826150688947524,75.38,76.97,77.41,74.83,20460690,73.6027,75.1552,75.5848,73.0656,20460690,"Jun 16, 20",2.950000000000003,0.0399
"June 16, 2020",Neurocrine Biosciences y Takeda anuncian una colaboraci√≥n para desarrollar y comercializar posibles tratamientos para trastornos psiqui√°tricos,"Neurocrine Biosciences, Inc. (Nasdaq:NBIX) y Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (¬´Takeda¬ª) acaban de anunciar una colaboraci√≥n estrat√©gica para desarrollar y comercializar compu...",118.89,119.42,114.75,117.72,NBIX,778445,HISTORICAL_PRICES,NBIX,,1606830572000,0.317632716391444,0.317632716391444,117.72,118.89,119.42,114.75,778445,117.72,118.89,119.42,114.75,778445,"Jun 16, 20",3.5600000000000023,0.0309
"June 16, 2020",Neurocrine Biosciences e Takeda anunciam colabora√ß√£o para desenvolver e comercializar potenciais terapias para dist√∫rbios psiqui√°tricos,"A Neurocrine Biosciences, Inc. (Nasdaq:NBIX) e a Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (‚ÄúTakeda‚Äù) anunciaram hoje uma colabora√ß√£o estrat√©gica para desenvolver e comercializar produ...",118.89,119.42,114.75,117.72,NBIX,778445,HISTORICAL_PRICES,NBIX,,1606830572000,0.317632716391444,0.317632716391444,117.72,118.89,119.42,114.75,778445,117.72,118.89,119.42,114.75,778445,"Jun 16, 20",3.5600000000000023,0.0309
"June 16, 2020",Abiomed ernennt Dr. med. Charles Simonton zum neuen Chief Medical Officer,"Abiomed (Nasdaq: ABMD), Hersteller der Impella Herzpumpe, gab heute die Ernennung von Dr. med. Charles (Chuck) Simonton zum Vice President und Chief Medical Officer bekannt. Dr. Simonton ist f√ºr seine...",249.14,252.49,246.295,252.49,ABMD,419003,HISTORICAL_PRICES,ABMD,,1606830572000,0.6960991217918171,0.6960991217918171,252.49,249.14,252.49,246.295,419003,252.49,249.14,252.49,246.295,419003,"Jun 16, 20",2.809999999999974,0.0114
"June 16, 2020",Genprex Expands Manufacturing Program with Aldevron to Advance Oncoprex‚Ñ¢ Clinical Development,"Genprex, Inc. (‚ÄúGenprex‚Äù or the ‚ÄúCompany‚Äù) (Nasdaq: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, announced toda...",3,3.12,2.91,3.09,GNPX,1280518,HISTORICAL_PRICES,GNPX,,1606830572000,0.07526881720430106,0.07526881720430106,3.09,3,3.12,2.91,1280518,3.09,3,3.12,2.91,1280518,"Jun 16, 20",-0.020000000000000018,-0.0066
"June 16, 2020",Neurocrine Biosciences and Takeda Announce Collaboration to Develop and Commercialize Potential Therapies for Psychiatric Disorders,"Neurocrine Biosciences, Inc. (Nasdaq:NBIX) and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (‚ÄúTakeda‚Äù) today announced a strategic collaboration to develop and commercialize compounds in...",118.89,119.42,114.75,117.72,NBIX,778445,HISTORICAL_PRICES,NBIX,,1606830572000,0.317632716391444,0.317632716391444,117.72,118.89,119.42,114.75,778445,117.72,118.89,119.42,114.75,778445,"Jun 16, 20",3.5600000000000023,0.0309
"June 16, 2020","Abiomed Launches Virtual Physician Education Program, CAMP PCI, to Improve High-Risk PCI Patient Outcomes","Today, Abiomed (NASDAQ: ABMD) launches a cutting-edge digital education platform called CAMP PCI, which stands for Coronary Artery & Myocardial Protected Percutaneous Coronary Intervention, to imp...",249.14,252.49,246.295,252.49,ABMD,419003,HISTORICAL_PRICES,ABMD,,1606830572000,0.6960991217918171,0.6960991217918171,252.49,249.14,252.49,246.295,419003,252.49,249.14,252.49,246.295,419003,"Jun 16, 20",2.809999999999974,0.0114
"June 16, 2020",Nemaura Participated as Guest Speaker at DiabetesMine‚Ñ¢ D-Data ExChange 2020,"Nemaura Medical, Inc. (NASDAQ: NMRD) (‚ÄúNemaura‚Äù or the ‚ÄúCompany‚Äù), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing suga...",11.9,14,10.51,10.55,NMRD,202393,HISTORICAL_PRICES,NMRD,,1606830572000,1.0033670033670032,1.0033670033670032,10.55,11.9,14,10.51,202393,10.55,11.9,14,10.51,202393,"Jun 16, 20",1.5199999999999996,0.1464
"June 15, 2020",Riassunto: Abiomed sceglie il Dott. Charles Simonton come nuovo Responsabile medico,"Abiomed (Nasdaq: ABMD), produttore della pompa cardiaca Impella, oggi ha annunciato la nomina del Dott. Charles (Chuck) Simonton alla carica di vicepresidente e responsabile medico dell'azienda. Il Do...",246.33,246.94,236.35,239.96,ABMD,402058,HISTORICAL_PRICES,ABMD,,1606830572000,0.6769691605963649,0.6769691605963649,239.96,246.33,246.94,236.35,402058,239.96,246.33,246.94,236.35,402058,"Jun 15, 20",4.650000000000006,0.0192
"June 15, 2020",Ocular Therapeutix‚Ñ¢ to Hold Virtual 2020 Annual Meeting Of Stockholders,"Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today...",8.255,8.395,7.22,7.25,OCUL,1704133,HISTORICAL_PRICES,OCUL,,1606830572000,0.6444223107569724,0.6444223107569724,7.25,8.255,8.395,7.22,1704133,7.25,8.255,8.395,7.22,1704133,"Jun 15, 20",0.8050000000000006,0.1081
"June 15, 2020","Abiomed nomme son nouveau m√©decin-chef, le Dr. Charles Simonton","Abiomed (Nasdaq: ABMD), fabricant de la pompe cardiaque Impella, a annonc√© aujourd‚Äôhui la nomination de Charles (Chuck) Simonton, D.M., au poste de vice-pr√©sident et m√©decin-chef de la soci√©t√©. Le Dr...",246.33,246.94,236.35,239.96,ABMD,402058,HISTORICAL_PRICES,ABMD,,1606830572000,0.6769691605963649,0.6769691605963649,239.96,246.33,246.94,236.35,402058,239.96,246.33,246.94,236.35,402058,"Jun 15, 20",4.650000000000006,0.0192
"June 15, 2020","Samenvatting: Abiomed benoemt nieuwe chief medical officer Charles Simonton, M.D.","Abiomed (Nasdaq: ABMD), maker van de Impella hartpomp, heeft vandaag aangekondigd dat het Charles (Chuck) Simonton, M.D., heeft aangesteld als vice-president en chief medical officer. Dr. Simonton sta...",246.33,246.94,236.35,239.96,ABMD,402058,HISTORICAL_PRICES,ABMD,,1606830572000,0.6769691605963649,0.6769691605963649,239.96,246.33,246.94,236.35,402058,239.96,246.33,246.94,236.35,402058,"Jun 15, 20",4.650000000000006,0.0192
"June 15, 2020",ACADIA Pharmaceuticals Submits Supplemental New Drug Application to U.S. FDA for NUPLAZID¬Æ (pimavanserin) for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis,ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that the company submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to support a potential n...,46.49,46.88,44.55,44.9,ACAD,929607,HISTORICAL_PRICES,ACAD,,1606830572000,0.221492380451918,0.221492380451918,44.9,46.49,46.88,44.55,929607,44.9,46.49,46.88,44.55,929607,"Jun 15, 20",0.6400000000000006,0.014
"June 15, 2020",Ocular Therapeutix‚Ñ¢ to Present Data at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting,"Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, annou...",8.255,8.395,7.22,7.25,OCUL,1704133,HISTORICAL_PRICES,OCUL,,1606830572000,0.6444223107569724,0.6444223107569724,7.25,8.255,8.395,7.22,1704133,7.25,8.255,8.395,7.22,1704133,"Jun 15, 20",0.8050000000000006,0.1081
"June 15, 2020","Resumen: Abiomed nombra a Charles Simonton, doctor en medicina, como su nuevo director m√©dico","Abiomed (Nasdaq: ABMD), fabricante de la bomba cardiaca Impella, ha anunciado hoy que ha nombrado vicepresidente y director m√©dico al Dr. Charles (Chuck) Simonton. El Dr. Simonton es reconocido por su...",246.33,246.94,236.35,239.96,ABMD,402058,HISTORICAL_PRICES,ABMD,,1606830572000,0.6769691605963649,0.6769691605963649,239.96,246.33,246.94,236.35,402058,239.96,246.33,246.94,236.35,402058,"Jun 15, 20",4.650000000000006,0.0192
"June 15, 2020",Catalent Signs Agreement with AstraZeneca to Manufacture COVID-19 Vaccine Candidate,"Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health...",70.32,71.46,68.86,71,CTLT,3573566,HISTORICAL_PRICES,CTLT,,1606830572000,0.45499689633767837,0.45499689633767837,71,70.32,71.46,68.86,3573566,71,70.32,71.46,68.86,3573566,"Jun 15, 20",0.75,0.0108
"June 15, 2020","Abiomed Appoints New Chief Medical Officer Charles Simonton, M.D.","Abiomed (Nasdaq: ABMD), maker of the Impella heart pump, announced today it has appointed Charles (Chuck) Simonton, M.D., as vice president and chief medical officer. Dr. Simonton is renowned for his...",246.33,246.94,236.35,239.96,ABMD,402058,HISTORICAL_PRICES,ABMD,,1606830572000,0.6769691605963649,0.6769691605963649,239.96,246.33,246.94,236.35,402058,239.96,246.33,246.94,236.35,402058,"Jun 15, 20",4.650000000000006,0.0192
"June 15, 2020",Xeris Pharmaceuticals Announces Positive Results From the Outpatient Stage of a Phase 2 Study of Its Developmental Gvoke Ready-to-Use (RTU) Micro‚Ñ¢ Glucagon in Adults at Risk of Hypoglycemia During and After Aerobic Exercise,"Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formula...",4.51,4.58,4.12,4.56,XERS,386458,HISTORICAL_PRICES,XERS,,1606830572000,1.398936170212766,1.398936170212766,4.56,4.51,4.58,4.12,386458,4.56,4.51,4.58,4.12,386458,"Jun 15, 20",0.019999999999999574,0.0045
"June 15, 2020",COVID-19 Home Testing Kit Provider LetsGetChecked Deploys 8x8 Contact Centre for Vital Support,"8x8, Inc. (NYSE: EGHT), a leading integrated cloud communications platform provider, today announced LetsGetChecked, the at-home health testing and insights company, deployed 8x8 Contact Centre to con...",15.07,15.42,13.9356,14.02,EGHT,2196635,HISTORICAL_PRICES,EGHT,,1606830572000,-0.16463414634146337,-0.16463414634146337,14.02,15.07,15.42,13.9356,2196635,14.02,15.07,15.42,13.9356,2196635,"Jun 15, 20",0.8000000000000007,0.0561
"June 12, 2020",FDA Approves Merck‚Äôs GARDASIL 9 for the Prevention of Certain HPV-Related Head and Neck Cancers,"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for GARDASIL 9 for the preven...",76.3,77.93,75.47,77.89,MRK,16221985,HISTORICAL_PRICES,MRK,,1615519125000,0.11844034007622396,0.11844034007622396,77.89,76.3,77.93,75.47,16221985,76.0535,74.501,76.0926,73.6906,16221985,"Jun 12, 20",-1.0499999999999972,-0.0136
"June 12, 2020",Concert Pharmaceuticals Releases Additional Data from Phase 2 Clinical Trial of CTP-543 in Alopecia Areata,"Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today released new data analyses from its Phase 2 dose-ranging clinical trial of its investigational agent CTP‚Äë543 for the treatment of moderate-to-severe...",9.83,9.85,9.41,9.48,CNCE,197699,HISTORICAL_PRICES,CNCE,,1606830572000,0.12086659064994305,0.12086659064994305,9.48,9.83,9.85,9.41,197699,9.48,9.83,9.85,9.41,197699,"Jun 12, 20",0.6699999999999999,0.0731
"June 12, 2020",New Efficacy and Biomarker Data From Rivipansel Phase 3 RESET Trial to Be Presented at Sickle Cell Meeting,"GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that a post hoc analysis of the Phase 3 RESET study evaluating the efficacy of rivipansel , its wholly-owned development candidate, in acute vaso-occ...",3,4.26,2.62,2.75,GLYC,13168441,HISTORICAL_PRICES,GLYC,,1606830572000,0.2658227848101265,0.2658227848101265,2.75,3,4.26,2.62,13168441,2.75,3,4.26,2.62,13168441,"Jun 12, 20",0.33000000000000007,0.1236
"June 12, 2020","Glancy Prongay & Murray LLP, a National Class Action Law Firm, Continues Investigation of Pilgrim's Pride Corporation (PPC) on Behalf of Investors","Glancy Prongay & Murray LLP (‚ÄúGPM‚Äù), a national investor rights law firm, continues its investigation on behalf of Pilgrim's Pride Corporation (""Pilgrim‚Äôs Pride"" or the ""Company"") (NASDAQ: PPC) in...",18.14,18.465,17.73,18.35,PPC,1355397,HISTORICAL_PRICES,PPC,,1606830572000,-0.0032967032967032264,-0.0032967032967032264,18.35,18.14,18.465,17.73,1355397,18.35,18.14,18.465,17.73,1355397,"Jun 12, 20",0.25,0.014
"June 12, 2020","Glancy Prongay & Murray LLP, a National Class Action Law Firm, Continues Investigation of Tactile Systems Technology, Inc. (TCMD) on Behalf of Investors","Glancy Prongay & Murray LLP (‚ÄúGPM‚Äù), a national investor rights law firm, continues its investigation on behalf of Tactile Systems Technology, Inc. (""Tactile"" or the ""Company"") (NASDAQ: TCMD) inve...",40.77,42.08,39.675,40.99,TCMD,405386,HISTORICAL_PRICES,TCMD,,1606830572000,0.06895647614053493,0.06895647614053493,40.99,40.77,42.08,39.675,405386,40.99,40.77,42.08,39.675,405386,"Jun 12, 20",1.2100000000000009,0.0306
"June 12, 2020","Glancy Prongay & Murray LLP, a National Class Action Law Firm, Continues Investigation of Townsquare Media, Inc. (TSQ) on Behalf of Investors","Glancy Prongay & Murray LLP (‚ÄúGPM‚Äù), a national investor rights law firm, continues its investigation on behalf of Townsquare Media, Inc. (""Townsquare Media"" or the ""Company"") (NYSE: TSQ) investor...",5.09,5.226,4.88,4.88,TSQ,50936,HISTORICAL_PRICES,TSQ,,1606830572000,0.053830227743271175,0.053830227743271175,4.88,5.09,5.226,4.88,50936,4.88,5.09,5.226,4.88,50936,"Jun 12, 20",0.20999999999999996,0.043
"June 12, 2020",Omeros‚Äô Narsoplimab Pivotal Trial Data Shared in Oral Presentation at Annual European Hematology Association Congress,Omeros Corporation (Nasdaq: OMER) today announced that the results of its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSC...,14.635,15.65,14.16,15.65,OMER,794202,HISTORICAL_PRICES,OMER,,1606830572000,0.38066037735849056,0.38066037735849056,15.65,14.635,15.65,14.16,794202,15.65,14.635,15.65,14.16,794202,"Jun 12, 20",-0.5250000000000004,-0.0346
"June 12, 2020",Cerus Corporation Celebrates World Blood Donor Day,"Cerus Corporation (Nasdaq:CERS) celebrates World Blood Donor Day this Sunday, June 14, 2020. Enacted by the World Health Organization (WHO), World Blood Donor Day highlights the need for safe blood an...",6.04,6.12,5.75,5.94,CERS,2513802,HISTORICAL_PRICES,CERS,,1606830572000,0.49504950495049505,0.49504950495049505,5.94,6.04,6.12,5.75,2513802,5.94,6.04,6.12,5.75,2513802,"Jun 12, 20",0.4400000000000004,0.0786
"June 12, 2020","Catabasis Pharmaceuticals Names Ben Harshbarger Senior Vice President, General Counsel","Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today that it has named Ben Harshbarger as Senior Vice President, General Counsel. Mr. Harshbarger...",6.55,6.58,6.25,6.42,CATB,97127,HISTORICAL_PRICES,CATB,,1606830572000,0.6053921568627451,0.6053921568627451,6.42,6.55,6.58,6.25,97127,6.42,6.55,6.58,6.25,97127,"Jun 12, 20",0.3799999999999999,0.0616
"June 12, 2020",Kite Receives European Medicines Agency Approval for CAR T Cell Therapy Manufacturing Facility in Europe,"Kite, a Gilead Company (Nasdaq: GILD), today announced it has received approval to implement a variation to the Yescarta¬Æ (axicabtagene ciloleucel) Marketing Authorization from the European Medicine A...",73.2,73.72,71.91,73.33,GILD,8375593,HISTORICAL_PRICES,GILD,,1615518976000,0.050818260120585795,0.050818260120585795,73.33,73.2,73.72,71.91,8375593,70.9499,70.8241,71.3273,69.576,8375593,"Jun 12, 20",0.35999999999999943,0.0049
"June 12, 2020",Scholar Rock Presents Clinical and Preclinical Data for SRK-015 at the 2020 Virtual Cure SMA Research and Clinical Care Meeting,"Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced two presen...",17.27,17.5,15.85,16.27,SRRK,96950,HISTORICAL_PRICES,SRRK,,1606830572000,0.32033639143730885,0.32033639143730885,16.27,17.27,17.5,15.85,96950,16.27,17.27,17.5,15.85,96950,"Jun 12, 20",1.4399999999999995,0.091
"June 12, 2020",New Data Show Near Elimination of Sickle Cell Disease-Related Vaso-Occlusive Crises and Acute Chest Syndrome in Phase 1/2 Clinical Study of bluebird bio‚Äôs LentiGlobin‚Ñ¢ Gene Therapy for Sickle Cell Disease at 25th EHA Congress,"bluebird bio, Inc. (Nasdaq: BLUE) announced that new data from its ongoing Phase 1/2 HGB-206 study of investigational LentiGlobin‚Ñ¢ gene therapy for adult and adolescent patients with sickle cell disea...",63.93,68,62.11,67.84,BLUE,2060682,HISTORICAL_PRICES,BLUE,,1606830572000,0.3510143702451395,0.3510143702451395,67.84,63.93,68,62.11,2060682,67.84,63.93,68,62.11,2060682,"Jun 12, 20",0.8100000000000023,0.0128
"June 12, 2020",Majority of Evaluable Patients Across Genotypes Achieve Transfusion Independence and Maintain It with Near-Normal Hemoglobin Levels in Phase 3 Studies of betibeglogene autotemcel (LentiGlobin‚Ñ¢ for Œ≤-thalassemia) Gene Therapy Presented at EHA Congress,"bluebird bio, Inc. (Nasdaq: BLUE) today announced that new data from ongoing Phase 3 studies of betibeglogene autotemcel (beti-cel; formerly LentiGlobin‚Ñ¢ for Œ≤-thalassemia gene therapy) show pediatric...",63.93,68,62.11,67.84,BLUE,2060682,HISTORICAL_PRICES,BLUE,,1606830572000,0.3510143702451395,0.3510143702451395,67.84,63.93,68,62.11,2060682,67.84,63.93,68,62.11,2060682,"Jun 12, 20",0.8100000000000023,0.0128
"June 11, 2020",Quidel Receives BARDA Funding to Develop Point-of-Care Diagnostic Assay That Includes COVID-19,"Quidel Corporation (NASDAQ: QDEL) (‚ÄúQuidel‚Äù), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has receive...",158.37,170.99,158.34,165.21,QDEL,1122786,HISTORICAL_PRICES,QDEL,,1606830572000,0.9626967406122198,0.9626967406122198,165.21,158.37,170.99,158.34,1122786,165.21,158.37,170.99,158.34,1122786,"Jun 11, 20",-8.389999999999986,-0.0503
"June 11, 2020",Quidel Announces Jack Schuler Will Retire From Quidel‚Äôs Board of Directors,"Quidel Corporation (NASDAQ: QDEL) (‚ÄúQuidel‚Äù), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Jack W. Schuler ha...",158.37,170.99,158.34,165.21,QDEL,1122786,HISTORICAL_PRICES,QDEL,,1606830572000,0.9626967406122198,0.9626967406122198,165.21,158.37,170.99,158.34,1122786,165.21,158.37,170.99,158.34,1122786,"Jun 11, 20",-8.389999999999986,-0.0503
"June 11, 2020",Omeros‚Äô Narsoplimab Pivotal Trial Data to be Shared as an Oral Presentation at Annual European Hematology Association Congress,Omeros Corporation (Nasdaq: OMER): The results of Omeros‚Äô pivotal trial of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) will be...,15.16,15.74,15,15.1,OMER,562145,HISTORICAL_PRICES,OMER,,1606830572000,0.4301886792452831,0.4301886792452831,15.1,15.16,15.74,15,562145,15.1,15.16,15.74,15,562145,"Jun 11, 20",-0.48499999999999943,-0.031
"June 11, 2020",Urovant Sciences to Report Fiscal Year and Fourth Quarter 2019 Results,"Urovant Sciences (Nasdaq: UROV) announced today that it will report fiscal year and fourth quarter 2019 results after the close of U.S. financial markets on Thursday, June 18, 2020. Management will ho...",10.73,11.0665,10.15,11,UROV,147086,HISTORICAL_PRICES,UROV,,1606830572000,0.06766169154228853,0.06766169154228853,11,10.73,11.0665,10.15,147086,11,10.73,11.0665,10.15,147086,"Jun 11, 20",-0.16000000000000014,-0.0147
"June 11, 2020","FDA Approves Pfizer‚Äôs Oncology Supportive Care Biosimilar, NYVEPRIA‚Ñ¢ (pegfilgrastim-apgf)","Pfizer Inc. (NYSE: PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved NYVEPRIA‚Ñ¢ (pegfilgrastim-apgf), a biosimilar to Neulasta¬Æ (pegfilgrastim).1 NYVEPRIA is...",33.3,35.68,33.28,35.6,PFE,59930390,HISTORICAL_PRICES,PFE,,1611800324000,0.11932773109243688,0.11932773109243688,35.6,33.3,35.68,33.28,59930390,34.521,32.2907,34.5986,32.2713,59930390,"Jun 11, 20",-2.6200000000000045,-0.0729
"June 11, 2020",Twist Bioscience Expands Offering of Synthetic SARS-CoV-2 RNA Controls,"Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the addition of four...",36.01,38.7,35.5,37.49,TWST,515210,HISTORICAL_PRICES,TWST,,1606830572000,0.29765765765765756,0.29765765765765756,37.49,36.01,38.7,35.5,515210,37.49,36.01,38.7,35.5,515210,"Jun 11, 20",-2.950000000000003,-0.0757
"June 11, 2020",Moderna Advances Late-Stage Development of its Vaccine (mRNA-1273) Against COVID-19,"Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, toda...",60.2,66.6867,58.77,62.95,MRNA,32085168,HISTORICAL_PRICES,MRNA,,1606830572000,1.2189458164393663,1.2189458164393663,62.95,60.2,66.6867,58.77,32085168,62.95,60.2,66.6867,58.77,32085168,"Jun 11, 20",0.13000000000000256,0.0022
"June 11, 2020",Magenta Therapeutics Provides Portfolio Update: Stem Cell Mobilization and Conditioning Programs Prioritized and Advancing Toward Clinical Milestones,"Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, today provided a portfolio...",9.035,10,8.93,10,MGTA,245350,HISTORICAL_PRICES,MGTA,,1606830572000,0.42958860759493667,0.42958860759493667,10,9.035,10,8.93,245350,10,9.035,10,8.93,245350,"Jun 11, 20",-1.3650000000000002,-0.1313
"June 11, 2020",Deciphera Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Forum,"Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that Tucker Kelly, Executive Vice President, Chief Financial Officer and Treasurer, will present at the JMP Securities Hematology and Onco...",52.55,55.305,52.49,54.73,DCPH,372133,HISTORICAL_PRICES,DCPH,,1606830572000,0.27116594097726154,0.27116594097726154,54.73,52.55,55.305,52.49,372133,54.73,52.55,55.305,52.49,372133,"Jun 11, 20",-3.9100000000000037,-0.0693
"June 11, 2020","Aerie Pharmaceuticals Appoints Peter J. McDonnell, M.D., to the Company‚Äôs Board of Directors","Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients wi...",13.27,14.575,12.79,14.5,AERI,1157402,HISTORICAL_PRICES,AERI,,1606830572000,0.02155504234026169,0.02155504234026169,14.5,13.27,14.575,12.79,1157402,14.5,13.27,14.575,12.79,1157402,"Jun 11, 20",-1.6900000000000013,-0.113
"June 10, 2020",U.S. Food and Drug Administration Approves Opdivo¬Æ (nivolumab) for the Treatment of Patients with Advanced Esophageal Squamous Cell Carcinoma (ESCC) After Prior Fluoropyrimidine- and Platinum-based Chemotherapy,"Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo¬Æ (nivolumab) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with unresectable advanced, recurren...",60.16,61.42,59.9,61.24,BMY,13343689,HISTORICAL_PRICES,BMY,,1609460168000,0.21904761904761894,0.21904761904761894,61.24,60.16,61.42,59.9,13343689,59.8453,58.7899,60.0212,58.5358,13343689,"Jun 10, 20",-0.7700000000000031,-0.0126
"June 10, 2020","Glancy Prongay & Murray LLP, a National Class Action Law Firm, Continues Investigation of Casper Sleep Inc. (CSPR) on Behalf of Investors","Glancy Prongay & Murray LLP (‚ÄúGPM‚Äù), a national investor rights law firm, continues its an investigation on behalf of Casper Sleep Inc. (""Casper"" or the ""Company"") (NYSE: CSPR) investors concernin...",8.22,8.87,7.895,8.75,CSPR,307122,HISTORICAL_PRICES,CSPR,,1606830572000,1.0969387755102042,1.0969387755102042,8.75,8.22,8.87,7.895,307122,8.75,8.22,8.87,7.895,307122,"Jun 10, 20",-0.4399999999999995,-0.0508
"June 10, 2020","Clovis Oncology Announces Completion of Target Enrollment in the ATHENA Trial, a Phase 3 Maintenance Treatment Study in Front-line, Newly-Diagnosed Advanced Ovarian Cancer","Clovis Oncology, Inc. (NASDAQ: CLVS) announced today the completion of target patient enrollment in the Clovis-sponsored Phase 3 ATHENA trial evaluating the combination of Clovis‚Äô Rubraca¬Æ (rucaparib)...",7.14,7.36,7.0791,7.32,CLVS,3735770,HISTORICAL_PRICES,CLVS,,1606830572000,0.6117381489841986,0.6117381489841986,7.32,7.14,7.36,7.0791,3735770,7.32,7.14,7.36,7.0791,3735770,"Jun 10, 20",-0.1900000000000004,-0.0259
"June 10, 2020",Turning Point Brands Announces Acquisition of Assets From Durfort Holdings,"Turning Point Brands, Inc. (‚ÄúTPB‚Äù) (NYSE: TPB), a leading provider of Other Tobacco Products (‚ÄúOTP‚Äù) and adult consumer alternatives, today announced the acquisition of certain tobacco assets and dist...",24.71,25.52,24.22,25.26,TPB,55499,HISTORICAL_PRICES,TPB,,1616033803000,0.13348623853211009,0.13348623853211009,25.26,24.71,25.52,24.22,55499,25.1135,24.5667,25.372,24.0796,55499,"Jun 10, 20",-0.6899999999999977,-0.0272
"June 10, 2020", NantKwest Announces Studies in Collaboration with the National Cancer Institute Demonstrating Enhanced Killing Activity of First-in-Class PD-L1 t-haNK Natural Killer Cell Across Every Cancer Cell Line Tested,"NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced the publication of two peer-reviewed manuscripts in the Journal of Immunotherapy of Canc...",6.21,6.63,6.0301,6.447,NK,1838216,HISTORICAL_PRICES,NK,,1606830572000,1.0769230769230769,1.0769230769230769,6.447,6.21,6.63,6.0301,1838216,6.447,6.21,6.63,6.0301,1838216,"Jun 10, 20",0.5599999999999996,0.0991
"June 10, 2020",Kala Pharmaceuticals Announces Virtual-Only Format for 2020 Annual Meeting of Stockholders,"Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that...",13.6,13.97,13.36,13.46,KALA,552677,HISTORICAL_PRICES,KALA,,1606830572000,0.8528610354223433,0.8528610354223433,13.46,13.6,13.97,13.36,552677,13.46,13.6,13.97,13.36,552677,"Jun 10, 20",0.34999999999999964,0.0264
"June 10, 2020",TransAct Secures BOHA! Solutions Order for Regional Convenience Store Chain,"TransAct¬Æ Technologies Incorporated (Nasdaq: TACT) (‚ÄúTransAct‚Äù or ‚Äúthe Company‚Äù), a global leader in software-driven technology and printing solutions for high-growth markets, today announced that it...",5.5001,6.27,5.35,6.27,TACT,36986,HISTORICAL_PRICES,TACT,,1606830572000,0.3889141414141414,0.3889141414141414,6.27,5.5001,6.27,5.35,36986,6.27,5.5001,6.27,5.35,36986,"Jun 10, 20",-0.2698999999999998,-0.0468
"June 10, 2020",Ocular Therapeutix‚Ñ¢ to Present at the 2020 Raymond James Human Health Innovation Conference,"Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today...",7.345,7.78,7.26,7.7,OCUL,780716,HISTORICAL_PRICES,OCUL,,1606830572000,0.4631474103585658,0.4631474103585658,7.7,7.345,7.78,7.26,780716,7.7,7.345,7.78,7.26,780716,"Jun 10, 20",-0.3050000000000006,-0.0399
"June 10, 2020",Pfizer Announces Positive Top-Line Results from JADE TEEN Trial of Abrocitinib in Adolescents with Moderate-to-Severe Atopic Dermatitis,"Pfizer Inc. (NYSE: PFE) announced today positive top-line results from the Phase 3 JADE TEEN study of abrocitinib, an investigational oral once-daily Janus kinase 1 (JAK1) inhibitor, in patients 12 to...",35.92,36.45,35.89,36.36,PFE,28042861,HISTORICAL_PRICES,PFE,,1611800399000,0.20739495798319332,0.20739495798319332,36.36,35.92,36.45,35.89,28042861,35.258,34.8313,35.3452,34.8022,28042861,"Jun 10, 20",-0.28999999999999915,-0.008
"June 10, 2020",Veeva k√ºndigt neue L√∂sung zur Beschleunigung von Erkenntnissen im Key Account Management an,"Auf dem heutigen Veeva Summit Online k√ºndigte Veeva Systems (NYSE: VEEV) Veeva Link f√ºr KAM an, eine neue L√∂sung, die kaufm√§nnischen und medizinischen Teams genaue Kundendaten und Echtzeit-Einblicke f...",226.55,227.86,215.26,215.45,VEEV,2023075,HISTORICAL_PRICES,VEEV,,1606830572000,0.6867694140421414,0.6867694140421414,215.45,226.55,227.86,215.26,2023075,215.45,226.55,227.86,215.26,2023075,"Jun 10, 20",13,0.0609
"June 10, 2020",Everbridge Launches Fully Integrated Critical Event Management (CEM) Solution in Europe That Helps Organizations Mitigate Crises and Manage the Safe Return to Work After COVID-19 Lockdowns,"Everbridge, Inc. (NASDAQ: EVBG), the global leader in critical event management (CEM), today announced the expansion of its award-winning software platform in Europe, just as businesses, healthcare fa...",135.72,137.9392,132.32,134.37,EVBG,609969,HISTORICAL_PRICES,EVBG,,1606830572000,0.22634860395771209,0.22634860395771209,134.37,135.72,137.9392,132.32,609969,134.37,135.72,137.9392,132.32,609969,"Jun 10, 20",3.759999999999991,0.0285
"June 9, 2020",Illumina Receives First FDA Emergency Use Authorization for a Sequencing-Based COVID-19 Diagnostic Test,"Illumina, Inc. (NASDAQ: ILMN) is paving the way for large-scale, next-generation sequencing-based (NGS) COVID-19 testing. Today, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Aut...",357.78,361.58,354,357.6,ILMN,655903,HISTORICAL_PRICES,ILMN,,1606830572000,0.4408021907216494,0.4408021907216494,357.6,357.78,361.58,354,655903,357.6,357.78,361.58,354,655903,"Jun 9, 20",-1.0300000000000296,-0.0029
"June 9, 2020",Neue Funktion in Vault PromoMats zur Beschleunigung der Zusammenstellung von Werbematerialien f√ºr die Einreichung bei der FDA,"Veeva Systems (NYSE: VEEV) k√ºndigte heute beim Veeva Summit Online eine neue Funktion in Veeva Vault PromoMats an, mit der die digitale Einreichung von Werbematerialien f√ºr Produkte mit beschleunigter...",213.55,220,212.91,220,VEEV,1113374,HISTORICAL_PRICES,VEEV,,1606830572000,0.5899784081602264,0.5899784081602264,220,213.55,220,212.91,1113374,220,213.55,220,212.91,1113374,"Jun 9, 20",-4.810000000000002,-0.022
"June 9, 2020",Quidel Receives Amended Emergency Authorization for Rapid Antigen COVID-19 Diagnostic Assay Using Sofia 1 Instrument,"Quidel Corporation (NASDAQ: QDEL) (‚ÄúQuidel‚Äù), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has receive...",155.8,160.01,154.39,155.26,QDEL,683291,HISTORICAL_PRICES,QDEL,,1606830572000,0.9308464493741482,0.9308464493741482,155.26,155.8,160.01,154.39,683291,155.26,155.8,160.01,154.39,683291,"Jun 9, 20",-0.5199999999999818,-0.0033
"June 9, 2020",Merck Provides Update on Phase 3 KEYNOTE-361 Trial Evaluating KEYTRUDA¬Æ (pembrolizumab) as Monotherapy and in Combination with Chemotherapy in Patients with Advanced or Metastatic Urothelial Carcinoma,"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Phase 3 KEYNOTE-361 trial evaluating KEYTRUDA, Merck‚Äôs anti-PD-1 therapy, in combination with chemotherap...",82.26,83.51,82.12,83.19,MRK,8440980,HISTORICAL_PRICES,MRK,,1615519169000,0.2058047493403695,0.2058047493403695,83.19,82.26,83.51,82.12,8440980,80.5879,79.687,80.8979,79.5514,8440980,"Jun 9, 20",-0.6400000000000006,-0.0077
"June 9, 2020",Samenvatting: Nieuwe mogelijkheid in Vault PromoMats om promotiemateriaal voor verpakkingen te versnellen voor FDA-indiening,Veeva Systems (NYSE: VEEV) heeft vandaag op Veeva Summit Online een nieuwe mogelijkheid aangekondigd in Veeva Vault PromoMats om de digitale indiening van promotiemateriaal voor versnelde goedkeurings...,213.55,220,212.91,220,VEEV,1113374,HISTORICAL_PRICES,VEEV,,1606830572000,0.5899784081602264,0.5899784081602264,220,213.55,220,212.91,1113374,220,213.55,220,212.91,1113374,"Jun 9, 20",-4.810000000000002,-0.022
"June 9, 2020",Applied DNA Secures Grant from National Grid Partnered with the New York State MEP to Support Manufacture of COVID-19 Diagnostic Kits and Vaccine Candidates,"Applied DNA Sciences Inc. (NASDAQ: APDN) (‚ÄúApplied DNA‚Äù or the ‚ÄúCompany,‚Äù ‚Äúour‚Äù) announced today it secured a $40,000 economic development grant from National Grid to support the Company‚Äôs efforts ass...",7.82,9.03,7.26,7.66,APDN,1621216,HISTORICAL_PRICES,APDN,,1606830572000,0.9166666666666667,0.9166666666666667,7.66,7.82,9.03,7.26,1621216,7.66,7.82,9.03,7.26,1621216,"Jun 9, 20",-0.040000000000000036,-0.0051
"June 9, 2020",FSD Pharma Announces Closing of C$10.125 Million Private Placement to Institutional Investors,"FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) (the ‚ÄúCompany‚Äù) announces the closing of a previously announced private placement of 1,500,000 of the Company‚Äôs Class B Subordinate Voting Sha...",4.65,4.99,4.53,4.89,HUGE,252466,HISTORICAL_PRICES,HUGE,,1609875856000,0.5448504983388707,0.5448504983388707,4.89,4.65,4.99,4.53,252466,4.89,4.65,4.99,4.53,252466,"Jun 9, 20",-0.3899999999999997,-0.0774
"June 9, 2020",Riassunto: Nuova funzionalit√† in Vault PromoMats velocizza la preparazione del materiale promozionale per la presentazione di prodotti alla FDA,Veeva Systems (NYSE: VEEV) ha annunciato oggi nel corso del Veeva Summit Online (vertice Veeva online) l‚Äôintroduzione di una nuova funzionalit√† in Veeva Vault PromoMats atta a velocizzare la presentaz...,213.55,220,212.91,220,VEEV,1113374,HISTORICAL_PRICES,VEEV,,1606830572000,0.5899784081602264,0.5899784081602264,220,213.55,220,212.91,1113374,220,213.55,220,212.91,1113374,"Jun 9, 20",-4.810000000000002,-0.022
"June 9, 2020",Resumen: Nueva capacidad de Vault PromoMats para acelerar el packaging de materiales promocionales para su presentaci√≥n a la FDA,"Veeva Systems (NYSE: VEEV) ha anunciado hoy en Veeva Summit Online, la cumbre online de Veeva, una nueva capacidad de Vault PromoMats de Veeva para acelerar la presentaci√≥n digital de materiales promo...",213.55,220,212.91,220,VEEV,1113374,HISTORICAL_PRICES,VEEV,,1606830572000,0.5899784081602264,0.5899784081602264,220,213.55,220,212.91,1113374,220,213.55,220,212.91,1113374,"Jun 9, 20",-4.810000000000002,-0.022
"June 9, 2020",Genprex Scheduled to Join Russell 3000¬Æ Index,"Genprex, Inc. (‚ÄúGenprex‚Äù or the ‚ÄúCompany‚Äù) (Nasdaq: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announce...",3.36,3.39,3.05,3.15,GNPX,3128625,HISTORICAL_PRICES,GNPX,,1606830572000,0.20430107526881713,0.20430107526881713,3.15,3.36,3.39,3.05,3128625,3.15,3.36,3.39,3.05,3128625,"Jun 9, 20",0.2999999999999998,0.098
"June 9, 2020",Veracyte Announces De Novo Classification Request to FDA for the nCounter Dx LymphMark Assay,"Veracyte, Inc. (Nasdaq: VCYT) today announced its submission of a De Novo classification request to the U.S. Food & Drug Administration (FDA) for the nCounter¬Æ Dx LymphMark‚Ñ¢ Assay, a novel, genomi...",26.79,27.17,25.85,25.85,VCYT,345024,HISTORICAL_PRICES,VCYT,,1606830572000,0.2174505794137696,0.2174505794137696,25.85,26.79,27.17,25.85,345024,25.85,26.79,27.17,25.85,345024,"Jun 9, 20",0.48999999999999844,0.0186
"June 9, 2020",Leading BioSciences Teams with Donnelley Financial Solutions to Create Innovative Study Tool for Clinical Trial Monitoring During COVID-19 Pandemic,"Donnelley Financial Solutions (NYSE: DFIN), a leading risk and compliance company, today announced that Leading BioSciences, Inc. (LBS), a drug development company focused on improving human health th...",9.06,9.99,8.81,9.9,DFIN,356160,HISTORICAL_PRICES,DFIN,,1606830572000,1.1990291262135924,1.1990291262135924,9.9,9.06,9.99,8.81,356160,9.9,9.06,9.99,8.81,356160,"Jun 9, 20",-0.9599999999999991,-0.0958
"June 9, 2020","Everbridge Wins New Patent for its Critical Event Management Solution, Expanding its Technology Leadership Amid COVID-19","Everbridge, Inc. (NASDAQ: EVBG), the global leader in critical event management (CEM), today announced that the U.S. Patent and Trademark Office (USPTO) awarded Everbridge Patent No. 10,652,080 for it...",131.96,133.535,127.73,131.23,EVBG,776230,HISTORICAL_PRICES,EVBG,,1606830572000,0.19237372368302164,0.19237372368302164,131.23,131.96,133.535,127.73,776230,131.23,131.96,133.535,127.73,776230,"Jun 9, 20",1.3000000000000114,0.0099
